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ABSTRACT
METABOLIC REGULATION OF MYOCARDIAL
ADAPTATION TO EXERCISE
Andrew Alan Gibb
September 1, 2017
While the benefits of exercise affect several organs, a significant adaptive
response occurs within the heart. Exercise promotes cardiac growth, increases
angiogenesis, and enhances cardiac function and these adaptations are
associated with a cardioprotective phenotype. Additionally, extensive evidence
shows that exercise dynamically regulates myocardial metabolism. This can be
attributed to both changes in hormonal stimulation, increases in bioenergetic
demand, and the bioavailability of circulating substrates. However, it is unclear
whether these changes in metabolism contribute to physiologic cardiac growth. We
reason that exercise-induced changes in metabolism are required to balance the
catabolic and anabolic reactions needed for growth. Specifically, we hypothesize
that exercise-induced changes in myocardial glycolytic activity are essential for
activation of the physiological growth program and the synthesis of metabolites
required for growth. Prior to investigating the effects of exercise on cardiac
metabolism, we established a model of cardiac adaptation to exercise training in
mice (Chapter II). Once established, as discussed in Chapter III, we found that the
exercise-adapted heart demonstrates enhanced glycolytic activity; however,
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during exercise glycolytic rate in the heart is diminished. To determine whether
high or low glycolytic rates may be a stimulus for cardiac growth, we assessed the
effect of cardiac-specific overexpression of phosphofructokinase isoforms that
decrease or increase myocardial glycolytic rate. We found that constitutive
reduction in glycolytic rate was sufficient to structurally and functionally phenocopy
the exercise-adapted heart, replete with activation of the physiologic growth
program; however, metabolic inflexibility invoked by constitutive changes in
glycolysis results in mild mitochondrial dysfunction. To assess how glycolytic
activity affects anabolic metabolism, we utilized stable isotope labeling in an in vitro
model to interrogate flux of carbon into collateral biosynthetic pathways of glucose
metabolism. Results from these studies, discussed in Chapter IV, show that PFK1
and glycolytic activity coordinate the allocation of glucose into pathways that would
be important for cardiac growth. Collectively, our results indicate that physiological
growth of the heart is intricately regulated by exercise-induced changes in
intermediary metabolism, and that preservation of metabolic flexibility is essential
for mitochondrial health. Importantly, these findings suggest a causal role of
metabolism in myocardial responses to stress.
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CHAPTER I
GENERAL INTRODUCTION

Significance of Physical Activity
Physical activity is firmly embedded in human culture. The ability to adapt
to periods of increased physical activity likely played a critical role in the evolution
of human physiology. For instance, our early ancestors with low “physical fitness,”
likely did not fare well at a time when hunting, gathering, shelter building, and
evasion from predators were a necessity. This period in time likely contributed to
the evolutionary physiologic advancement of the human species. Much later in
ancient Greece, Hippocrates was the first to realize the importance of physical
activity and stated that “eating alone will not keep a man well; he must also take
exercise. For food and exercise…work together to produce health.”1 Today,
physical activity as a way of life is simply an afterthought. With the obvious
transition from manual labor jobs to sedentary desk jobs and the technological
advancements made over the last century, a sedentary lifestyle has become the
new “normal” for human physiology. Unfortunately, this new “normal” could be
considered evolutionarily “abnormal.” While exercise has been labeled as
providing “health benefits,” it is in fact the lack of exercise that carries health risks.2
This deviation from “normal” and change in lifestyle led the World Health
1

Organization (WHO) to classify physical inactivity as the fourth leading risk factor
for global mortality.3
While physical inactivity is a health risk, it is a modifiable one. The first
documented study of the beneficial effects of an active lifestyle was in 1953. This
study showed that those in more physically active jobs (e.g., train conductors and
postmen) in London had a lower incidence of cardiovascular events and a lower
early mortality-rate than their sedentary, desk-based, civil servant counterparts.4
Along with this observation, the benefits of physical activity have only become
more noticeable over the years. Regular exercise has been shown to promote
cardiovascular health,5-7 augment skeletal muscle function,8 and increase both
healthspan8-10 and lifespan.5,

11-13

An individual’s level of physical fitness,

commonly measured by their exercise capacity, is a more powerful predictor of
mortality among men than other established cardiovascular risk factors such as
hypertension, blood lipids, and smoking.12 The indication that physical fitness is
the most powerful predictor of mortality risk highlights the importance of an active
lifestyle.
Despite irrefutable evidence that exercise imparts health benefits, or
perhaps more accurately prevents sedentary health risks, the mechanisms by
which exercise does so remain poorly understood. For instance, epidemiologic
evidence suggests that while exercise training significantly lowers traditional
cardiovascular risk factors (i.e. hypertension, inflammation, and blood lipids), only
half of the reduction in event risk can be explained by these changes.6, 7 These
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observations suggest that a large portion of the benefits of exercise remain
unexplained and warrant further investigation.

Exercise and the Cardiovascular System
The complexity of studying exercise is rooted in the coordinated response
of the body’s organ systems. For example, even before beginning exercise (e.g.
running), the centers in the brain prime the body for an increase in energy
expenditure by increasing respiratory and heart rates (refs). At the onset of
exercise, skeletal muscle contracts in response to the increased workload,
requiring an increase in the utilization of fuel substrates such as glucose, glycogen,
and fatty acids to meet the higher energy demand. This increase in muscle
metabolism must be met by an equal increase in oxygen delivery, which is
accomplished by a further increase in pulmonary respiratory rates and heart rates
to increase oxygen delivery. These changes from homeostasis in the muscular,
respiratory and circulatory systems are driven in part by changes in both the
autonomic tone of the nervous system and the release of circulating hormones and
catecholamines from the endocrine system. Interestingly, exercise profoundly
affects the cardiovascular system in particular, resulting in significant adaptive
responses of the heart. For instance, exercise promotes cardiac growth, increases
perfusion, and enhances cardiac function and substrate utilization, all of which
contribute to cardioprotection (Fig. 1). Understanding the mechanisms that
underlie this response could lead to therapeutic strategies to improve cardiac
health in disease.
3

Figure 1: Summary of the cardiac benefits of exercise. SV, stroke volume; CO,
cardiac output.
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The heart is highly susceptible to changes in workload brought upon by
exercise. Simply put, the primary response of the circulatory system is to increase
blood flow to active areas (e.g. skeletal muscle) and to decrease it to non-working,
less critical ones (e.g. GI tract). This is critical as the working muscle requires an
increase in oxygen delivery to match the increase in metabolic demand required
for the maintenance of contractile function. Not surprising, the heart is quite
efficient at matching oxygen delivery to metabolic demand, resulting in little
energetic waste. To accomplish this, the heart increases cardiac output, the
product of heart rate (HR) and stroke volume (SV). Several factors determine
cardiac performance and are discussed below:

1) Heart rate: The single greatest factor determining cardiac output is heart
rate. Under resting conditions, the human heart beats approximately 70
times per minute (bpm); however, during intense exercise this can
increase nearly 3-fold to 200 bpm. Under parasympathetic control via
the Vagus nerve, vagal tone is diminished during exercise and
sympathetic stimulation predominates, leading to an increased HR. In
addition to its significant contributions to cardiac output, heart rate is the
most important factor determining myocardial oxygen consumption. This
increase in oxygen utilization is essential to match the increase in
metabolic demand. For this reason, increases in HR and cardiac output
are tightly regulated to be directly proportional to the increase in oxygen
requirements of not only the skeletal muscle, but the heart itself. Lastly,
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HRs are useful in estimating the myocardial metabolic cost of exercise.
For example, the product of HR and systolic blood pressure is the ratepressure product (RPP), a rough index of the coronary blood flow
myocardial oxygen consumption.

2) Preload: Several factors contribute to SV with preload being one of
them. Preload, also known as end diastolic volume (EDV), is the volume
of blood that stretches the ventricles to their greatest dimensions prior
to contraction. Preload directly contributes to SV by means of the FrankStarling law. This law describes the positive relationship between SV
and EDV and is driven by the length-tension relationship of the
cardiomyocyte sarcomeres. As blood fills the ventricles, the myocyte
myofibrils are stretched, creating more opportunities for cross-bridge
interactions. An increased number of possible cross-bridges promotes
greater contractile force, resulting in a larger volume of blood ejected,
i.e., SV. Preload is directly related to the venous return of blood to the
heart: its increase during exercise is caused by augmented skeletal and
respiratory

muscle

pump

function,

higher

venous

tone

(i.e.

venoconstriction), and elevated cardiac output. Interestingly, it has been
suggested that high heart rates may in fact decrease preload due to the
loss of filling time; however, this remains controversial.14

7

3) Afterload: Unlike preload, afterload is referred to as a pressure and is
negatively correlated to SV and cardiac output. Afterload is defined as
the load which the ventricles must overcome to eject blood. The typical
afterload (systolic blood pressure) in a healthy adult is 120 mmHg;
however, during resistance exercise, such as weight lifting, arterial
pressures can reach 480 mmHg and is due to the arterial constriction of
contracting skeletal muscle.15 These pressures, however, are not
maintained as weight lifting is typically intermittent and dynamic. While
this acute increase in afterload causes an immediately and relatively
large decrease in SV, this leads to an increase in preload during the next
cardiac cycle, increasing the effect size of Frank-Starling’s law and
increasing SV on the subsequent beat. While the increase observed with
endurance exercise is much less severe (~ 100 mmHg), this increase in
afterload is overcome by the heart due to the increases in preload and
contractility.

4) Contractility: Contractility can be defined as the degree of force the heart
muscle produces to eject blood and is positively correlated with SV.
Unlike skeletal muscle, which is capable of recruiting additional fibers,
the myocardium is fully engaged. Therefore, changes in contractility are
completely dependent on intracellular Ca2+ availability, critical for muscle
excitation-contraction coupling. When intracellular Ca2+ levels rise, Ca2+
binds to troponin-C causing a conformation change allowing actin-

8

myosin cross-bridge interactions to occur. Utilizing ATP, the actin and
myosin filaments slide past each other, shortening the sarcomeres and
contracting the cell. Increased sympathetic stimulation and circulating
catecholamines released during exercise increase intracellular Ca2+,
resulting in enhanced myocardial contractility during exercise.

Similar to the effects on skeletal muscle,8 the plasticity of the heart allows
for adaptation to repetitive bouts of exercise. This adaptive state following training
elicits significant cardioprotection from cardiac insults including myocardial
ischemia,16, 17 pressure-overload (i.e. TAC),18 and diabetic cardiomyopathy.19 Part
of this cardioprotection is associated with improvements in cardiac function. The
exercise-adapted heart, also known as athlete’s heart, is associated with modestly
enhanced diastolic function, whereas systolic function is primarily unaffected.20
This improvement in diastolic function can be linked back to those factors affecting
preload. Endurance exercise training has been well documented to result in
hypervolemia21 which contributes to increases in preload and cardiac output.
Additionally, exercise reduces not only resting HR, but also the HR achieved at
submaximal workloads, providing additional filling time for preload.14 The chronic
effects of exercise on decreasing afterload in heathy individuals are not as large,
as systolic blood pressures are only slightly reduced; however, in hypertensive
individuals, exercise has a slightly greater effect size.22 At the cellular level,
enhanced cardiac contractility contributes significantly to the improvement in
cardiac performance. In exercise-trained rodents, fractional shortening improves
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40-50% while relaxation rates improve 20-40%.23 These improvements are, in part,
explained by an increase in myofilament sensitivity to Ca2+.24 Additionally, exercise
has been shown to increase the activity of SERCA2a and phospholamban,
contributing not only to enhanced Ca2+ release required for excitation-contraction
coupling but also Ca2+ reuptake into the sarcoplasmic reticulum for relaxation.23, 25
In addition to improving Ca2+ handling, regular exercise promotes cardiac
growth, also referred to as physiological hypertrophy. This form of remodeling is
characterized by a 10-20% increase in cardiac mass. Endurance exercise
selectively induces an eccentric form of hypertrophy, wherein an increase in left
ventricular (LV) volume is met with an equal increase in LV and septal wall
thicknesses, coordinated by an increase in cardiomyocyte width and length. This
is in stark contrast to a pathologic form of hypertrophy, where a much larger
increase in LV volume is accompanied by a preferential myocyte lengthening,
leading to wall thinning. Concentric hypertrophy, more prominent in pathology due
to chronic elevations of afterload, is characterized by wall thickening as
cardiomyocytes increase in width more so than length, reducing LV volume. While
some strenuous exercise, such as weight training may induce a milder form of
concentric hypertrophy, it is not believed to pathologic.26, 27 Also, different from
pathological hypertrophy is the observation that following only a few weeks of
detraining in college and Olympic athletes, physiological hypertrophy regresses,
indicating exercise-induced cardiac growth is a reversible phenotype.28, 29
Other important factors also clearly distinguish these different forms of
hypertrophy. For example, physiologic and pathologic hypertrophy differ

10

significantly in their signaling mediators and transcriptional responses. In
particular, while pathological hypertrophy is associated with the induction of the
fetal gene program (e.g. ANP, BNP, β-MHC, smooth muscle α-actin), physiological
hypertrophy is not.30 Additionally, the molecular signaling events driving
physiologic growth of the myocardium following exercise training are distinct. The
most well established signaling and transcriptional events governing exerciseinduced physiologic growth are discussed below and in Fig. 2:

1. IGF1: Insulin-like growth factor 1 (IGF1), and its receptor (IGF1r) is the
best described and potentially most important signaling event governing
exercise-induced cardiac growth. Acute exercise increases the release
of growth hormone (GH) from the anterior pituitary gland which acts
distally on the liver to increase IGF1 production.31 Additionally, exercise
increases local IGF1 production in several target tissues, including the
heart, thereby acting in an autocrine and/or paracrine fashion.32 Several
transgenic mouse models have demonstrated the critical role of IGF1 in
regulating physiologic cardiac growth. Both Igf1- and Igf1r1-null mice
display a growth retardation phenotype with high perinatal mortality33
while Igf1 overexpressing mice display a physiologic form of cardiac
hypertrophy.34 Furthermore, cardiomyocyte-specific deletion of Igf1r1 in
adult mice prevents exercise-induced cardiac growth.35 These results
clearly demonstrate the importance of IGF1 signaling in not only
exercise-induced cardiac growth, but perinatal development as well.
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Figure 2: Exercise-mediated cardiac adaptive signaling pathways. Signaling
pathways involved in the adaptation to exercise training. Physiologic growth is
initiated by IGF1 through the IGF1/PI3K/AKT axis. Activation of AKT
downregulates Cebpb transcription, allowing the upregulation of CITED4. This
cascade leads to the upregulation of gene sets specific to promote cardiomyocyte
growth. Inactivation of PTEN is also associated with the upregulation of the
IGF1/PI3K/AKT signaling cascade. Nrg1, through ErbB, also activates AKT and
leads to adaptive signaling events. Mitochondrial biogenesis also occurs through
the IGF1/PI3K axis that may or may not involve AKT signaling. However, AKT
signaling does upregulate the transcription of Pgc1α, resulting in the upregulation
of adaptive metabolic gene sets. Catecholamine surges during exercise activate
β-adrenergic receptors, leading to eNOS activation and the production of NO to
increase cardiac perfusion. AMPK, an cellular sensor of the energy state of the
cell, is also involved in the activation of eNOS as well as AKT, contributing to the
overall adaptive response. Abbreviations: IGF1, insulin-like growth factor-1; IGF1r,
insulin-like growth factor-1 receptor; Nrg1, neureglin1; ErbB, member of epidermal
growth factor receptors; β-AR, beta-adrenergic receptor; PI3K, phosphoinositide3 kinase; PTEN, phosphatase and tensin homolog; Akt, protein kinase B; C/EBPβ,
CCAAT/enhancer binding protein β; Cited4, cbp/p300-interacting transactivator
with Glu/Asp-gamma co-activator 1α; PGC1α, peroxisome proliferator-activated
receptor gamma coactivator 1-alpha; eNOS, endothelial nitric oxide synthase; NO,
nitric oxide; AMPK, AMP-activated protein kinase.
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2) PI3K: IGF1r phosphorylation causes the activation of PI3-kinase, an
intracellular family of signal transducing enzymes. Specifically, the
activity of the PI3K (110 α) isoform appears to be necessary and
sufficient for IGF1-mediated physiologic growth, as expression of a
cardiac-specific dominant-negative PI3K (110 α) prevented exerciseinduced cardiac growth in mice.36 Conversely, constitutive activation of
PI3K (110 α) in the heart promotes a physiologic form of hypertrophy.36,
37

In addition to the direct role of PI3Ks in regulating cardiac growth,

deletion

of

Pten

(phosphatase

and

tensin

homolog),

which

dephosphorylates PI3Ks, has also been shown to mediate cardiac
growth.38 Thus, the signaling events propagated by PI3K, and its
regulation by PTEN, are critical for the physiologic growth response.

3) AKT: The serine/threonine-specific protein kinase B, also known as
AKT, also plays a critical role in physiologic hypertrophy. Functioning
downstream of PI3K, exercise training enhances the phosphorylation
state of AKT at both the threonine 308 and 473 residues.35, 39-42 This
activation of AKT is required for the hypertrophic response as mice with
genetic deletion are resistant to exercise-induced cardiac growth.43
Interestingly, cardiac-specific overexpression of a constitutively active
form of AKT, while initially promoting a physiologic form of hypertrophy,
progressed to a pathologic form, suggesting that duration, and likely also
intensity, determine the cardiac response to AKT signaling.44
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4) C/EBPβ and CITED4: Recent studies have identified transcriptional
events downstream of AKT activation that are essential for exerciseinduced physiologic growth. For example, exercise training was shown
to downregulate cardiomyocyte expression of the CCAAT/enhancer
binding protein-β (C/EBPβ), in an AKT-dependent manner. In that study,
cardiomyocyte-specific

overexpression

of

C/EBPβ

resulted

in

physiological hypertrophy and resistance to the pathologic response to
pressure overload.45 Additionally, the exercise-induced transcriptional
downregulation of Cebpb led to the transcriptional upregulation of
Cited4,45 and overexpression of Cited4 was show to be sufficient to drive
physiologic cardiac growth and promote recovery from ischemic injury.46
While C/EBPβ and CITED4 are important for mediating the response to
exercise, additional mechanisms of activation and downstream targets
require further investigation.

5) Additional effectors of physiologic cardiac growth: Several other factors
have been shown to be involved to some degree in the response to
exercise. Nueregulin 1 signaling through the ErbB family of tyrosine
kinase receptors produces similar effects to that observed in the
exercise-adapted heart, in part, through the activation of AKT.47 AMPactivated protein kinase (AMPK), important for its role in cellular energy
homeostasis, has been suggested to play a role in the development of
both physiologic and pathologic hypertrophy.27 Additionally, signaling

15

though MAPK (mitogen-activated protein kinase)48 and mTOR
(mechanistic target of rapamycin)44 have also been suggested to play
roles in governing the cardiac hypertrophic program.

Recent evidence suggests that cardiomyocytes, once thought incapable of
regeneration and proliferation, may in fact do so at a low rate in the adult heart.4951

Increasing lines of evidence also suggest that exercise not only stimulates

cardiomyocyte hypertrophy, but potential hyperplasia as well. Rodents subjected
to exercise show elevated makers of proliferation such as PCNA expression, Ki67
positivity, and BrdU incorporation in the heart along with the activation of c-kit+ and
Sca-1+ cells, believed to be cardiac progenitor cells.45, 52-54 While these results
suggest that exercise-activated cardiomyocyte proliferation may contribute to
physiological growth, more detailed studies, such as cell fate-mapping are required
before more definitive conclusions can be drawn.
As cardiomyocytes grow in response to exercise, several other adaptive
responses, both intrinsic to the cardiomyocyte and within the myocardium as a
whole, must occur as well. One such response is an enhancement of cardiac
perfusion. This is a critical adaptive response as both increases in workload and a
larger myocyte both have a higher energy and oxygen demand. This increase in
cardiac perfusion occurs primarily through two modes of action, vasodilation and
angiogenesis. First, exercise results in the release of catecholamines which, in
addition to their effect on Ca2+ dynamics and contractility, increases the
phosphorylation of endothelial nitric oxide synthase (eNOS).55 Enhanced eNOS
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activity increases nitric oxide (NO) bioavailability, a potent vasodilator. This effect
is also driven by the exercise-induced activation of AKT and AMPK, both of which
promote the phosphorylation of eNOS.56, 57 Secondly, chronic exercise training
induces an angiogenic response within the myocardium, resulting in de novo
capillary formation.58 This angiogenic response is in part associated with exercisemediated increases in VEGF secretion59 and circulating angiogenic progenitor
cells.60
The most common metabolic adaptation of the heart to exercise is
mitochondrial biogenesis.61-63 While various signaling events likely lead to an
increase in mitochondrial mass, exercise-induced increases in peroxisome
proliferator-activated receptor 𝛾 coactivator 1α (PGC-1α) play a critical role.64
Interestingly, induction of PGC-1α in response to exercise was prevented in IGF1r
knockout mice, and it has been shown that signaling through PI3K, but not AKT,
is required for this biogenic response.35,

65

Accompanying the increase in

mitochondrial mass, respiratory function and capacity appears to be enhanced in
the physiologically hypertrophied heart. In both isolated permeabilized cardiac
muscle fibers65 and the isolated perfused heart,40, 66 exercise training increased
the rate of mitochondrial fatty acid oxidation (FAO). This is in part due to the
increase in mitochondrial mass, but also the upregulation of genes associated with
FAO.67
In addition to FAO rates, others have shown an increase in glucose
oxidation (GO) as well.66 This enhanced metabolic capacity of the exercised heart
is a hallmark characteristic, distinguishing it from pathologic forms of hypertrophy
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where it is well accepted that metabolic flexibility and energy homeostasis are
compromised. Therefore, studying the metabolic phenotype of the physiologically
hypertrophied heart may provide therapeutic avenues to treat or delay the onset
of maladaptive pathologic remodeling. In the following section, the acute and
chronic effects of exercise on cardiac metabolism will be discussed in detail.

Cardiac Metabolism in Exercise
The heart has an incredibly high energy demand, which requires continuous
adenosine triphosphate (ATP) generation to sustain contractile function, ionic
homeostasis, metabolic processes, and signaling. While myocardial ATP turnover
is high (~30 µmol ● g wet wt−1 ● min−1), ATP content is relatively low (~5 µmol ● g
wet wt−1) resulting in complete turnover approximately every 10 s.68-70 The heart
fuels this turnover by generating >95% of its ATP from mitochondrial oxidative
phosphorylation with the remaining 5% derived primarily from glycolysis.70,

71

Although the majority (60-70%) of the ATP generated supports contractile function,
30−40% is necessary to maintain ionic homeostasis through ion pumps,
specifically the Ca2+-ATPase in the sarcoplasmic reticulum.72, 73
Basally, it is well accepted that the oxidation of free fatty acids (FFA)
contributes 70−90% to oxidative phosphorylation with glucose, glycogen, lactate,
ketones, and amino acids contributing the remaining 10−30%. With the ability to
utilize a myriad of substrates, the heart is considered a metabolic “omnivore”,
utilizing whichever substrates are available at a given time; however, with multiple
substrates consistently available for use, competition for utilization exists. The
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competition of substrates has long been demonstrated in both in vivo arterialcoronary sinus difference studies74-77 and perfused heart preparations ex vivo.78,
79

The first observation of substrate competition was observed in the isolated

perfused heart by Philip Randle in 196380 In this study, Randle demonstrated that
increasing delivery of FFAs to the heart increased FAO and decreased glucose to
pyruvate conversion and oxidation. Interestingly, exercise is also associated with
the competition of substrates for utilization.
Acute exercise (i.e. an acute increase in workload) has a robust effect on
not only cardiac metabolism. For example, it is estimated that TCA cycle flux
increases 70- to 100-fold in an effort to match energy production to the large
increase in consumption in working muscle.81 In the heart, exercise increases LV
contractile power and myocardial oxygen consumption 4- to 6-fold above resting
rates, which requires a significant increase in the generation of NADH and FADH2,
from substrate oxidation.82 Several ex vivo78, 83 and in vivo84-87 studies demonstrate
that an increase in myocardial workload is accompanied by significant, yet
selective, increases in the metabolism of various substrates. This increase in
myocardial metabolism is accomplished by increased substrate availability and
delivery to the myocardium as well as through extensive intracellular signaling that
regulates substrate selection and utilization, coordinating myocardial metabolism.
The effects of exercise on individual substrate metabolism is discussed below and
in Fig. 3:
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Fatty Acids: As already mentioned, the oxidation of FFA contributes the most to
energy provision in the normal healthy heart. Because of their hydrophobic
properties, FFA are bound to albumin for transport in circulation at a concentration
of 0.2−0.6 mM;88, 89 however, during an acute bout of exercise, these levels can
increase to 2.4 mM.89 Because the availability of circulating FFAs is a primary
determinant of their uptake by the myocardium,74 the exercising heart
demonstrates enhanced rates of FFA uptake.90 This increase in circulating FFAs
during exercise is primarily due to elevations in catecholamines, which activate
hormone sensitive lipase in adipose and skeletal muscle tissues to de-esterifies
FFAs and promote their release into circulation.91 Exercise likely also facilities the
translocation of fatty acid translocase (FAT)/CD36, the primary protein carriermediated transporter for FFA uptake, as it has been shown that contracting
skeletal muscle acutely increased its localization to the plasma membrane;92, 93
however, this effect has yet to be confirmed in the heart.
Following uptake, FFAs are esterified to fatty acyl-coenzyme A (CoA) by
fatty acyl CoA synthase and either transported into the mitochondria for eventual
beta-oxidation or used for the synthesis of triacylglycerides (TAGs). At rest, human
isotopic labeling studies measuring

14

CO2 production in coronary venous blood

indicate that 84% of the FFA taken up by the cell are immediately oxidized, leaving
~26% available for entry into the TAG pool.94 This contribution to the TAG pool is
not trivial, as intramyocardial TAG turnover occurs in as little as 5 h and contributes
10% to the total energy expenditure of the heart.82, 95 Interestingly, myocardial TAG
utilization rates were found to be increased considerably under exercise conditions
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as measured by a significant release of free glycerol, suggesting increased
hydrolysis of intramyocardial stores.87 In an ex vivo heart preparation, this increase
in TAG turnover was a function of increased lactate availability, suggesting that
lactate, which is elevated during exercise, stimulates FAO and the turnover of TAG
stores. This conclusion was made by the observation that lactate in the perfusion
buffer increased intracellular fatty acid content and free glycerol release, while
maintaining TAG levels in the myocardium.96 With respect to FAO rates, elevated
circulating FFA levels, as occurs during exercise, enhances myocardial utilization
for beta-oxidation and ATP production as indicated by isotopic labeling studies
measuring 14CO2 production.94

Lactate: While the heart produces a considerable amount of lactate at rest,

14

C-

lactate tracer studies calculating arterial-coronary sinus differences indicate the
heart consumes an even greater amount of lactate, making the heart a net lactate
consumer.77, 90, 97, 98 Myocardial lactate uptake, which is positively correlated with
arterial lactate concentration, is almost entirely used for oxidation.84 Under
conditions of elevated arterial concentrations (e.g. exercise), lactate oxidation is
significantly enhanced.79,

85

This increase in lactate oxidation appears to be

correlated with exercise intensity, which determines arterial lactate levels. Under
lower exercise intensities, the contribution of lactate oxidation to myocardial
oxidative metabolism increased from 13% to 28% and was considerably higher
than glucose oxidation (8-14%).84 However, during intense exercise lactate levels
can increase 10-fold, from 1 mM to 10 mM, and it has been suggested that the
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Figure 3: Myocardial metabolism during exercise. Schematic of cardiac
metabolism in exercise. Acute exercise results in changes in the bioavailability and
utilization of both external (arterial concentrations) and internal (intracellular
storage depots) energy substrates for ATP production. Arrows are indicative of
changes in both bioavailability and utilization by the myocardium during exercise.
For diagrammatic simplicity, the mitochondrion is shown as a single membrane,
with CPT1/2 shown as an aggregate of the canitinylation and reCoAcylation steps
required for entry of fats into the mitochondrion for beta oxidation. Similarly, as
several GLUT and MCT isoforms are present in the heart, they are
diagrammatically represented as a family of transporters. Abbreviations: FFA, freefatty acids; FAT/CD36, fatty acid translocase; GLUTs, glucose transporters; MCTs,
monocarboxylate transporters; G6P, glucose-6-phosphate; F6P, fructose-6phosphate;

F-1,6-P2,

fructose-1,6-bisphosphate;

F-2,6-P2,

fructose-2,6-

bisphosphate; GAP, glyceraldehyde-3-phosphate; DHAP, dihydroxyacetone
phosphate;

PFK1,

phosphofructokinase

1;

PFK2,

phosphofructokinase-

bisphosphatase 2; LDH, lactate dehydrogenase; PDC, pyruvate dehydrogenase
complex; TAG, triacylglyceride; CPT1,2, carnitine palmitoyl transferase 1 and 2.

22

FIGURE 3
FFA

Glucose

Lactate
Blood Vessel

MCTs

Glycogen
GLUTs

Glucose

PFK2

F-2,6-P2
+

F6P

G6P

PFK1

-

LDH

F-1,6-P2

Citrate, ATP,

TAG Turnover

GAP/DHAP

CPT1

FAT/CD36

Pyruvate

H+
Cytosol

PDC

Mitochondria

Fatty
acyl-CoA

Cardiomyocyte

Acetyl-CoA

CPT2
Mitochondrial
β-Oxidation

ATP
Production

23

Citric Acid
Cycle

contributions of lactate to total oxidative metabolism under these conditions may
in fact be much higher, accounting for 60-90% of substrate utilization.85, 99-101
The effects of exercise training on myocardial lactate metabolism are not
well known and is complicated by the fact that a primary effect of training is the
reduction of arterial lactate levels for a given sub-maximal intensity.102 Because
lactate utilization is a consequence of its availability, this would suggest that lactate
oxidation and its contribution to myocardial oxidative metabolism may be
diminished in the trained heart. However, it is likely that training results in metabolic
adaptations similar to those seen for fatty acid metabolism. For example, recent
studies have suggested that training increases LDH activity,103 decreases the Km
for conversion of lactate to pyruvate,104 and increases the monocarboxylic
transporter (MCT1) responsible for lactate uptake,105 all of which would contribute
to enhanced lactate oxidation at a given concentration. Often rarely considered as
a myocardial substrate, the importance of lactate to energetics and performance
should not be understated. In a recent study by Levy et. al., systemic lactate
deprivation resulted in cardiac energy deprivation and dysfunction,106 highlighting
the importance of lactate as an energy source.

Glucose: Under resting conditions, glucose is the most abundant substrate
available to the myocardium with a circulating concentration of 4–5.5 mM in healthy
individuals. While availability is not an issue, the heart preferentially utilizes FFA
for oxidative metabolism with contributions of glucose equal to that of lactate
(~17%).107 This is somewhat surprising considering that glucose is a much more
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efficient carbon source than FFAs, indicated by the phosphate to oxygen ratio
(P/O) for complete oxidation of substrates,108 which would make glucose a more
efficient source of energy during increased workloads. As with FFAs and lactate,
glucose uptake by the myocardium is also dependent on arterial concentrations;
however, arterial glucose concentrations are tightly controlled and do not generally
fluctuate. During highly intense (e.g. weightlifting) and prolonged endurance
exercise, arterial glucose concentrations have been shown to diminish,89 while
others report that high intensity aerobic exercise resulted in an increase in blood
glucose.86 Interestingly, this increase in arterial glucose was not associated with
an increase in glucose uptake indicated by positron emission tomography utilizing
2-[18F]fluoro-2-deoxy-D-glucose; however, during lower intensities glucose uptake
was increased with no change in arterial levels.86 These results of glucose uptake
under lower intensities were in agreement with a previous report by Gertz et al.;84
however, others have reported diminished glucose uptake during exercise.87, 109
Glucose uptake is facilitated by protein carrier-mediated transport through
a family of glucose transporters (GLUT), with the insulin-dependent GLUT4 as the
most abundant in cardiac tissue.110 Exercise increases the translocation of GLUT4
to the cellular membrane in part by catecholamine activated β-adrenergic
signaling111,

112

and through the exercise-induced activation of AMPK.113

Interestingly, this translocation appears to be insulin-independent as circulating
insulin levels are diminished during exercise.114 Activation of AMPK also increases
phosphorylation of phosphofructokinase 2 (PFK2) at the S483 residue, which
increases the levels of fructose-2,6-bisphosphate (F-2,6-P2), a potent activator of
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PFK1 activity in the heart. If this occurs in the exercising heart, glycolytic rates
would likely be elevated. Interestingly, increased utilization of glucose during
exercise does not increase lactate release from the myocardium but rather
promotes enhanced glucose oxidation,84 in part, by increasing muscle pyruvate
kinase activity.115 This would suggest that a primary effect of exercise is to increase
the coupling of glycolysis to glucose oxidation. Improved coupling of glycolysis and
glucose oxidation, especially if glucose uptake is diminished during exercise,
would be advantageous as it would increase the proportion of glucose that
contributes to energy production.
Another source of glucose for the myocardium is the intracellular storage of
glycogen. Although the glycogen pool is only 20% of that of skeletal muscle,
myocardial glycogen turnover can be high.116 Interestingly, a small amount of
glucose that enters the glycogen pool is immediately cycled back out for eventual
conversion to pyruvate;117 the significance of this cycling, however, and its
relevance in exercise, is not well understood. The effects of glycogen content are
more well defined under increased workloads. Acute increases in work stimulated
by epinephrine increase glycogen breakdown via glycogen phosphorylase,83, 117,
118

which is preferentially used for oxidation rather than lactate production as

shown by isotopically (13C) saturating the glycogen pool.118,

119

Conversely,

glycogen synthesis by glycogen synthase, increases during fasting120-122 and when
competing substrates (FFA and lactate) predominate in their oxidation.123,

124

Because catecholamines, FFA, and lactate are all elevated during exercise, the
effects of exercise on glycogen content are likely subject to duration, intensity, and
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the time at which such measurements are made. For instance, it is likely that at
the onset of exercise, prior to an increase in substrate availability, glycogen is
broken down to meet the abrupt increase in ATP demand. Once arterial FFA and
lactate levels rise over time, glycogen breakdown is inhibited and synthesis occurs.
Because of these competing effectors of glycogen metabolism, a well-controlled
study is required to fully understand the effects of exercise intensity and duration
on glycogen metabolism.

Ketones and Amino Acids: Ketone bodies, acetoacetate and βhydroxybutyrate, can contribute to oxidative metabolism through their conversion
to acetyl-CoA, and similar to FFA and carbohydrates, uptake and oxidation is
positively correlated to their arterial concentration.125 However, ketone bodies
themselves are insufficient to meet the energetic need of the heart, both in vivo126
and ex vivo.127 While ketone bodies may play a significant role in energy provisions
in the pathologic heart,128 their contributions to the exercising and physiologically
hypertrophied heart are likely minimal.
Amino acids play an important role in contributing several carbon-based
intermediates to the TCA cycle. For instance, alanine can undergo transamination
to form pyruvate for oxidation, glutamine can enter at the point of α-ketoglutarate,
and aspartate can be converted to oxaloacetate, all providing TCA intermediates.
Additionally, the malate-aspartate shuttle is important in transferring the reducing
equivalent NADH generated from cytosolic glycolysis and lactate to pyruvate
conversion, into the mitochondria for the ETC. This reaction in turn regenerates
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cofactor levels of NAD+, required for glycolysis and LDH activity. In the working
heart, only leucine, a branched chain amino acid, has been shown to contribute to
oxidative substrate utilization, albeit to a minimal (0.4%) degree.129 Similar to
ketone bodies, amino acid metabolism in the context of exercise is not well
understood.

While understanding how exercise affects the metabolism of individual
substrates provides invaluable information, integration of the metabolism of all
substrates becomes much more complex, but provides a more complete picture.
A more complete and thorough interrogation of myocardial metabolism can be
obtained by measuring the utilization of all substrates and the regulation each
imposes on the other. For example, in a study by Schonekess, hearts perfused at
a constant workload had significantly diminished contributions of glycolysis and
glucose oxidation to ATP production when FFA levels were increased to a
physiologic range associated with exercise; interestingly, this observation was also
made when lactate in the perfusion buffer was increased to physiologic exercising
levels.79 In a similar ex vivo study, workload was increased by epinephrine in the
presence of exercising levels of lactate and FFAs, which blunted the increase in
glucose utilization.78 Similar results from in vivo studies further support that
although an increase in cardiac workload is typically associated with an increase
in glucose uptake and oxidation in the myocardium,78, 83, 84, 86 when concentrations
of lactate and FFAs were increased, glucose uptake and oxidation were
diminished.78, 86, 87, 109
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The diminishment in glucose utilization most likely occurs through allosteric
inhibition of key glucose-metabolizing enzymes. For instance, acetyl-CoA derived
from the oxidation of FFA in the mitochondria inhibits PDH activity, reducing the
oxidation of glucose-derived pyruvate. Furthermore, the subsequent increase in
citrate is inhibitory to the rate-limiting and committed step of glycolysis,
phosphofructokinase 1, and to a lesser extent glucose uptake. The magnitude of
inhibition increases along the glycolytic pathway with PDH inhibition being the most
severe and glucose uptake the least.130, 131 Lactate oxidation also acts to inhibit
glycolytic flux by reducing the bioavailability of NAD+, a cofactor for
glyceraldehyde-3-phosphate dehydrogenase, and decreasing H+ extrusion which
is inhibitory to PFK1. Collectively these results suggest that during exercise, when
arterial lactate and FFAs increase, glucose utilization is likely diminished.

Metabolism as a Contributing Factor to Growth
In tissues such as skeletal muscle, adaptive changes in gene expression
are thought to be initiated by the repetitive bouts of metabolic stress triggered by
strenuous physical activity.8 As acute and chronic exercise alter cardiac
metabolism, it could be hypothesized that these changes could contribute to the
adaptive response; however, understanding the mechanisms and pathways
involved is difficult due to the complex and integrative nature of metabolism. Of
particular interest is the metabolism of glucose via glycolysis, which is highly
regulated during exercise. A central pathway of intermediary metabolism, the fate
of glucose is not only limited to pyruvate or lactate for energy production, but it also
29

contributes to several ancillary pathways of glucose metabolism, such as the
pentose phosphate pathway (PPP) and the glycerolipid synthesis pathway (GLP).
These pathways provide the first rationale for how changes in glucose utilization
could contribute to the cardiac adaptation to exercise.
The simplest explanation as to why changes in metabolism would precede
and contribute to cardiac growth is by providing a material cause necessary for
that growth. This material cause comes in the form of the DNA, amino acids,
proteins, and phospholipids that are required for cellular growth. For example, in
the oxidative phase of the PPP, the metabolism of glucose-6-phosphate (G6P)
reduces NADP+ to NADPH which is required for glutathione recycling and anabolic
reactions. End products of the non-oxidative phase, however, are critical in the
generation of ribose 5-phosphate, the precursor for purine and pyrimidine
nucleotide biosynthesis. These nucleotides are the organic structure serving as
the basis for the synthesis of DNA, RNA, and nucleic acids, without which growth
cannot occur. In the heart, the PPP is activated during pathological hypertrophy132134

and heart failure,135 and modulating pathway activity regulates the severity of

cardiac pathology.136-141 Similarly, growth of a cell cannot occur without expansion
of the cellular membrane which requires increased bioavailability of phospholipids
derived from the GLP. Although less is known about the GLP, increased pathway
activity may in fact contribute to pathologic cardiac hypertrophy.142 In the
exercising heart, very little is known with regards to pathway flux through the PPP
and GLP. However, during exercise when FFA and lactate oxidation increase,
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allosteric inhibition at the point of PFK1 may in fact coordinate flux through these
pathways, as has been shown in several non-cardiac cell types.143-146
Another biosynthetic pathway branching off glycolysis is the hexosamine
biosynthetic pathway (HBP), which could also be influenced by changes in PFK
and glycolytic activity. Requiring a sugar donor, the synthesis of O-linked β-Nacetylglucosamine (O-GlcNAc), a monosaccharide donor for nuclear and cytosolic
proteins, can alter protein function, gene transcription, and modulates cell survival
under conditions of stress.147-150 While several molecular signaling pathways are
well understood in the exercised heart, post-translational O-GlcNAcylation is a
relatively new area of investigation. In rats, an acute bout of swim training resulted
in a 30% increase in skeletal muscle UDP-hexosamine concentrations that
persisted for 16 h following exercise;151 however, in mouse hearts following 15
mins of treadmill exercise, O-GlcNAc levels were diminished. Interestingly, in these
same mice, de-O-GlcNAcylation of O-GlcNAc transferase (OGT), the enzyme
responsible for catalyzing the addition of the GlcNAc moiety to proteins, resulted
in dissociation from the repressor element 1 silencing transcription factor complex
and initiation of physiological growth signaling.152 Following training, the
physiological hypertrophied heart is associated with decreased O-GlcNAc levels
and a reduced expression of several regulatory enzymes in the HBP.153, 154 The
results from these studies suggest that exercise-induced changes in metabolism
and coordinate changes in HBP flux could contribute to the physiologic growth
program.
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Another potential role for metabolism in regulating the cardiac adaptive
response to exercise is through direct intracellular signaling of metabolites
themselves. For instance, an increase in G6P levels in ex vivo hearts subjected to
increased workload, which is likely to occur in vivo during exercise when glucose
utilization rates are diminished, leads to the activation of mTOR.155 Another
example of a metabolite acting in a direct signaling manner is 5-Aminoimidazole4-carboxamide ribonucleotide (AICAR), an intermediate of the PPP. An analog of
adenosine monophosphate (AMP), AICAR stimulates AMPK, increasing its
activation state.156 As mTOR and AMPK are implicated to play a role in the
exercise-induced adaptation, metabolites as direct signalers may play a critical role
in the activation of the physiologic growth program.
Based on the literature discussed within this section, there appears to be
ample evidence to suggest that metabolism may play a contributing role to the
adaptive response to exercise, preceding and triggering physiologic growth of the
heart. This raises several questions: How does exercise acutely and chronically
affect myocardial metabolism?; Do changes in metabolism contribute to the
exercise-induced adaptation of the heart?; and if so, how does metabolism activate
the programs of exercise-induced physiologic growth? These questions and
fundamental concepts led to the development of the following studies, which
sought to identify the role of metabolism in exercise-induced cardiac remodeling.
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CHAPTER II
FVB/NJ MICE ARE A USEFUL MODEL FOR EXAMANING CARDIAC
ADAPTATIONS TO TREADMILL EXERCISE

Introduction
Regular

exercise

improves

cardiovascular

health,5-7

augments

musculoskeletal function,8 and increases both healthspan8-10 and lifespan.5, 11-13
Nevertheless, the molecular mechanisms by which exercise promotes health are
poorly understood.157 Exercise studies commonly use murine models, which are
valuable for identifying critical gene programs that contribute to exercise
adaptation, primarily, because they offer the benefit of relatively rapid and
controlled genetic modification [e.g.,

25, 40, 158, 159

]. Nevertheless, sources of

variability in such studies could confound our understanding of how exercise
mitigates disease or increases overall health. Minimization of confounding factors
is an important consideration for designing exercise studies as well as for
interpreting the results obtained.
Although mouse models cannot perfectly recapitulate the complex
physiological changes occurring in humans with physical activity, they can
phenocopy particular aspects of physiological adaptation. For this purpose, three
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models of mouse exercise are used frequently: treadmill training, forced swimming,
and voluntary wheel running. While each of these models have advantages and
limitations,158,

160

treadmill training provides the investigative advantage of

controlling the amount of work performed in each training session, which is critical
for understanding dependency of (patho)physiological adaptations on exercise
workload and becomes increasingly important in studies of mice having different
masses (e.g., obesity studies). Unlike the treadmill modality, work cannot be
calculated easily in swimming or voluntary wheel exercise. For these reasons,
treadmill training is a reliable, well-controlled, and often superior model of exercise
for research studies. Nevertheless, several factors contribute to treadmill exercise
(non)compliance and to exercise-induced adaptations. These include, but are not
limited to, mouse strain, exercise environment, acclimatization, motivation, and
assessments of exhaustion.52, 161
Of these, mouse strain is of principal importance. Inbred strains of mice and
rats have pronounced differences in their ability to exercise, or their choice to do
so.162-166 A preponderance of genetic mouse models are on the C57BL/6J or the
FVB/NJ background167,

168

; however, these strains show strikingly different

preferences and capacities for exercise. For instance, C57BL/6J mice appear to
be poor treadmill runners, yet display superior capacity on voluntary exercise
wheels, while the opposite is true for FVB/NJ mice.163, 166 The reason(s) for these
differences in training modality preference remain unclear. One reason could relate
to the fact that laboratory mice are primarily nocturnal animals, demonstrating the
highest activity and food consumption during the night cycle169-171; however, to our
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knowledge, the impact of time of exercise (day or night) on treadmill exercise
capacity and compliance has not been investigated. The goals of this study were:
(1) to test for differences in treadmill exercise capacity and compliance between
C57BL/6J and FVB/NJ mice; (2) to delineate whether diurnal or nocturnal training
influences exercise compliance and adaptive responses to training; and (3) to
assess systemic and cardiac-specific exercise adaptations in mice compliant with
treadmill exercise protocols. Our study demonstrates that FVB/NJ mice are a
superior strain for treadmill exercise and that the timing of treadmill exercise, at
least in this strain, does not influence compliance or exercise-induced adaptation.

Experimental Procedures
Animals. All procedures were approved by the University of Louisville Institutional
Animal Care and Use Committee. C57BL/6J and FVB/NJ mice were ordered from
Jackson Laboratory (Bay Harbor, ME) at 12 weeks of age and allowed to acclimate
at the University of Louisville animal facility for three weeks. At 15 weeks of age,
male mice were assigned randomly by strain to sedentary (SED) or exercise (EXEDay or EXE-Night) groups. Food and water were provided ad libitum, and the mice
were maintained on a 12:12-h light-dark schedule. Because the majority of
published studies regarding exercise in mice have utilized male mice, we chose
this gender for our study, which enables comparison with the literature. At the
conclusion of the study and 24 h after the last exercise session, the mice were fully
anaesthetized with sodium pentobarbital (40 mg/kg, i.p.), followed by euthanasia
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via excision of the heart. These procedures are consistent with the AVMA
Guidelines on Euthanasia.

Metabolic phenotyping. To assess for differences in basal metabolism and
diurnal/nocturnal behavior, metabolic cage analyses were performed in naïve 15week-old C57BL/6J and FVB/NJ mice, essentially as described.172, 173 Body weight
was recorded prior to the initial and final exercise capacity tests to assess for
changes in total body mass. Oxygen consumption rates, carbon dioxide production
rates, respiratory exchange ratios, food consumption, water consumption and
activity (sum of ambulatory and fine movements) were measured using a
physiological/metabolic cage system (TSE PhenoMaster System, Bad Homberg,
Germany) as previously described.172, 173

Exercise capacity testing. We performed exercise familiarization and capacity
testing in a manner similar to that outlined previously,166 with minor modifications
(Fig. 4A,B). Mice were familiarized to the motorized rodent treadmill (Columbus
Instruments, Columbus OH) on the Wednesday and Thursday before the first week
of training. Familiarization consisted of an initial 10 min period where the treadmill
speed and incline were set to zero with shock grid settings of 25 V, 0.34 mA, and
2 Hz. The treadmill speed was then increased steadily to 10 m/min (Wed) and 12
m/min (Thurs) for an additional 10 min.
On the Friday immediately following familiarization to the treadmill, we
subjected mice to an exercise capacity test (Fig. 4B). For this, the mice were
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acclimated to the treadmill for 10 min, with the speed and incline set initially to
zero. The treadmill speed was then increased to 8.5 m/min with an angle of
inclination set to 0° for 9 min. Next, the treadmill speed and incline were increased
to 10 m/min and 5°, respectively, for 3 min. The speed was then increased by 2.5
m/min every 3 min to a maximum speed of 40 m/min, while inclination increased
by 5° every 9 min until a maximum incline of 15° was achieved.
We developed strict a priori criteria for exercise-induced exhaustion. These
criteria were: 1) 10 consecutive seconds on the electric grid; 2) spending more
than 50% of time on the grid; and/or 3) lack of motivation to manual prodding. Each
mouse was removed immediately from their respective lane once one or more of
these criteria was reached. Following the protocol, the mice were housed
separately for 30 min to avoid noticeable aggressive behavior following exercise.
Following 4 weeks of training, we repeated this testing protocol to assess
changes in exercise capacity. Exercise capacity was measured using the
parameters of distance run (meters achieved prior to exhaustion) and work
accomplished [calculated as the product of body weight (kg) and vertical distance
(m); vertical distance = (distance run)(sinθ), where θ = the angle of inclination of
the treadmill from 0°-15°] as outlined previously.166

Exercise training. Mice assigned to exercise training groups were subjected to a
4-week protocol of forced treadmill running. The training protocol commenced the
Monday after the initial exercise capacity testing with mice exercising 5 d/wk (MonFri) at 70 or 75% of the maximal speed achieved during the initial exercise capacity
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Figure 4: Exercise testing and training design. Schematic of the familiarization,
testing, and treadmill training design: (A) General treadmill training design
including: familiarization, pre- and post-exercise capacity testing, and exercise
training regimen; (B) Exercise capacity testing protocol; and (C) Treadmill training
regimen including: warm-up and exercise training intensity and durations, and
post-training housing.
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FIGURE 4
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test and an inclination appropriate to the speed (Fig. 4C). Prior to each training
bout, we provided mice with a “warm-up” period of 10 min at 0 m/min and 10 min
at 12 m/min to promote exercise protocol compliance and to minimize risk of injury.
For strain comparison and night versus day training groups, training intensity was
set at 20.8 m/min, 10° incline for FVB/NJ mice and 16.4 m/min, 5° incline for
C57BL/6J mice, which corresponded to 70% of the maximal speed and the
appropriate incline at the calculated speed for each strain during the initial exercise
capacity test. In subsequent studies of FVB/NJ mice, mice were exercised only
during the day, and in these groups, we implemented a more intensive training
protocol to further examine systemic, cardiometabolic and skeletal muscle
adaptations to treadmill running. For this, training intensity was set at 75% of the
maximal initial exercise capacity, which corresponded to 22.3 m/min at a 10°
incline. In all groups, we progressively increased the workload of the mice, such
that they trained for 40 min during week 1, 50 min during week 2, and 60 min during
weeks 3 and 4. We chose this progressive intensity protocol to prevent training
plateau and to stimulate systemic as well as cardiovascular and skeletal muscle
adaptations.166, 174-176

Assessment of protocol compliance. To prevent injury and record protocol
compliance, we monitored the mice carefully during each exercise session. Upon
meeting pre-established indicators of exhaustion, mice were removed from the
treadmill, and the time run was recorded (See Table 1). We used the percentage
of total sessions and total minutes completed throughout the 4-week training
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program as a measure of compliance. Before and after the initial exercise capacity
test, we measured blood lactate levels, which provided a biochemical indicator of
exercise-induced

exhaustion

at

or

near

maximal

oxygen

consumption

(VO2max).177-180 We recorded lactate concentration in 0.7 μl of blood from a small
tail clip (Lactate Plus meter; Nova Biomedical) prior to the protocol and upon
meeting the exhaustion criteria defined above. High lactate levels increase
confidence in a successful exercise capacity test by ensuring that failure to
continue is due to exhaustion at or near VO2max and not a failure to comply with
the protocol.181-183

Histology. Following euthanasia, tissue was excised and rapidly fixed for
immunohistochemical analysis or immediately snap frozen in liquid nitrogen and
stored at –80 °C. Tissue was fixed in 10% formalin, paraffin embedded, and
sectioned at 4 µm. Heart cross-sections were stained with 4'6-diamidino-2phenylindole (DAPI; Invitrogen) and wheat germ agglutinin (WGA; ThermoFisher)
for

quantification

of

cardiomyocyte

cross-sectional

area.

Quantitative

measurements were determined using Nikon Elements software.

Relative mitochondrial DNA measurements. Mitochondrial abundance in heart
tissue was estimated by measuring mitochondrial DNA (mtDNA) abundance
relative to nuclear DNA (nDNA), similar to our previous studies.172, 184 Briefly, total
DNA was isolated using a QIAamp DNA Mini Kit (Qiagen). A 25-mg aliquot of the
tissue was homogenized, followed by overnight digestion in proteinase K at 55 °C.
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Following isolation, relative amounts of mtDNA and nDNA were compared using
quantitative real-time PCR, using 2 ng of the isolated DNA. Primers for cytochrome
b (mtDNA) and β-actin (nDNA) were used. The sequences are: cytochrome b, 5’TTGGGTTGTTTGATCCTGTTTCG-3’

and

CTTCGCTTTCCACTTCATCTTACC-3’;

and

5’β-actin,

5’-

CAGGATGCCTCTCTTGCTCT-3’ and 5’-CGTCTTCCCCTCCATCGT-3’.

Statistical analysis: Unpaired or paired Student’s t test was used for direct
comparisons; multiple groups were compared by one-way and two-way ANOVA
followed by Bonferroni or Sidak Multiple Comparison test, as appropriate. For ratiobased statistical comparisons, the data were log-transformed, and unpaired
Student’s t test was applied for assessing statistical significance between groups;
we used a one-sample t test for intragroup differences from a ratio of 1 (used to
determine significant chronobiological differences in metabolic cage endpoints,
i.e., food and water intake, physical movement, VO2, VCO2, RER). A p value of ≤
0.05 was considered statistically significant.

Results
FVB/NJ mice are not nocturnal. Laboratory mice, in general, are a nocturnal
species,169-171 and they typically choose to participate in voluntary exercise at
night.185 Thus, the time at which treadmill protocols are executed could be critical
for ensuring exercise regimen compliance and adaptation. Therefore, we first
examined the circadian characteristics of the mouse strains by measuring their
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food and water intake, locomotion, VO2, VCO2 and RER by placing untrained
(naïve) mice in metabolic chambers. To assess differences between day and night
behavior, a ratio (night values:day values) was calculated for each parameter.
Although overall food consumption was not different between the two strains, the
C57BL/6J mice consumed, on average, 3-fold more food at night. In contrast, the
FVB/NJ mice showed no difference in food consumption in the night compared
with the day (Fig. 5A). Cumulative water intake was not different between the
strains; however, C57BL/6J mice showed significantly higher water intake at night
(Fig. 5B). Similarly, C57BL/6J mice were more active at night compared with
FVB/NJ mice (Fig. 5C). In general, FVB/NJ mice had fewer total beam breaks per
hour (C57BL/6J = 2583 ± 711; FVB/NJ = 1736 ± 582; p < 0.01), indicating that
cage behavioral activity is lower in this strain.
Metabolic analysis yielded analogous results. In C57BL/6J mice, oxygen
consumption (VO2; Fig. 5D), carbon dioxide production (VCO2; Fig. 5E), and
respiratory exchange ratios (RER; Fig. 5F) were higher at night compared with the
day. Conversely, the FVB/NJ mice did not show metabolic differences in the day
versus the night. Thus, the behavioral and metabolic qualities of C57BL/6J mice
are supportive of their known nocturnal nature and are in stark contrast to FVB/NJ
mice which demonstrate a relative lack of features characteristic of the nocturnal
phenotype. Additionally, FVB/NJ mice had higher rates of oxygen consumption
(C57BL/6J = 3,713 ± 327 ml/h/kg; FVB/NJ = 4058 ± 346 ml/h/kg; p < 0.05) which
contributed to lower respiratory exchange ratios (C57 BL/6J = 0.93 ± 0.02; FVB/NJ
= 0.86 ± 0.02; p < 0.0001).
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Figure 5: Chronobiological characteristics of C57BL/6J and FVB/NJ mice.
Ratios of the average night and day values from metabolic cage analysis: (A) Food
intake, (B) Water intake, (C) Total activity, (D) VO2, (E) VCO2, and (F) Respiratory
exchange ratio (RER). n = 10 per group. (*) significance between C57BL/6 and
FVB/NJ, (#) significance from a ratio of 1; *,#p < 0.05, **,##p < 0.01, ***,###p < 0.001.
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Effect of strain and time of treadmill running on initial exercise capacity. To
determine the effects of mouse genetic background on initial exercise capacity, we
subjected 15-week-old C57BL/6J and FVB/NJ mice to exercise capacity testing.
The mice were exercised either during the day (i.e., between 9 am–12 pm) under
normal laboratory lighting or at night (i.e., between 7:00 pm–10:00 pm) under dark
room conditions (safelight red lamp). We chose the latter time based on metabolic
cage activity data, which showed increased voluntary locomotor activity starting at
6 pm. Compared with C57BL/6J mice, the FVB/NJ strain ran ~1.5-fold farther (Fig.
6A) and demonstrated ~2-fold greater initial capacity for treadmill work (Fig. 6B),
regardless of when the mice were tested. Despite an apparent trend toward lower
initial exercise capacity at night, we found no statistically significant differences
between C57BL/6J mice exercised during the day or the night (Fig. 6B&C);
however, FVB/NJ mice showed significantly lower levels of work performed at night
(Fig. 6B).
In preliminary assessments, we observed that C57BL/6J mice received
more shocks than FVB/NJ mice during treadmill exercise. Therefore, to confirm
that reliable exercise capacity values were obtained and to rule out noncompliance to the testing protocol, we recorded blood lactate levels prior to and
immediately following the initial exercise capacity test. Resting blood lactate values
were similar in C57BL/6J and FVB/NJ mice (Fig. 6C). Although it should be noted
that the night C57BL/6J group had a slightly higher resting lactate level, in general,
blood lactate increased by 2–4-fold in both strains upon meeting criteria for
exhaustion (Fig. 6C); both resting and maximal lactate abundances are within the
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Figure 6: FVB/NJ mice display a higher initial exercise capacity than
C57BL/6J mice. Measurements of exercise capacity and fatigue in 15-week old
C57BL/6J and FVB/NJ mice tested during the day or at night: (A) Comparison of
distance achieved; (B) comparison of work accomplished; (C) Blood lactate levels
in C57BL/6J and FVB/NJ mice basally and following fatigue from exercise testing.
n = 10 mice per group, *p < 0.05, ****p < 0.0001.
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ranges previously published for resting mice and mice exercising at or near their
VO2max, respectively.178-180 Collectively, these results suggest that FVB/NJ mice
demonstrate a superior ability to perform treadmill work compared with C57BL/6J
mice, and they have higher initial exercise capacities when tested during the day.

Effect of strain and time of training on exercise compliance and adaptation. To
determine if mouse strain or the time of training (i.e., day vs. night) influences
exercise protocol compliance and adaptive responses to exercise, C57BL/6J and
FVB/NJ mice were subjected to a 4-week training program, with one group from
each strain training at night, and one group training during the day. Each day, we
recorded compliance to the training program for individual mice (Table 1). The
C57BL/6J mice completed only 50–60% of their training sessions (Fig. 4A&C),
resulting in less time exercising in general (Fig. 7D). Interestingly, compliance in
C57BL/6J mice diminished progressively with duration of the training protocol (Fig.
4A, Table 1). While FVB/NJ mice were generally compliant when exercised during
the day or the night, 100% of the day FVB/NJ group complied with the protocol,
whereas FVB/NJ mice exercising at night appeared to show modestly
compromised compliance (Fig. 7B&D); however, this did not achieve statistical
significance.
Pre-training and post-training exercise capacity tests showed that, while
both FVB/NJ exercise groups significantly increased exercise capacity after four
weeks of training, the C57BL/6J mice showed either no improvement or a
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Figure 7: Compliance of FVB/NJ and C57BL/6J to the treadmill training
protocol. Compliance to a four-week treadmill training protocol in mice: (A,B)
Compliance curves indicating the % of mice that completed each training session;
(C) Compliance measured as the % of total sessions; or (D) total minutes
completed by mice throughout the exercise training program. n = 10 per group. *
p < 0.05, *** p < 0.001.
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Table 1. Exercise compliance chart. Daily records of minutes completed each
day during the 4 wk training program.
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decrease in the distance run or the work accomplished following training (Fig.
8A&B). This lack of response to exercise in the C57BL/6J mice is likely due to poor
compliance to the protocol.
To determine if compliance of C57BL/6J mice to the protocol correlated with
improvements in exercise capacity, we plotted the percent improvement in
distance and work against the percent time completed during the exercise
regimen. As shown in Fig. 8C&D, there is a significant, albeit weak, correlation
between the percent time completed and exercise capacity in this strain.
Collectively, these results show that, unlike FVB/NJ mice, C57BL/6J mice are not
compliant with this extended treadmill exercise protocol, and that the time at which
FVB/NJ mice exercise does not markedly influence their exercise capacity.
Physiological cardiac growth is a common endpoint used to verify
cardiometabolic adaptation to exercise.27 Exercise training increased heart weight
to tibia length (HW/TL) in both FVB/NJ exercise groups, whereas the C57BL/6J
mice showed no changes in heart size (Table 2). We did not find a significant
correlation between exercise
time completed and HW/TL in the C57BL/6J strain (data not shown). These results
indicate that exercise causes cardiac growth in FVB/NJ mice and that C57BL/6J
mice, likely due to lack of compliance to this treadmill protocol, fail to demonstrate
physiological cardiac growth.

FVB/NJ mice display robust adaptations following exercise training. It is known
that, compared with the C57BL/6J strain, FVB/NJ mice can achieve higher critical
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Figure 8: Treadmill training-induced improvements in exercise capacity in
C57BL/6J and FVB/NJ mice. Changes in exercise capacity in the mouse strains:
(A) Distance run and (B) work accomplished during initial and final exercise testing
following four weeks of treadmill training. n = 10 per group. *p < 0.05, ***p < 0.001.
Panels C and D show correlations of compliance and (C) % distance and (D) %
work improved (in the C57BL/6J strain). n = 20 mice (includes the C57BL/6J day
and the C57BL/6J night groups)
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Table 2: Measurements of exercise-induced cardiac growth. Mice were trained
for 4 weeks at 70% of their initial exercise capacity. Values are means ± SD;
n=10/group. HW/BW, heart weight-to-body weight ratio; HW/TL, heart weight-totibia length ratio. Statistical comparisons are between SED and EXE-Day and SED
and EXE-Night. n = 10 per group. * p < 0.05, *** p < 0.001, **** p < 0.0001.
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TABLE 2

C57BL/6J
Body Mass, g
SED
EXE-Day
EXE-Night
Heart Mass, mg
SED
EXE-Day
EXE-Night
HW/BW, mg/g
SED
EXE-Day
EXE-Night
HW/TL, mg/mm
SED
EXE-Day
EXE-Night

FVB/NJ

28.2±2.3
27.3±1.4
26.4±1.8

30.5±2.6
29.9±1.7
28.5±1.0

123.7±15.0
118.7±10.1
118.0±13.0

115.4±6.1
135.8±5.5***
130.5±9.1*

4.4±0.4
4.3±0.2
4.5±0.4

3.8±0.3
4.6±0.2****
4.6±0.2****

6.9±0.9
6.6±0.5
6.6±0.7

6.3±0.3
7.6±0.3***
7.3±0.4*
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running speeds on the treadmill,181 which indicates that their training regimen could
be intensified further to evoke more robust adaptations to exercise. To test this,
we trained an independent group of FVB/NJ mice at a slightly higher intensity (75%
of their initial maximum exercise capacity) for 4 weeks. Compared with pre-training
exercise capacity values, this more intensive protocol yielded a ~1.7-fold
improvement in distance run and a ~2.4-fold increase in work in the mice (Fig.
9A&B). As expected, cardiac size was significantly higher in exercised mice (Fig.
9C&D). In exercise-adapted hearts, myocyte cross sectional area was found to be
22% higher than that found in hearts of sedentary mice, and the myocyte area
distribution curves were shifted to the right (Fig. 9E-G), indicating that the exerciseinduced cardiac growth in this strain is due primarily to an increase in
cardiomyocyte size. Furthermore, mitochondrial biogenesis, estimated using the
ratio of relative mtDNA to nDNA content, was 53% higher in the exercise-adapted
mice (Fig. 9H). These findings indicate that treadmill training in FVB/NJ mice
promotes robust increases in systemic exercise capacity and elicits physiological
cardiac growth. Collectively, these results indicate that treadmill exercise in
FVB/NJ mice elicits robust systemic and cardiac muscle adaptations.

Discussion
The goals of this study were to examine treadmill exercise capacity, compliance,
and adaptation in two commonly used strains of laboratory mice. We found that
C57BL/6J mice have significantly lower treadmill exercise capacity compared with
FVB/NJ mice. C57BL/6J mice, in our hands, became progressively non-compliant
60

Figure 9: FVB/NJ mice display robust cardiometabolic adaptations to
treadmill exercise training. Adaptations to a 4-week treadmill training program in
FVB/NJ mice, where the training regimen was set based on 75% of their initial
exercise capacity: (A) Distance run and (B) work accomplished during exercise
testing; (C) Representative images of hearts from Sed and Exe mice; (D) HW/TL;
(E) Representative cross section; (F,G) quantification of cross sectional area in
heart sections stained with WGA and DAPI; and (H) Mitochondrial biogenesis, as
indicated by relative mitochondrial (mt) DNA content. n = 6-10 mice per group. *p
< 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
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with the exercise protocol, which is a likely reason underlying their lack of
adaptation to exercise. Conversely, FVB/NJ mice demonstrated near perfect
compliance and showed robust increases in exercise capacity as well as cardiac
adaptations. Because laboratory mice are typically nocturnal, we also compared
night and day behavior in the strains as well as exercise compliance and capacity.
Our metabolic cage data suggest that, contrary to the C57BL/6J strain, FVB/NJ
mice have no proclivity for activity and feeding at night, and that their metabolic
phenotype lacks circadian variation. Moreover, despite the nocturnal nature of
C57BL/6J mice, exercising them at night did not improve compliance or exercise
capacity. Collectively, these results indicate that FVB/NJ mice are a superior model
for examining systemic and tissue-specific adaptation to treadmill exercise and that
diurnal training appears to promote higher exercise compliance and capacity.
The increase in exercise capacity and cardiac adaptations in FVB/NJ mice
are likely a consequence of their remarkable compliance as well as their superior
ability to perform treadmill work. Indeed, other studies show that the FVB/NJ strain
has a higher critical running speed181 and is able to run farther than C57BL/6J
mice.163, 166 To compare exercise capacity and adaptations between the strains in
a controlled manner, we used equivalent relative intensities of training in the
strains, which equated to 70% of the speed achieved during initial exercise
capacity tests. These experiments showed that FVB/NJ mice could improve their
exercise capacity and that exercise in this strain causes physiologic cardiac
growth. Training FVB/NJ mice at a higher workload (initiated at 75% of their initial
maximum speed) appeared to evoke superior improvements in distance run and
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work and provoked physiologic cardiac growth. These results indicate that the FVB
strain is useful for examining intensity-dependent adaptations to exercise.
The usefulness of the treadmill model lies in its ability to control the level of
exercise-associated work and to relate biochemical and physiological adaptations
to workload. This is, of course, dependent on compliance to the treadmill protocol.
We show that C57BL/6J mice completed the protocol during the first week of
training, but that they become increasingly unwilling to run thereafter. It is unlikely
that this decrease in compliance is due to overtraining because it occurred upon
only the second week of training (and after a two-day rest period), and the mice
did not resume their ability to exercise, even after long periods of refusing to
comply with the protocol. Furthermore, the mice did not lose weight during the
protocol, which can be an indicator of overtraining.186 Although it remains unclear
why the C57BL/6J mice choose to run less after the first week, it could be that their
tendency to receive more shocks is a negative stimulus for running, or that they
associate the shocks with a positive outcome, i.e., removal from the treadmill.
Interestingly, C57BL/6J mice are prone to footshock-induced analgesia,187, 188 and
they show progressively decreased shock avoidance behavior compared with
other strains.189 It is also conceivable that this strain is more susceptible to
negative stress in the brain caused by forced running,190 as opposed to voluntary
running. Thus, it is possible that this strain acclimates to the repeated treadmill
shocks that they receive during training.
Escape behavior is another potential contributing factor to the lack of
compliance of C57BL/6J mice. A study by Mori and Makino showed that C57BL/6J
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mice escape and avoid shock by moving to an adjacent compartment in an L-type
movement pattern rather than an R-type (rearing and jumping forward) pattern.191
This is of particular importance because the R-type pattern must be invoked to
escape shock in our treadmill apparatus. Regardless, it would appear that the lack
of both physiologic cardiac growth and improvements in exercise capacity in
C57BL/6J mice is a result of non-compliance with the treadmill protocol.
We also show that FVB/NJ mice lack biological rhythmicity compared with
C57BL/6J mice and that the time of day does not appear to affect compliance to
the treadmill protocol. Lack of circadian behavior in FVB/NJ mice is a likely
consequence of expression of the retinal degenerative (rd) mutation, which
renders them blind to visual images and appears to underlie aberrant circadian
wheel running behavior and spatial awareness.192 Conversely, C57BL/6J mice
appear to see well: they demonstrate entrainment to a 12:12 h light:dark cycle, and
they re-entrain to phase advances.192 Of note, while FVB/NJ mice are blind,
C57BL/6J mice become deaf, progressively losing their hearing during the first
year of life.193-195 Nevertheless, despite the impaired senses of these strains, the
lack of circadian variation in the FVB/NJ strain, and the presence of a nocturnal
phenotype in C57BL/6J mice, the timing at which the mice were tested and trained
did not appear to have a strong impact. However, we do show that, for FVB/NJ
mice, running during the day is associated with a higher initial exercise capacity.
Because calculations for the 4-week training regimen are based on this initial
capacity, it is possible that testing initial exercise capacities of mice during the day
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could result in a higher training workload, which could equate to increased
physiological adaptations.
Although it is unclear whether the mutations that underlie loss of sight or
hearing in FVB/NJ or C57BL/6J mice contribute to their compliance to exercise
protocols, it is clear that C57BL/6J and FVB/NJ mice have different exercise
capabilities and preferences. Consistent with previous studies,163, 166 we found that
C57BL/6J mice have lower treadmill exercise capacity, which did not improve even
when they were tested at night. Nevertheless, several studies show that C57BL/6J
mice are quite adept at voluntary wheel exercise [e.g.,

163, 166, 196-201

], even load

bearing wheels which simulate resistance training202; and, consistent with their
nocturnal behavior, wheel activity in C57BL/6J mice peaks during the night.192 This
suggests that the C57BL/6J strain is more amenable to the wheel running modality
than treadmill exercise. While several investigators have exercised C57BL/6J mice
using a treadmill protocol successfully [reviewed in

161

], only a few studies

document robust increases in exercise capacity or physiological adaptations to
extended treadmill training in this strain.203-205 Most studies show adaptations that
appear relatively minimal compared with other strains [e.g.,

166, 206, 207

] or

demonstrate that additional exercise mimetics (e.g., AMPK or PPARδ agonists)
may be required to promote robust physiological adaptations to treadmill exercise
in C57BL/6J mice.208
Several limitations of our study deserve mention. We did not measure VO2
max

or identify anaerobic thresholds, which can delineate metabolic crossover

points209; however, we used stringent criteria for determining fatigue (i.e.,
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behavioral criteria decided upon a priori) as well as blood lactate measurements
to ensure that mice meeting these criteria were fatigued and not simply incompliant
with the exercise capacity protocol. Although we show that FVB/NJ mice are
proficient treadmill runners, their lack of circadian behavior suggests that they may
not be suitable for investigating chronobiological changes associated with exercise
(e.g., exercise-induced changes in clock genes). In addition, we did not test
whether lower speeds in C57BL/6J mice or different motivating stimuli would
increase compliance to the protocol. Some studies in rats,210 as well as C57BL/6J
mice,203 use chocolate as a reward-based incentive to comply with the protocol.
We did not test the use of reward in our study, nor did we examine whether
alternative aversive stimuli (e.g., air puffs instead of shocks) would improve
exercise compliance in the C57 strain. Thus, we do not rule out the possibility that
C57BL/6J mice could be coaxed to run with an intensity and compliance similar to
that of FVB/NJ mice; however, it is clear to us that improved treadmill compliance
in C57BL/6J mice would appear to require a different protocol than that used here,
or a reward that encourages continual compliance.
In summary, our findings indicate that FVB/NJ mice are a useful strain for
testing treadmill exercise-mediated adaptations. This strain complies well with
forced treadmill training and shows a robust capacity for cardiac exercise
adaptation. Unlike C57BL/6J mice, FVB/NJ mice do not have a strong nocturnal
nature, and they appear to show higher initial exercise capacities and comply
better when trained during daytime hours. We also found that, in our hands,
C57BL/6J mice show poor compliance to the treadmill exercise regimen,
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regardless of when they exercise. These findings demonstrate that FVB/NJ mice
are a suitable and robust model for understanding the mechanisms underlying
cardiac adaptations to exercise.i
i

This chapter previously appeared as an article in the journal Frontiers in Physiology. The
original citation is as follows: Gibb AA, et al. FVB/NJ mice are a useful model for examining
cardiometabolic adaptations to treadmill exercise. Front Physiol, 2016.
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CHAPTER III
EXERCISE−INDUCED CHANGES IN GLUCOSE METABOLISM PROMOTE
PHYSIOLOGIC CARDIAC GROWTH

Introduction
Exercise promotes cardiovascular wellness,211 augments musculoskeletal
function,8 and lengthens lifespan.212 These salutary effects of exercise are
dependent on the ability of the body to adapt to recurrent bouts of physical activity.
Cumulative adaptation of the circulatory, pulmonary, and musculoskeletal systems
augment exercise capacity,213 which is the strongest indicator of cardiovascular
health and a robust predictor of mortality.214 Cardiovascular adaptations to
exercise are particularly critical to enable adequate oxygen and nutrient delivery
to peripheral tissues, and they help preserve circulatory system health with age.215,
216

Physiological cardiac growth due to exercise is a key component of these

cardiovascular adaptations and contributes not only to exercise capacity, but
protects the heart from injury as well.217 Nevertheless, the mechanisms by which
regular exercise triggers and sustains cardiac adaptation remain unclear.
Understanding how exercise promotes healthy cardiac remodeling could provide
the knowledge required to delay the progression of heart disease or reverse tissue
pathology.
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Previous studies have identified signaling pathways and gene programs
essential for cardiac adaptation.27,

218

For example, C/EBPβ and CITED4 are

known to be critical for regulating the transcriptional programs that instigate cardiac
growth45, 46, 219; however, the mechanisms by which such transcriptional programs
are activated with exercise are unclear. In tissues such as skeletal muscle,
adaptive changes in gene expression are thought to be initiated by the repetitive
bouts of metabolic stress triggered by strenuous physical activity.8 While it follows
that the heart should conform to this paradigm, this has not been tested and it
remains unclear which metabolic pathways and flux control steps may be important
to provoke tissue adaptation to exercise.
In this study, we examined exercise-induced changes in glucose
metabolism and their relationship to cardiac remodeling. We provide evidence that
exercise regulates the activity of myocardial phosphofructokinase 1 (PFK1) and
that the resulting changes in metabolism are sufficient to activate a transcriptional
program influencing exercise-induced cardiac growth. Nonetheless, our data also
indicate that chronically low or high relative levels of glycolysis, such as occurs in
type II diabetes or heart failure, are damaging to mitochondria. These findings
suggest that changes in myocardial glucose metabolism, brought about by regular
exercise, regulate transcriptional programming and physiologic remodeling of the
heart and that maintenance of metabolic flexibility is required to preserve
mitochondrial health.
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Experimental Procedures
Experimental Animals. All procedures were approved by the University of Louisville
Institutional Animal Care and Use Committee. The mice used in this study include
transgenic mice expressing a kinase-deficient (kd) form of PFK2 under the control
of the α-MHC promoter (i.e., GlycoLo mice), transgenic mice expressing a
phosphatase-deficient form of PFK2 under the control of the α-MHC promoter (i.e.,
GlycoHi mice), and wild-type (WT) littermates.220,

221

Male mice on the FVB/NJ

background were used for all studies, except for F-2,6-P2 measurements in
isolated cardiomyocytes, where both male and female mice were used. All studies
began at 15 weeks of age; food and water were provided ad libitum; and the mice
were maintained on a 12:12-h light-dark schedule, as described previously.63 At
the conclusion of animal experiments, and following a 6 h fast, mice were
anaesthetized with sodium pentobarbital (150 mg/kg, i.p.), followed by euthanasia
via excision of the heart.

Exercise Capacity Testing. Mice were familiarized to the motorized rodent treadmill
(Columbus Instruments, Columbus OH) on the Wednesday and Thursday before
the first week of training. Familiarization consisted of an initial 10 min period where
the treadmill speed and incline were set to zero with shock grid settings of 25 V,
0.34 mA, and 2 Hz. The treadmill speed was then increased steadily to 10 m/min
(Wed) and 12 m/min (Thurs) for an additional 10 min.
On the Friday immediately following treadmill familiarization, we subjected
mice to an exercise capacity test. For this, the mice were acclimated to the
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treadmill for 10 min, with the speed and incline set initially to zero. The treadmill
speed was then increased to 8.5 m/min with an angle of inclination set to 0° for 9
min. Next, the treadmill speed and incline were increased to 10 m/min and 5°,
respectively, for 3 min. The speed was then increased by 2.5 m/min every 3 min
to a maximum speed of 40 m/min, while inclination increased by 5° every 9 min
until a maximum incline of 15° was achieved.
A priori criteria for exercise-induced exhaustion were: 10 consecutive
seconds on the electric grid; spending more than 50% of time on the grid; and/or
lack of motivation to manual prodding. Each mouse was removed immediately
from their respective lane once one or more of these criteria was reached. Blood
lactate levels provided a biochemical indicator of exercise-induced exhaustion at
or near maximal oxygen consumption (VO2max).177-180 We recorded lactate
concentration in 0.7 μl of blood from a small tail clip (Lactate Plus meter; Nova
Biomedical) prior to the protocol and upon meeting the exhaustion criteria defined
above. High lactate levels increase confidence in a successful exercise capacity
test by ensuring that failure to continue is due to exhaustion at or near VO2max
and not a failure to comply with the protocol.181-183
Following 4 weeks of training, we repeated this testing protocol to assess
improvements in exercise capacity. Exercise capacity was measured using the
parameters of distance run (meters achieved prior to exhaustion) and work
accomplished [calculated as the product of body weight (kg) and vertical distance
(m); vertical distance = (distance run)(sinθ), where θ = the angle of inclination of
the treadmill from 0°-15°] as outlined previously.63, 166
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Exercise Training. Mice assigned to exercise training groups were subjected to a
4-week protocol of forced treadmill running. The training protocol commenced the
Monday after the initial exercise capacity testing with mice exercising 5 d/wk (Mon–
Fri) at 75% of their maximal speed achieved during the initial exercise capacity test
and an inclination appropriate to the speed. Prior to each training bout, we provided
mice with a “warm-up” period of 10 min at 0 m/min and 10 min at 12 m/min to
promote exercise protocol compliance and to minimize risk of injury. In all groups,
we progressively increased the workload of the mice, such that they trained for 40
min during week 1, 50 min during week 2, and 60 min during weeks 3 and 4. We
chose this progressive intensity protocol to prevent training plateau and to
stimulate systemic and cardiac adaptations.63
To test the effects of chronic exercise in the adapted and recovery state,
mice were euthanized 24 h or 1 h after the last training session of the 4 wk training
regimen, respectively. To interrogate the effects of an acute, single-bout of
exercise on cardiac metabolism, mice were subjected to familiarization as
previously outlined and euthanized immediately following the completion of a 1 d,
single exercise training session; 40 min at 75% intensity. Mice were excluded from
the study if they were non-compliant with the exercise protocol or if they were found
to be injured or in poor health, e.g., due to fighting, etc.

Echocardiographic Assessment. Transthoracic echocardiography of the left
ventricle was performed as previously described.222, 223 Measurements were made
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on the Vevo 770 echocardiography instrument. Body temperature was maintained
(36.5–37.5°C) using a rectal thermometer interfaced with a servo-controlled heat
lamp. Mice were anesthetized with 2% isoflurane, maintained under anesthesia
with 1.5% isoflurane, and examined. Using short-axis B-modes and endocardial
values, stroke volume (SV) was calculated as: diastolic volume – systolic volume;
ejection fraction (EF%) as SV/diastolic volume × 100%; cardiac output as SV ×
heart rate (HR). Left ventricular diameters during diastole (LVIDd), left ventricular
diameters during systole (LVIDs), and heart rate were determined from long-axis
M-modes. Relative wall thickness was calculated as (diastolic posterior wall
thickness + diastolic anterior wall thickness)/LVIDd. To prevent bias, the
individuals performing echocardiography and image tracing were unaware of the
group assignments.

Radiometric measurement of myocardial glucose utilization. Hearts were excised
and perfused in non-recirculating Langendorff mode with Krebs-Henseleit (KH)
buffer (37ºC; 5% CO2/95% O2; containing in mmol/L: 118.5 NaCl, 25 NaHCO3, 4.7
KCl, 1.2 MgSO4, 1.2 KH2PO4, 2.5 CaCl2 and 5 mM glucose; pH 7.4). Glycolytic flux
was assessed by measuring the amount of 3H2O released through the metabolism
of exogenous [5-3H]glucose (Perkin Elmer), as previously described.220, 221 Briefly,
following a 20 min period of perfusion (equilibration), KH buffer containing 25
μCi/ml of [5-3H]glucose was infused into the cannula via a syringe infusion pump
(Harvard Apparatus) at a proportion 1:100 to that of the flow rate (final
concentration = 0.25 μCi/ml). The perfusate was collected in two separate 5-min
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intervals. From the collected perfusate, 400 μl of perfusate was added to 25 µl of
0.6 M HCl in a microcentrifuge tube. The microcentrifuge tube was then placed in
a scintillation vial containing 2 ml of H2O to allow for evaporation diffusion of [3H]2O
in the microcentrifuge tubes into the water contained in the scintillation vial. To
account for incomplete equilibration of [3H]2O, in parallel vials, known amounts
(µCi) of [5-3H]glucose and [3H]2O (Moravek Biochemicals) were placed in
microcentrifuge tubes, and placed into separate scintillation vials containing 0.5 ml
dH2O. After 72 h incubation at 37°C, the microcentrifuge tube was removed from
the vial, 10 ml of scintillation fluid was added, and scintillation counting was
performed using a Tri-Carb 2900TR Liquid Scintillation Analyzer (Packard
Bioscience Company). Glucose utilization was then calculated using the formula
reported by Ashcroft,224 with considerations for: the specific activity of [53

H]glucose; incomplete equilibration and background; the dilution of [5-3H]- to

unlabeled-glucose; and scintillation counter efficiency. Glucose utilization was
normalized to total heart weight and represented as a fold change to the control
group. To prevent bias, the individual assisting in hanging the hearts for perfusion
was unaware of the group assignments.

Measurement of blood glucose and lactate. Blood lactate concentration was
measured in 0.7 μl of blood from a small tail clip using a Lactate Plus meter (Nova
Biomedical). Blood glucose concentration was measured from the same tail clip
using the Accu-Check Aviva blood glucose monitoring meter (Roche).
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Assessment of plasma free fatty acid.: Circulating plasma free fatty acids (FFA)
were assessed via a colorimetric enzymatic assay, per manufacturers guidelines
(Sigma-Aldrich). Briefly, plasma was incubated with acyl-CoA synthetase for 30
min at 37ºC, in a 96-well microplate. A master reaction mix was added to each well
and samples were again incubated for 30 min at 37ºC. Absorbance was then
measured at 570 nm wavelength and the concentration of FFA in each sample
was calculated based on a standard curve.

Measurement of plasma IGF-1. Plasma IGF-1 was quantified using a mouse/rat
IGF-1 quantikine ELISA kit (R&D Systems, Minneapolis, MN). Briefly, plasma was
diluted 500-fold, added to microplate, and incubated for 2 h at room temperature
with constant shaking. The microplate was then washed 5× followed by addition of
secondary antibody and incubation at room temperature for 2 h with constant
shaking. The microplate was then washed five times. For colorimetric
determination, substrate solution was added to each well for 30 min, followed by
addition of stop solution and determination of color intensity by measuring at 450
nm with wavelength correction at 540 nm. The concentration of IGF-1 was
calculated using a standard curve.

Mitochondrial function. Heart mitochondria were isolated and subjected to
respiratory function assays using the Seahorse XF24, similar to that described
previously.225 Briefly, whole hearts were washed 5× with cold buffer A (220 mM
mannitol, 70 mM sucrose, 5 mM MOPS, 1 mM EDTA; pH 7.2 with KOH) followed
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by homogenization using a glass-col homogenizer in 2 ml of buffer A containing
0.2% fatty acid-free BSA. Homogenate was then subjected to centrifugation at
800g for 10 min followed by supernatant collection and centrifugation at 10,000g
for 10 min. The pellet containing mitochondria was then resuspended in 1 ml fresh
buffer A (without BSA) and centrifuged at 10,000g, with this step repeated once.
The washed mitochondrial pellet was then resuspended in 150 µl respiration buffer
(120 mM KCl, 25 mM Sucrose, 10 mM HEPES, 1 mM MgCl2, 5 mM KH2PO4; pH
7.2 with KOH) and kept on ice.
To determine mitochondrial function, samples were diluted to a
concentration of 5 µg (protein) in 50 µl respiration buffer per well, and centrifuged
onto XF24 microplates at 500g for 3 min at 4ºC. State 3 respiration in response to
substrates were measured after injection of pyruvate + malate (5.0 mM + 2.5 mM,
final concentrations), succinate + rotenone (10 mM + 1 µM, final concentrations),
or palmitoylcarnitine + malate (50 µM + 0.5 mM, final concentrations). The oxygen
consumption rates recorded after injection of oligomycin (1 µg/ml), an inhibitor of
ATP synthase, served as a measure of State 4 respiration. Respiratory control
ratios, state 3/state 4, was calculated as a measure of the coupling of oxygen
consumption to ATP production.

Measurement of F-2,6-P2 metabolite concentration. Metabolite levels of F-2,6-P2
were measured in isolated cardiac myocytes as outlined previously.220, 221
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Glycogen Assay. To assess myocardial glycogen content, 15 mg of heart tissue
powder was added to 100 µl of ice-cold dH2O, homogenized using a glass col
homogenizer, boiled for 10 min, and centrifuged at 16,000g for 10 min. Glycogen
was then hydrolyzed in a 384-well plate for 1 h at 37°C followed by addition of
reaction mix containing the OxiRed probe for 1 h at 37°C. Absorbance was then
measured at 590 nm. The amount of glycogen was determined against a standard
curve and normalized to tissue wet weight.

Histology. Following euthanasia, the heart tissue was excised, flushed with 1 M
KCl solution, and fixed in 10% formalin, embedded in paraffin, and sectioned at 4
µm. Heart cross-sections were stained with 4'6-diamidino-2-phenylindole (DAPI;
Invitrogen, Carlsbad, CA) and wheat germ agglutinin (WGA; ThermoFisher,
Waltham, MA) for quantification of cardiomyocyte cross-sectional area.
Additionally, sections were stained with isolectin B4 (Vector Laboratories,
Burlingame, CA) to assess capillary density and sirius red for fibrosis. Quantitative
measurements were determined using Nikon Elements software, with no less than
100 myocytes with centrally located nuclei assessed for area measurements. To
prevent bias, the individual analyzing all histology was unaware of the group
assignments. A subset of slides from each group was used based on power
calculations

to

detect

a

20%

difference

capillary:myocyte ratio at α < 0.05.
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Protein and mRNA Expression Analysis. For measuring protein abundance,
tissues and cells were homogenized in buffer containing 50 mM HEPES (pH 7.0),
2 mM EDTA, 1% NP-40, 10% glycerol, 1 mM MgCl2, 1 mM CaCl2, and 150 mM
NaCl; fresh phosphatase and protease inhibitors were added immediately prior to
tissue homogenization. The homogenates were sonicated on ice and centrifuged
at 13,000g for 20 min. Proteins in the supernatant were separated by SDS-PAGE,
electroblotted to PVDF membranes, and probed according to the manufacturers’
protocols. A horseradish peroxidase-linked secondary antibody (Cell Signaling
Technology, Danvers, MA) was used to detect immunoreactive proteins. Images
were recorded using a Fujifilm LAS-300 imager, and relative protein abundance
was measured via densitometric analysis using TotalLab software.
For transcriptional expression analysis via RT-PCR, RNA was extracted
from tissues and cells using the RNeasy Plus Universal Kit (Qiagen, Germantown,
MD), followed by cDNA synthesis. Real-time PCR amplification was performed
with SYBR Green quantitative PCR (qPCR) Master Mix (SA Biosciences,
Germantown, MD) using a 7900HT Fast Real-Time PCR System (Applied
Biosystems, Foster, CA). Relative expression was determined by the 2-ΔΔCt
method. A list of the antibodies and primers used can be found below.
Antibodies used in these studies.
Antibodies

Source

Identifier

DAPI (4',6-Diamidino-2Phenylindole, Dihydrochloride)

ThermoFisher

Cat#D1306

WGA (Wheat germ agglutinin,
Alexa Fluor 647 conjugate)

ThermoFisher

Cat#W32466

Fluorescein labeled griffonia
simplicifolia lectin I (GSL I)
isolectin B4

Vector Laboratories

Cat#FL-1201
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Sirius Red
Rabbit monoclonal anti-p-Akt
(S473)
Rabbit polyclonal anti-Akt

Sigma-Aldrich

Cat#365548

Cell Signaling Technology

Cat#4060

Cell Signaling Technology

Cat#9272

Rabbit monoclonal anti-p-PFK2
(S483;PFKFB2)

Cell Signaling Technology

Cat#13064

Rabbit polyclonal anti-PFK2
(PFKFB2; heart isoform)

Bethyl Labs

Cat#A304-286A-M

Rabbit monoclonal anti-HK1

Cell Signaling Technology

Cat#2024

Rabbit monoclonal anti-HK2
Rabbit polyclonal anti-PFK1

Cell Signaling Technology
Santa Cruz Biotechnology

Cat#2867
Cat#sc-67028

Rabbit polyclonal anti-PFK2
(PFKFB1; liver isoform)

Novus Biologicals

Cat#NB100-92391

Rabbit polyclonal anti-PFK2
(PFKFB3; ubiquitous isoform)

Proteintech

Cat#13763-1-AP

Rabbit monoclonal anti-PKM1/2
Rabbit polyclonal anti-GFAT1
Rabbit polyclonal anti-GS
Mouse monoclonal anti-LDHB

Cell Signaling Technology
Santa Cruz Biotechnology
Cell Signaling Technology
Abcam

Cat#3106
Cat#sc-134894
Cat#3893
Cat#ab85319

PCR primers used in these studies.
Sequence-Based Reagents
Gene of
Forward
Interest
Cited4
CATGGACACCGAGCTCATC
Cebpb
GGGGTTGTTGATGTTTTGGT
Nfatc2
HPRT

CACAGATACGGTGACCCCT
AGGACCTCTCGAAGTGTTGG

Reverse
CTGACCCCAGGTCTGAGAAG
TCGAAACGGAAAAGGTTCTCA
GTGGGATCGGGTTCTTCTTC
AGGGCATATCCAACAACAAAC

Analysis of cardiac ultrastructure. Transmission electron microscopy analysis, left
ventricular tissue was dissected into 3 mm3 pieces and fixed in 2.5%
glutaraldehyde overnight.

The samples were then post-fixed in 2% aqueous

osmium tetroxide, dehydrated in ascending concentrations of ethanol and
embedded in Araldite 502 (Electron Microscopy Sciences, Hatfield PA). Onemicron thick sections were stained with toluidine blue for screening under a light
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microscope. Selected blocks in which the muscle had a longitudinal orientation
were cut into 800 Å thick sections, mounted on 200-mesh copper grids, doubly
stained with uranyl acetate and lead citrate, and examined in a Phillips CM-10
electron microscope with a LaB 6 cathode (Phillips Electronic Instruments Co.,
New York, NY) operating at 80 kV.

Metabolomic Analysis. Hearts were freeze-clamped in situ using liquid nitrogencooled Wollenberger Tongs, which helps to capture the metabolome as it is in the
beating mouse heart in vivo. Samples were prepared by Metabolon using their
automated MicroLab STAR system (Hamilton Company, Reno, NV). First, tissue
®

homogenates were made in water at a ratio of 5 uL per mg of tissue. For quality
control, several recovery standards were added prior to the first step in the
extraction process. To remove protein, dissociate small molecules bound to protein
or trapped in the precipitated protein matrix, and to recover chemically diverse
metabolites, proteins were then precipitated with methanol (final concentration
80% v/v) under vigorous shaking for 2 min (Glen Mills GenoGrinder 2000) followed
by centrifugation. For quality assurance and control, a pooled matrix sample was
generated by taking a small volume of each experimental sample to serve as a
technical replicate throughout the data set. Extracted water samples served as
process blanks. A cocktail of standards known not to interfere with the
measurement of endogenous compounds was spiked into every analyzed sample,
allowing instrument performance monitoring and aiding chromatographic
alignment.
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The extract was divided into fractions for analysis by reverse phase
(RP)/UPLC-MS/MS with positive ion mode electrospray ionization (ESI), by
RP/UPLC-MS/MS with negative ion mode ESI, and by HILIC/UPLC-MS/MS with
negative ion mode ESI. Samples were placed briefly on a TurboVap® (Zymark) to
remove the organic solvent. All methods utilized a Waters ACQUITY UPLC and a
Thermo Scientific Q-Exactive high resolution/accurate mass spectrometer
interfaced with a heated electrospray ionization (HESI-II) source and Orbitrap
mass analyzer operated at 35,000 mass resolution. The sample extract was
reconstituted in solvents compatible with each MS/MS method. Each reconstitution
solvent contained a series of standards at fixed concentrations to ensure injection
and chromatographic consistency. One aliquot was analyzed using acidic positive
ion conditions, chromatographically optimized for hydrophilic compounds. In this
method, the extract was gradient eluted from a C18 column (Waters UPLC BEH
C18-2.1x100 mm, 1.7 µm) using water and methanol, containing 0.05%
perfluoropentanoic acid (PFPA) and 0.1% formic acid (FA). For more hydrophobic
compounds, the extract was gradient eluted from the aforementioned C18 column
using methanol, acetonitrile, water, 0.05% PFPA and 0.01% FA. Aliquots analyzed
using basic negative ion optimized conditions were gradient eluted from a separate
column using methanol and water, containing 6.5 mM ammonium bicarbonate (pH
8). The last aliquot was analyzed via negative ionization following elution from a
HILIC column (Waters UPLC BEH Amide 2.1×150 mm, 1.7 µm) using a gradient
consisting of water and acetonitrile with 10 mM ammonium formate (pH 10.8). The
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MS analysis alternated between MS and data-dependent MSn scans using
dynamic exclusion. The scan range covered 70–1000 m/z.
Raw data were extracted, peak-identified and processed using Metabolon’s
proprietary hardware and software. Compounds were identified by comparison to
library entries of purified, authenticated standards or recurrent unknown entities,
with known retention times/indices (RI), mass to charge ratios (m/z), and
chromatographic signatures (including MS/MS spectral data). Biochemical
identifications were based on three criteria: retention index within a narrow RI
window of the proposed identification, accurate mass match to the library±10 ppm,
and the MS/MS forward and reverse scores between experimental data and
authentic standards. Proprietary visualization and interpretation software
(Metabolon, Inc., Durham, NC) was used to confirm the consistency of peak
identification among the various samples. Library matches for each compound
were checked for each sample and corrected, if necessary. Area under the curve
was used for peak quantification.
Original scale data (raw area counts) were analyzed using Metaboanalyst
3.0 software (http://www.metaboanalyst.ca/).226 Metabolites with greater than 50%
of the values missing were omitted from the analysis, and missing values were
imputed by introducing values with half the minimum positive value in the original
data. An interquartile range filter was used to identify and remove variables
unlikely to be of use when modeling the data. The data were log-transformed and
auto-scaled (mean-centered and divided by the standard deviation of each
variable). Univariate (e.g., volcano plots) and multivariate (e.g., PCA) analyses
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were then performed. For multiple comparison testing, q values were calculated
as in R using a method embedded within the Metaboanalyst software, controlling
for the false discovery rate.227 Radar charts were constructed in R using average
Z-scores of significantly different metabolites from each biochemical pathway.

Transcriptomic analyses. Hearts of male WT, GlycoLo and GlycoHi mice (15–16
weeks of age) were subjected to transcriptomic analysis using the GeneChip®
Mouse Genome 430 2.0 Array (Affymetrix, Inc.). Array data were analyzed using
the affy228 and limma229 packages of R for Robust Multi-array Average (RMA) for
normalization and for moderate t-statistics to derive p-values, respectively. The pvalues were adjusted using the Bejamini and Hochberg method for false discovery
rate control.227 For the genes with multiple probe set IDs, the probe set with the
highest standard deviation among all samples was kept for further analsyis. Gene
Ontology

analysis

was

performed

using

DAVID

(https://david.ncifcrf.gov/home.jsp.230

Data and Software Availability. Cytoscape software was used to visualize changes
in metabolic pathways and networks and was facilitated using the MetaboLync
Cytoscape Plugin (Metabolon, Inc). Metabolomic data were analyzed using
Metaboanalyst 3.0 software. Gene array data has been deposited in the Gene
Expression Omnibus databank (GSE100176) and will be made available to
readers upon publication.
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Statistical analysis. Statistical parameters including the value of n (number of
mice), the definition of center, dispersion and precision measures (mean ± SEM or
SD), and statistical significance is reported in the Figures and Figure Legends. A
p value of ≤ 0.05 was considered statistically significant. In the Figures, asterisks
denote statistical significance as calculated by unpaired or paired Student’s t test
(for direct comparisons); Levene’s test was used to assess the equality of group
variances between groups, and if found to be significantly different, a Welchmodified t-test was used to assess significance. Multiple comparisons were
assessed by one-way or two-way ANOVA followed by Bonferroni or Sidak Multiple
Comparison tests (*, p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001), as
appropriate. Statistical analysis was performed using GraphPad Prism 7,
Metaboanalyst, and/or the R program.

Results
Exercise promotes physiologic cardiac growth. Wild-type mice subjected to 4
weeks of treadmill training showed a 48% increase in distance run and a 77%
increase in work accomplished (Fig. 10A, B); successful exercise testing was
validated by elevated blood lactate levels, indicating that the mice ran to
exhaustion (Fig. 10C). In comparison with untrained mice, trained mice had 15%
higher levels of circulating plasma IGF-1 (Fig. 10D), further demonstrating
systemic adaptation to the training regimen. Exercise-adapted mice displayed
physiologic cardiac growth characterized by a 10% increase in heart weight to tibia
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Figure 10: Exercise training improves exercise capacity. Systemic adaptation
to a 4-wk treadmill training protocol: Pre- and post-training (A) distance and (B)
work; (C) Validation of a successful high-intensity exercise capacity test as
indicated by levels of blood lactate measured at rest and immediately after the
criteria for exercise-induced fatigue were met; and (D) Plasma levels of insulin-like
growth factor-1 (IGF-1). Sed, sedentary; Exe, exercise. Data represented as mean
± SEM; ***p < 0.001, ****p < 0.0001; n = 6 per group.
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Figure 11: Exercise training promotes physiologic cardiac growth. Effect of
treadmill training on the exercise-induced cardiac growth program: (A) Gravimetric
measurements of cardiac size (HW/TL, heart weight/tibia length); (B)
Representative myocardial sections stained with wheat germ agglutinin (red) and
isolectin B4 (green). Nuclei are stained with DAPI (blue); (C) Cardiomyocyte crosssectional area; (D) Capillary-to-myocyte ratio; (E) Phosphorylation of AKT (Ser473)
24 h following the last training session; (F) Relative Mrna expression of Cebpb,
Cited4, and Nfatc2. Data are represented as mean ± SEM; *p<0.05, **p<0.01,
***p<0.001; n = 5–6 per group.
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Table 3: Echocardiographic data from sedentary and exercised WT mice.
After acclimatization and an initial exercise capacity test, male FVB/NJ mice (15
weeks of age) were subjected to exercise training 5 d a week for 4 wk. One day
following the final exercise capacity test, the mice were anesthetized and cardiac
structure and function were assessed by echocardiography. Abbreviations: Sed,
sedentary; Exe, exercised; HR, heart rate; EDV, end-diastolic volume; ESV, endsystolic volume; SV, stroke volume; EF, ejection fraction; CO, cardiac output;
LVIDd, left ventricular internal diameter in diastole; LVIDs, left ventricular internal
diameter in systole; LVPWd, left ventricular posterior wall in diastole; LVPWs, left
ventricular posterior wall in systole; LVAWd, left ventricular anterior wall in diastole;
LVAWs, left ventricular anterior wall in systole; RWT, relative wall thickness.
*p<0.05, **p<0.01 vs. Sed.
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TABLE 3

HR (bpm)
Endocardial Values
EDV (µl)
ESV (µl)
SV (µl)
EF (%)
CO (ml/min)
Chamber Diameter
LVIDd (mm)
LVIDs (mm)
Wall Thickness
LVPWd (mm)
LVPWs (mm)
LVAWd (mm)
LVAWs (mm)
RWT
n

WT-Sed
Mean
SD
482 ± 32
38
11
27
71
13

±
±
±
±
±

3
3
3
7
2

3.7 ± 0.2
2.2 ± 0.2
0.8
1.2
0.8
1.1
0.46
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±
±
±
±
±
12

0.1
0.1
0.1
0.2
0.07

WT-Exe
Mean
SD
492 ± 25
45
13
32
72
16

±
±
±
±
±

6**
2
5**
4
2**

4.0 ± 0.2**
2.5 ± 0.2**
0.9
1.3
0.8
1.1
0.42

±
±
±
±
±
10

0.1*
0.1*
0.1
0.2
0.07

length (HW/TL; Fig. 11A), a 24% increase in cardiomyocyte cross-sectional area,
and a 35% increase in capillary-to-myocyte ratio (Fig. 11B–D). Furthermore,
exercise increased chamber diameter and wall thicknesses, improved indices of
cardiac function (EDV, SV, and CO; Table 3), and activated the pro-hypertrophic
signaling intermediate protein kinase B (AKT)35, 39-42 (Fig. 11E). Exercise
training downregulated Cebpb and upregulated Cited4, an observation which is
consistent with previous findings showing necessary involvement of these
transcriptional mediators in regulating physiologic growth.45, 46, 217-219 Moreover, the
expression of Nfatc2, the deletion of which ameliorates pathological hypertrophy
and heart failure but does not prevent physiological hypertrophy,231 was markedly
lower in hearts from exercise-adapted mice (Fig. 11F). Collectively, these results
indicate that exercise training elicits robust cardiac adaptation in mice.

Metabolomic changes in the exercise-adapted heart at steady state. To examine
global metabolic changes in exercise-adapted hearts, we first compared the
relative abundance of 424 metabolites in hearts isolated from sedentary and
exercise-adapted mice. To capture the metabolic state of the adapted heart as
accurately as possible, the hearts were freeze-clamped in situ 24 h after the final
exercise bout (Fig. 12A). Principal component analysis (PCA) showed little
separation between the groups (Fig. 12B), and only 20 metabolites (out of 424
measured) were found to be significantly different (Fig. 12C). Of these, only two
metabolites had a q value below 0.05 (Table 4). These findings demonstrate that
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Figure 12: Metabolomic changes in the exercise-adapted mouse heart. (A)
Mice were either exercised for 4-wk (EXE) or remained sedentary (SED) under
similar handling conditions. Following a 6 h fast and 24 h after the final exercise
session, hearts were freeze-clamped in situ.

The relative abundance of

metabolites in the hearts was examined by LC/MS/MS; (B) 2D PCA analysis; (C)
Volcano plot showing metabolites that changed ≥ 1.25-fold (p ≤ 0.05) in Exe hearts
compared with Sed hearts. A list of metabolites found to be significantly different
in exercise-adapted hearts can be found in Table S2. N = 9 Sed and 11 Exe mouse
hearts per group.
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Table 4: Significantly different metabolites in hearts from exercise-adapted
mice. Hearts from WT, exercise-adapted (EXE) mice [(and corresponding WT
sedentary controls (SED)] were freeze-clamped in situ, 24 h after the final exercise
bout. Metabolites extracted from the hearts were subjected to LC/MS analysis.
Raw area counts from each identified metabolite were log-transformed,
autoscaled, and then subjected to t-test analysis. Missing values were imputed
using half the minimum value of observed raw area count data, and metabolites
with >50% values missing were omitted from the analysis. Asterisks (*) indicate
compounds that were not officially confirmed based on a standard, but whose
identity matches the expected exact mass using the UHPLC/MS/MS2 accurate
mass platform. Shown are those metabolites with a p value threshold of 0.05 and
a fold change threshold of 1.25. n = 9 SED mice and n = 10 EXE mice.
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hexanoylglycine
p-cresol-glucuronide*
3-hydroxybutyrylcarnitine
3-hydroxylaurate
2-hydroxyadipate
3-hydroxymyristate
prolylglycine
3-hydroxydecanoate
cytidine-5'-diphosphoethanolamine
oleoylcholine
galactitol (dulcitol)
cytidine 5'-diphosphocholine
N-monomethylarginine
3-hydroxyoctanoate
lysine
fumarate
N-delta-acetylornithine
pipecolate
4-ethylphenyl sulfate
4-vinylphenol sulfate

Metabolite

Identifier
(KEGG or
HMBD)
HMDB00701
HMDB11686
HMDB13127
HMDB00387
HMDB00321
HMDB11178
HMDB02203
HMDB01564
HMDB00107
HMDB01413
HMDB29416
HMDB01954
HMDB00182
HMDB00134
HMDB00070
C13637
HMDB04072

Relative Fold
Change
(EXE/SED)
1.88
1.77
1.47
1.44
1.44
1.43
1.42
1.41
1.38
1.37
1.32
1.32
1.31
1.27
1.26
1.25
0.78
0.71
0.53
0.13
0.005
0.001
0.023
0.008
0.013
0.026
0.010
0.011
0.011
0.003
0.002
0.025
0.021
0.038
<0.001
0.032
0.021
0.019
0.033
<0.001

p value
0.241
0.161
0.380
0.256
0.300
0.389
0.278
0.282
0.282
0.241
0.161
0.389
0.363
0.434
0.003
0.422
0.363
0.363
0.422
0.003

q value
Lipid
Amino Acid
Lipid
Lipid
Lipid
Lipid
Peptide
Lipid
Lipid
Lipid
Carbohydrate
Lipid
Amino Acid
Lipid
Amino Acid
Energy
Amino Acid
Amino Acid
Xenobiotics
Xenobiotic

Super Pathway

Fatty Acid Metabolism(Acyl Glycine)
Phe and Tyr Metabolism
Fatty Acid Metabolism (Acyl Carnitine)
Fatty Acid, Monohydroxy
Fatty Acid, Dicarboxylate
Fatty Acid, Monohydroxy
Dipeptide
Fatty Acid, Monohydroxy
Phospholipid Metabolism
Phospholipid Metabolism
Fructose, Mannose and Galactose Metabolism
Phospholipid Metabolism
Urea cycle; Arg and Pro Metabolism
Fatty Acid, Monohydroxy
Lys Metabolism
TCA Cycle
Urea cycle; Arg and Pro Metabolism
Lys Metabolism
Benzoate Metabolism
Benzoate metabolism

Metabolic Subpathway(s)

TABLE 4
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the steady-state abundance of most metabolites in the exercise-adapted heart is
unchanged compared with that of sedentary mice.

Exercise induces periodicity in glucose metabolism. Because the steady-state
abundance of biochemical pathway intermediates may not be reflective of pathway
flux,222,

232

and because several studies show that exercise changes cardiac

metabolism (e.g.,40,

66

), we next measured the metabolism of [5-3H]glucose in

hearts from sedentary and
exercise-adapted mice. Radiometric assays of perfused hearts showed a nearly 2fold increase in glucose utilization in exercise-adapted hearts compared with
hearts from sedentary mice (Fig. 13A). Glycolytic enzymes were found in similar
abundances in exercise-adapted hearts relative to hearts from sedentary mice
(Fig. 14). These data indicate that changes in enzyme abundance are unlikely to
contribute to the increase in glycolysis that occurs in the exercise-adapted heart.
Because glycolysis is influenced by rate-limiting steps, such as occurs at
the phosphofructokinase reaction, we next examined factors that regulate PFK1—
the rate-limiting and committed step of glycolysis.233, 234 The PFK1 reaction exerts
more control on glycolysis than any other step235 and is dependent on several
factors including: the levels of fructose-2,6,-bisphosphate (F-2,6-P2), substrate
availability, energy charge, the levels of citrate and ATP, and pH. Because PFK2
regulates the levels of F-2,6-P2, a potent activator of PFK1, we examined the
phosphorylation

status

of

the

myocardial

isoform

of

PFK2,

PFKFB2.

Phosphorylation of PFKFB2 at S483 can increase F-2,6-P2 levels and is known to
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be under the influence of insulin-like growth factor-1/AKT signaling.35,

236-238

Notably, both cardiac AKT phosphorylation and plasma insulin-like growth factor1 were elevated in exercise-adapted mice (see Fig. 11E and Fig. 10D). In
agreement with radiometric findings, S483 phosphorylation of PFKFB2 (p-PFK2)
was 50% higher in exercise-adapted hearts compared with hearts of sedentary
mice (Fig. 13B, upper panel and 13C, left panel). Taken together, the radiometric
and immunologic data provide convergent evidence that glycolysis is increased in
the exercise-adapted heart and indicate that this increase in glycolytic activity may
be attributable at least in part to PFK activation.
Because exercise is a dynamic challenge that leads to rapid changes in
metabolism, we next examined glycolytic changes that occur early after exercise,
i.e., in the trained state during recovery. Because ex vivo measurements of flux in
the recovery period following an exercise session are unlikely to provide
meaningful data (e.g., due to lack of a metabolic steady-state), we measured levels
of p-PFK2 as a possible indicator of phosphofructokinase activity and glucose
utilization through glycolysis. Compared with corresponding sedentary controls,
hearts excised from exercise-adapted mice 1 h after the last exercise session
showed significantly diminished PFK2 phosphorylation (Fig. 13B, lower panel
and 13C, right panel).
To determine whether these changes in metabolism precede cardiac
adaptation, we eliminated the variable of extended training and examined PFK2
activation immediately after a single bout of exercise. For this, a separate group of
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Figure 13: Exercise dynamically regulates PFK2 and glycolysis in the heart.
Measurements of glucose metabolism in the heart: (A) Measurement of relative
myocardial glucose utilization in isolated perfused hearts from mice that remained
sedentary (Sed) or that were exercised for 4 weeks (Exe). Measurements were
performed on hearts excised 24 h after the last exercise session; (B)
Representative immunoblots from a separate cohort of mice of S483
phosphorylation of the cardiac isoform of PFK2 (PFKFB2) in the sedentary and the
exercise-adapted state: upper panel, levels of PFK2 phosphorylation 24 h after the
last bout of exercise; lower panel, PFK2 phosphorylation occurring 1 h after the
last exercise bout. (C) Quantification of PFK2 phosphorylation from blots
represented in panel B; (D) Representative immunoblots of S483 phosphorylation
of PFK2 in hearts of mice exercised for 1 d; these hearts were excised immediately
after exercise, which would appear to be indicative of the state of PFK2 occurring
during or immediately after exercise; (E) Schematic representation of glycolysis
showing relationship of PFK activity with glycogen storage; (F) Myocardial
glycogen content in hearts of Sed mice and in hearts excised immediately after 1
bout of exercise; Circulating levels of (G) blood glucose, (H) blood lactate, and (I)
plasma free fatty acids (FFA) in mice subjected to a single bout of exercise; (J)
Schematic illustrating changes in glucose utilization occurring with acute and
chronic exercise, i.e., exercise-induced metabolic periodicity. Data are
represented as mean ± SEM; *p<0.05, **p<0.01, ****p<0.0001; n = 5–8 per group.
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FIGURE 13
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Figure 14: Exercise training does not alter the abundance of key glucosemetabolizing enzymes. Western blot analysis of enzymes in glycolysis and
glucose metabolism: (A) Representative western blots of hexokinase 2 (HK2),
phosphofructokinase (PFK1), phosphofructo-kinase/fructose-bisphosphatase 2
(PFKFB2; PFK2), phosphofructo-kinase/fructose-bisphosphatase 3 (PFKFB3;
PFK2), pyruvate kinase (PKM1/2), pyruvate dehydrogenase kinase 1 (PDHK1),
glutamine:fructose-6-phosphate aminotransferase 1 (GFAT1), glycogen synthase
(GS), and lactate dehydrogenase b (LDHB); (B) Quantification of western blots
from A. Data are represented as mean ± SEM; n = 6 per group; in all cases, p>0.05
after Bonferroni correction.
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mice was subjected to a single bout of exercise for 40 min. Immediately following
this exercise bout, mice were euthanized and the hearts were excised for
biochemical analysis. We found that p-PFK2 levels in these hearts were
remarkably lower than those in sedentary controls (Fig. 13D), suggesting that a
bout of exercise might acutely decrease the rate of glycolysis in the heart. Because
measurement of glycolytic rate ex vivo would likely obfuscate the metabolic
changes that occur during or shortly after a bout of exercise (due to loss of
hemodynamic, metabolic, and paracrine [e.g. catecholamine] influence), we chose
to measure glycogen content as an additional surrogate of PFK activity and
glycolysis. Thus, we hypothesized that, during exercise, PFK-mediated decreases
in glycolytic rate should promote glycogen accumulation (Fig. 13E), which is
consistent with the notion that decreases in PFK activity promote glycogenesis.239
Indeed, glycogen content was elevated >5-fold in hearts collected immediately
after a single bout of exercise (Fig. 13F). Notably, this elevation in cardiac
glycogen is not related to the short (6 h) fasting period occurring in sedentary and
exercised mice because independent experiments showed that fasting mice for
this duration does not affect myocardial glycogen content (unfasted, 0.17±0.03
µg/mg tissue; 6 h fasted, 0.18±0.05 µg/mg tissue; n=7–8 per group).
Because substrate availability and delivery are key determinants of
myocardial substrate preference and utilization,75,

78, 79, 100

we measured the

circulating levels of glucose, lactate, and free fatty acids in mice immediately
following a bout of exercise. Compared with pre-exercise levels, mice subjected to
40 min of treadmill exercise showed a 50% decrease in blood glucose and a 2.5-
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fold increase in blood lactate (Fig. 13G,H). Moreover, plasma free fatty acids were
significantly elevated (Fig. 13I), which along with the changes in blood glucose
and lactate, would stimulate lactate and fat oxidation and diminish overall glucose
utilization. These data are concordant with our biochemical measurements and
provide convergent evidence suggesting that, during and immediately after
exercise, the rate of myocardial glycolysis is diminished; however, upon adaptation
and full recovery, the steady-state rates of glycolysis appear to be increased in the
heart (Fig. 13J).

Phosphofructokinase is a strong regulator of the glucose-fatty acid cycle in the
heart. We next examined whether exercise-induced periodicity in glucose
metabolism might be essential for structural and functional cardiac adaptation. This
hypothesis is consistent with the notion that repetitive bouts of exercise are a
trigger for the transcriptional adaptation in skeletal muscle.8 As tools to examine
the relationship between changes in myocardial glucose metabolism and cardiac
remodeling, we used genetically modified mice expressing kinase-deficient
(GlycoLo) or phosphatase-deficient (GlycoHi) point-mutant isoforms of PFK2 under
the control of the α-MHC promoter, which constitutively decrease or increase PFK1
activity and myocardial glycolytic rate.220,

221

Compared with cardiomyocytes

isolated from WT mice, the abundance of F-2,6-P2 was >2-fold lower in GlycoLo
cardiomyocytes and >5-fold higher in GlycoHi cardiomyocytes (Fig. 15A). The rate
of glycolysis in perfused hearts was in accordance with transgene-induced
alterations in F-2-6-P2 (Fig. 15B). Consistent with the notion that PFK activity
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regulates glycogen storage,239 GlycoLo hearts showed 1.6-fold higher myocardial
glycogen content, and GlycoHi hearts demonstrated 4-fold lower levels of glycogen
(Fig. 15C).
To determine how glycolysis affects myocardial metabolism, we measured
the steady-state abundance of myocardial metabolites in both GlycoLo and GlycoHi
hearts (Fig. 15D). PCA showed that the relative abundances of metabolites could
discriminate between the genotypes (Fig. 15E). Volcano plot analysis
demonstrated that, out of the 424 metabolites measured, 108 metabolites in
GlycoLo hearts (Fig. 16A, Table 5) and 109 metabolites in GlycoHi hearts (Fig. 16B,
Table 6) were significantly different from WT hearts. Visualization of changes in
the metabolic network demonstrated the greatest impact on the lipid superfamily,
with acylcarnitines (subfamily 1) showing robust, diametrically opposite changes
in the GlycoLo and GlycoHi hearts (Fig. 15F, G). Z-score analyses illustrate
remarkable increases in medium and long chain acylcarnitines in GlycoHi hearts;
the corresponding species were lower in abundance in GlycoLo hearts (Fig. 17A
and Tables 5, 6). In addition, long chain fatty acids (saturated and unsaturated)
were lower in GlycoLo mice, while many of the same species were elevated in
GlycoHi mice (Fig. 15F, G, Fig. 17A, and Tables 5, 6). Interestingly, GlycoLo hearts
demonstrated elevated levels of aconitate, homocitrate, and α-ketoglutarate (Fig.
15F, G and Table 5), suggesting that high rates of lipid oxidation in these hearts
might flood the Krebs cycle. Glycolytic intermediates were lower in GlycoHi mice,
while most glycolytic intermediates were unchanged in abundance in GlycoLo
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Figure 15: Cardiac F-2,6-P2 regulates myocardial glucose and lipid
metabolism. Metabolic phenotyping of GlycoLo and GlycoHi mice: (A) Levels of FLo
Hi
2,6-P2 in cardiomyocytes isolated from WT, Glyco , and Glyco mice. N = 3–6 per

group; (B) Relative myocardial glucose utilization in isolated perfused hearts. n =
5–7 per group; (C) Myocardial glycogen content. N = 7–9 per group; (D) Schematic
of 106hosphor106ics analysis of WT, GlycoLo, and GlycoHi hearts; (E) 2D PCA
analysis; (F) Metabolic network visualization of metabolites in GlycoLo and GlycoHi
hearts, compared with corresponding WT hearts. Circle size is indicative of the
magnitude of change (blue and red circles indicate significantly decreased or
increased metabolites abundance compared with WT controls, respectively).
Numbers represent metabolites in the following subpathways: 1: Acylcarnitines; 2:
Monacylglycerols; 3: Monohydroxy fatty acids; 4: Phospholipid metabolism; 5:
Lysolipids; 6: Polyunsaturated fatty acids; 7: Sphingolipids; 8: Dicarboxylic fatty
acids; 9: Long chain fatty acids; 10: Glycolysis; 11: Fructose, Mannose, Galactose
metabolism; 12: Pentose metabolism; 13: TCA cycle; 14: Purine metabolism,
(hypo)xanthine/inosine; 15: Purine metabolism, adenine; 16: Gly, Ser, Thr
metabolism; 17: BCAA metabolism; 18: Met, Cys, SAM, Tau metabolism; (G)
Overview of changes in major metabolic subpathways in GlycoLo and GlycoHi
hearts (F). *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 vs. the indicated group.
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Figure 16: Metabolomic changes in the GlycoLo and GlycoHi mouse hearts.
Following a 6 h fast, hearts were freeze-clamped in situ. The relative abundance
of metabolites in the hearts was measured by LC/MS/MS. Volcano plot showing
metabolites that changed ≥ 1.25-fold (p ≤ 0.05) in (A) GlycoLo and (B) GlycoHi
hearts compared with WT hearts; A list of metabolites found to be significantly
different in these hearts can be found in Tables S3 and S4. N = 9 WT, 10 GlycoLo,
10 GlycoHi mouse hearts per group.
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Table 5: Significantly different metabolites in hearts from WT and GlycoLo
mice. Metabolites extracted from the hearts of WT and cardiac-specific kd-PFK2
transgenic mice (GlycoLo mice) were subjected to LC/MS analysis. Raw area
counts from each identified metabolite were log-transformed, autoscaled, and then
subjected to statistical analyses (t-test). Missing values were imputed using half
the minimum value of observed raw area count data, and metabolites with >50%
values missing were omitted from the analysis. Asterisks (*) indicate compounds
that were not officially confirmed based on a standard, but whose identity matches
the expected exact mass using the UHPLC/MS/MS2 accurate mass platform.
Shown are those metabolites with a p value threshold of 0.05 and a fold change
threshold of 1.25. n = 9 WT mice and n = 10 GlycoLo mice. #S-methylmethionine
was not detected in any of the WT samples, and campesterol was detected only
in one WT sample; thus, the relative fold change values are based upon imputed
values (i.e., half the minimum value reported for the particular metabolite).

110

#

S-methylmethionine
maltotriose
ribonate
N-acetylaspartate (NAA)
aconitate [cis or trans]
p-cresol-glucuronide*
p-cresol sulfate
1-linoleoyl-2-arachidonoyl-GPE (18:2/20:4)*
orotidine
methyl glucopyranoside (alpha + beta)
1-stearoyl-2-oleoyl-GPC (18:0/18:1)
hexanoylglycine
glutamate
stachydrine
maltose
kynurenine
1-(1-enyl-palmitoyl)-2-oleoyl-GPC (P16:0/18:1)*
deoxycarnitine
2-methylcitrate/homocitrate
mannitol/sorbitol
gulonic acid*
1-stearoyl-2-arachidonoyl-GPE (18:0/20:4)
alpha-ketoglutarate
1-palmitoyl-2-arachidonoyl-GPE (16:0/20:4)*
N-acetylmethionine
methylsuccinate
1,2-dioleoyl-GPC (18:1/18:1)*
1-palmitoyl-2-palmitoleoyl-GPC (16:0/16:1)*
glycerophosphoglycerol
nicotinamide ribonucleotide (NMN)
1,2-dilinoleoyl-GPE (18:2/18:2)*
methionine sulfone
1-stearoyl-2-oleoyl-GPE (18:0/18:1)
thiamin monophosphate
4-hydroxy-2-nonenal
beta-hydroxyisovalerate
palmitate (16:0)

Metabolite

HMDB01161
HMDB00247
HMDB00208
HMDB05323
HMDB11745
HMDB01844
C03274
HMDB00229
HMDB02666
HMDB04362
HMDB00754
HMDB00220

Identifier
(KEGG or
HMBD)
C05319
HMDB01262
HMDB00867
HMDB00812
HMDB00072
HMDB11686
HMDB11635
HMDB00788
HMDB00701
HMDB00148
HMDB04827
HMDB00163
HMDB00684
<0.0001
0.0054
<0.0001
<0.0001
0.0018
0.0031
0.0015
0.0391
<0.0001
0.0002
<0.0001
0.0299
<0.0001
0.0152
0.0133
0.0262
<0.0001
0.0009
0.0068
0.0007
0.0107
0.0017
0.0017
0.0007
0.0035
0.0098
0.0019
0.0009
0.0223
<0.0001
0.0062
0.0269
0.0002
0.0012
0.0131
0.0139
0.0019

1.45
1.42
1.40
1.37
1.36
1.36
1.34
1.33
1.32
1.32
1.29
1.28
1.28
1.28
1.27
1.27
1.26
1.25
0.80
0.78

p value

Relative Fold
Change
(GlycoLo /WT)
1228
4.29
3.49
2.26
2.20
1.90
1.89
1.81
1.74
1.61
1.61
1.60
1.53
1.52
1.52
1.52
1.49
0.0088
0.0367
0.0080
0.0508
0.0133
0.0133
0.0080
0.0214
0.0481
0.0137
0.0088
0.0885
0.0015
0.0339
0.1038
0.0032
0.0106
0.0577
0.0594
0.0137

<0.0001
0.0304
0.0004
<0.0001
0.0137
0.0197
0.0120
0.1349
<0.0001
0.0032
<0.0001
0.1094
<0.0001
0.0632
0.0577
0.1028
0.0004

q value

Lipid
Lipid
Energy
Carbohydrate
Cofactor/Vitamin
Lipid
Energy
Lipid
Amino acid
Amino acid
Lipid
Lipid
Lipid
Cofactor/Vitamin
Lipid
Amino acid
Lipid
Cofactor/Vitamin
Lipid
Amino acid
Lipid

Amino acid
Carbohydrate
Carbohydrate
Amino acid
Energy
Amino acid
Amino acid
Lipid
Nucleotide
Xenobiotic
Lipid
Lipid
Amino acid
Xenobiotic
Carbohydrate
Amino acid

Super Pathway

Plasmalogen
Carnitine metabolism
TCA cycle
Fructose, mannose, galactose metabolism
Ascorbate/Alderate metabolism
Phospholipid
TCA cycle
Phospholipid
Met, Cys, SAM, Tau metabolism
BCAA metabolism
Phospholipid
Phospholipid
Glycerolipid
Nicotinate/Nicotinamide metabolism
Phospholipid
Met, Cys, SAM, Tau metabolism
Phospholipid
Thiamine metabolism
Fatty acid, oxidized
BCAA metabolism
Long chain fatty acid

Met, Cys, SAM, Tau metabolism
Glycogen metabolism
Pentose metabolism
Ala, Asp metabolism
TCA cycle
Phe, Tyr metabolism
Phe, Tyr metabolism
Phospholipid
Pyrimidine metabolism, orotate containing
Food component
Phospholipid
Fatty acid metabolism, acylglycine
Glutamate metabolism
Food component
Glycogen metabolism
Tryptophan metabolism

Metabolic Subpathway(s)
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N6-carboxyethyllysine
5-dodecenoate (12:1n7)
12-HEPE
azelate (nonanedioate)
1-linoleoyl-GPC (18:2)
2-methylmalonyl carnitine
oleate/vaccenate (18:1)
octadecanedioate
3-hydroxyoctanoate
nonadecanoate (19:0)
argininosuccinate
1-palmitoyl-GPC (16:0)
homoarginine
1-methylimidazoleacetate
succinylcarnitine
1-oleoyl-GPG (18:1)*
1-palmitoyl-2-linoleoyl-glycerol (16:0/18:2)*
arachidonate (20:4n6)
1-palmitoyl-GPE (16:0)
2-hydroxyadipate
glycerol
1-arachidonoyl-GPI (20:4)*
1-linoleoyl-GPE (18:2)*
15-HETE
10-nonadecenoate (19:1n9)
linolenate [alpha or gamma; (18:3n3 or 6)]
1-oleoyl-3-linoleoyl-glycerol (18:1/18:2)
13-HODE + 9-HODE
arachidate (20:0)
1-stearoyl-GPE (18:0)
linoleate (18:2n6)
stearidonate (18:4n3)
trans-4-hydroxyproline
isovalerylcarnitine
2-hydroxyglutarate

Metabolite

Identifier
(KEGG or
HMBD)
HMDB00529
HMDB10202
HMDB00784
HMDB10386
HMDB13133
HMDB00782
HMDB01954
HMDB00772
HMDB00052
HMDB10382
HMDB00670
HMDB02820
HMDB01043
HMDB11503
HMDB00321
HMDB00131
HMDB61690
HMDB11507
HMDB02110
HMDB13622
HMDB03073
HMDB02212
HMDB11130
HMDB00673
HMDB06547
HMDB00725
HMDB00688
HMDB00606

Relative Fold
Change
(GlycoLo /WT)
0.78
0.77
0.76
0.76
0.76
0.75
0.75
0.74
0.74
0.74
0.74
0.73
0.73
0.72
0.71
0.70
0.69
0.68
0.68
0.67
0.67
0.67
0.67
0.65
0.64
0.64
0.63
0.63
0.63
0.63
0.63
0.63
0.63
0.62
0.62
0.0104
0.0113
0.0036
0.0132
0.0028
<0.0001
0.0132
0.0052
0.0320
0.0019
0.0474
<0.0001
0.0166
0.0446
<0.0001
0.0048
0.0424
0.0050
0.0407
0.0083
0.0008
0.0079
0.0449
0.0147
0.0008
0.0078
0.0344
0.0009
<0.0001
0.0398
0.0004
0.0286
0.0004
0.0478
0.0054

p value
0.0506
0.0528
0.0216
0.0577
0.0187
0.0002
0.0577
0.0299
0.1151
0.0137
0.1525
<0.0001
0.0678
0.1466
<0.0001
0.0285
0.1408
0.0296
0.1373
0.0419
0.0087
0.0407
0.1466
0.0617
0.0086
0.0407
0.1217
0.0088
0.0002
0.1364
0.0053
0.1075
0.0051
0.1526
0.0304

q value
Amino acid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Amino acid
Lipid
Amino acid
Amino acid
Energy
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Amino acid
Amino acid
Lipid

Super Pathway
Lysine metabolism
Medium chain fatty acid
Eicosanoid
Fatty acid, dicarboxylate
Lysolipid
Fatty acid synthesis
Long chain fatty acid
Fatty acid, dicarboxylate
Fatty acid, monohydroxy
Long chain fatty acid
Urea cycle; Arg/Pro metabolism
Lysolipid
Urea cycle; Arg/Pro metabolism
Histidine metabolism
TCA cycle
Lysolipid
Diacylglycerol
Long chain fatty acid
Lysolipid
Fatty acid, dicarboxylate
Glycerolipid metabolism
Lysolipid
Lysolipid
Eicosanoid
Long chain fatty acid
Polyunsaturated fatty acid
Diacylglycerol
Fatty acid, monohydroxy
Long chain fatty acid
Lysolipid
Polyunsaturated fatty acid
Polyunsaturated fatty acid
Urea cycle; Arg/Pro metabolism
BCAA metabolism
Fatty acid, dicarboxylate

Metabolic Subpathway(s)
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N6-carboxyethyllysine
5-dodecenoate (12:1n7)
12-HEPE
azelate (nonanedioate)
1-linoleoyl-GPC (18:2)
2-methylmalonyl carnitine
oleate/vaccenate (18:1)
octadecanedioate
3-hydroxyoctanoate
nonadecanoate (19:0)
argininosuccinate
1-palmitoyl-GPC (16:0)
homoarginine
1-methylimidazoleacetate
succinylcarnitine
1-oleoyl-GPG (18:1)*
1-palmitoyl-2-linoleoyl-glycerol (16:0/18:2)*
arachidonate (20:4n6)
1-palmitoyl-GPE (16:0)
2-hydroxyadipate
glycerol
1-arachidonoyl-GPI (20:4)*
1-linoleoyl-GPE (18:2)*
15-HETE
10-nonadecenoate (19:1n9)
linolenate [alpha or gamma; (18:3n3 or 6)]
1-oleoyl-3-linoleoyl-glycerol (18:1/18:2)
13-HODE + 9-HODE
arachidate (20:0)
1-stearoyl-GPE (18:0)
linoleate (18:2n6)
stearidonate (18:4n3)
trans-4-hydroxyproline
isovalerylcarnitine
2-hydroxyglutarate

Metabolite

Identifier
(KEGG or
HMBD)
HMDB00529
HMDB10202
HMDB00784
HMDB10386
HMDB13133
HMDB00782
HMDB01954
HMDB00772
HMDB00052
HMDB10382
HMDB00670
HMDB02820
HMDB01043
HMDB11503
HMDB00321
HMDB00131
HMDB61690
HMDB11507
HMDB02110
HMDB13622
HMDB03073
HMDB02212
HMDB11130
HMDB00673
HMDB06547
HMDB00725
HMDB00688
HMDB00606

Relative Fold
Change
(GlycoLo /WT)
0.78
0.77
0.76
0.76
0.76
0.75
0.75
0.74
0.74
0.74
0.74
0.73
0.73
0.72
0.71
0.70
0.69
0.68
0.68
0.67
0.67
0.67
0.67
0.65
0.64
0.64
0.63
0.63
0.63
0.63
0.63
0.63
0.63
0.62
0.62
0.0104
0.0113
0.0036
0.0132
0.0028
<0.0001
0.0132
0.0052
0.0320
0.0019
0.0474
<0.0001
0.0166
0.0446
<0.0001
0.0048
0.0424
0.0050
0.0407
0.0083
0.0008
0.0079
0.0449
0.0147
0.0008
0.0078
0.0344
0.0009
<0.0001
0.0398
0.0004
0.0286
0.0004
0.0478
0.0054

p value
0.0506
0.0528
0.0216
0.0577
0.0187
0.0002
0.0577
0.0299
0.1151
0.0137
0.1525
<0.0001
0.0678
0.1466
<0.0001
0.0285
0.1408
0.0296
0.1373
0.0419
0.0087
0.0407
0.1466
0.0617
0.0086
0.0407
0.1217
0.0088
0.0002
0.1364
0.0053
0.1075
0.0051
0.1526
0.0304

q value
Amino acid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Amino acid
Lipid
Amino acid
Amino acid
Energy
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Amino acid
Amino acid
Lipid

Super Pathway
Lysine metabolism
Medium chain fatty acid
Eicosanoid
Fatty acid, dicarboxylate
Lysolipid
Fatty acid synthesis
Long chain fatty acid
Fatty acid, dicarboxylate
Fatty acid, monohydroxy
Long chain fatty acid
Urea cycle; Arg/Pro metabolism
Lysolipid
Urea cycle; Arg/Pro metabolism
Histidine metabolism
TCA cycle
Lysolipid
Diacylglycerol
Long chain fatty acid
Lysolipid
Fatty acid, dicarboxylate
Glycerolipid metabolism
Lysolipid
Lysolipid
Eicosanoid
Long chain fatty acid
Polyunsaturated fatty acid
Diacylglycerol
Fatty acid, monohydroxy
Long chain fatty acid
Lysolipid
Polyunsaturated fatty acid
Polyunsaturated fatty acid
Urea cycle; Arg/Pro metabolism
BCAA metabolism
Fatty acid, dicarboxylate

Metabolic Subpathway(s)
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Table 6: Significantly different metabolites in hearts from WT and GlycoHi
mice. Metabolites extracted from the hearts of WT and cardiac-specific pd-PFK2
transgenic mice (GlycoHi mice) were subjected to LC/MS analysis. Raw area
counts from each identified metabolite were log-transformed, autoscaled, and then
subjected to t-test analysis. Missing values were imputed using half the minimum
value of observed raw area count data, and metabolites with >50% values missing
were omitted from the analysis. The asterisk (*) indicates compounds that were
not officially confirmed based on a standard, but whose identity matches the
expected exact mass using the UHPLC/MS/MS2 accurate mass platform. Shown
are those metabolites with a p value threshold of 0.05 and a fold change threshold
of 1.25. n = 9 WT mice and n = 10 GlycoHi mice.
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cis-4-decenoyl carnitine
linoleoylcarnitine*
palmitoleoylcarnitine*
myristoleoylcarnitine*
butyrylcarnitine
decanoylcarnitine
myristoylcarnitine
isovalerylcarnitine
laurylcarnitine
1,2-dilinoleoyl-GPE (18:2/18:2)*
palmitoylcarnitine
octanoylcarnitine
cystathionine
1-stearoyl-2-linoleoyl-GPE (18:0/18:2)*
1-myristoylglycerol (14:0)
hexanoylcarnitine
1-palmitoleoyl-2-linoleoyl-GPC (16:1/18:2)*
oleoylcarnitine
stearoylcarnitine
1-oleoyl-2-linoleoyl-GPC (18:1/18:2)*
saccharopine
1,2-dilinoleoyl-GPC (18:2/18:2)
isobutyrylcarnitine
2-myristoylglycerol (14:0)
2-methylbutyrylcarnitine (C5)
1-stearoyl-2-oleoyl-GPC (18:0/18:1)
1-palmitoyl-2-linoleoyl-GPG (16:0/18:2)
adenosine 5'-monophosphate (AMP)
glycerophosphoglycerol
1-oleoyl-2-linoleoyl-GPE (18:1/18:2)*
1-palmitoyl-2-arachidonoyl-GPE (16:0/20:4)*
beta-hydroxyisovaleroylcarnitine
1-palmitoyl-2-palmitoleoyl-GPC (16:0/16:1)*
1-palmitoyl-2-linoleoyl-GPE (16:0/18:2)
1-stearoyl-2-arachidonoyl-GPC (18:0/20:4)
1-arachidonoyl-GPE (20:4n6)*

Metabolite

Identifier
(KEGG or
HMBD)
HMDB06469
HMDB02013
HMDB00651
HMDB05066
HMDB00688
HMDB02250
HMDB00222
HMDB00791
HMDB00099
HMDB11561
HMDB00705
HMDB05065
HMDB00848
HMDB00279
HMDB00736
HMDB00378
HMDB00045
C03274
HMDB05349
HMDB05323
HMDB05322
HMDB11517

Relative Fold
Change
(GlycoHi/WT)
4.63
3.38
3.34
3.27
3.26
3.07
2.63
2.62
2.56
2.53
2.52
2.51
2.46
2.14
2.13
2.08
2.08
1.98
1.97
1.96
1.89
1.86
1.85
1.81
1.77
1.76
1.76
1.76
1.74
1.74
1.73
1.72
1.72
1.71
1.70
1.68
0.0060
0.0007
0.0009
0.0004
0.0033
0.0024
0.0026
0.0018
0.0016
<0.0001
0.0038
0.0008
<0.0001
<0.0001
0.0247
0.0003
<0.0001
0.0099
0.0030
<0.0001
0.0037
<0.0001
0.0233
0.0496
0.0070
<0.0001
<0.0001
0.0393
0.0002
<0.0001
<0.0001
0.0005
<0.0001
<0.0001
<0.0001
0.0007

p value
0.0330
0.0070
0.0080
0.0048
0.0215
0.0177
0.0180
0.0141
0.0127
<0.0001
0.0226
0.0075
<0.0001
<0.0001
0.1000
0.0039
<0.0001
0.0500
0.0200
<0.0001
0.0226
<0.0001
0.0962
0.1649
0.0298
<0.0001
0.0008
0.1330
0.0027
<0.0001
<0.0001
0.0051
<0.0001
0.0003
<0.0001
0.0071

q value
Lipid
Lipid
Lipid
Lipid
Lipid/Amino acid
Lipid
Lipid
Amino acid
Lipid
Lipid
Lipid
Lipid
Amino Acid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Lipid
Amino acid
Lipid
Amino acid
Lipid
Amino acid
Lipid
Lipid
Nucleotide
Lipid
Lipid
Lipid
Amino acid
Lipid
Lipid
Lipid
Lipid

Super Pathway
Acylcarnitine
Acylcarnitine
Acylcarnitine
Acylcarnitine
Acylcarnitine/BCAA metabolism
Acylcarnitine
Acylcarnitine
BCAA metabolism
Acylcarnitine
Phospholipid
Acylcarnitine
Acylcarnitine
Met, Cys, SAM, Tau metabolism
Phospholipid
Monoacylglycerol
Acylcarnitine
Phospholipid
Acylcarnitine
Acylcarnitine
Phospholipid
Lysine metabolism
Phospholipid
BCAA metabolism
Monoacylglycerol
BCAA metabolism
Phospholipid
Phospholipid
Purine, Adenine containing
Glycerolipid
Phospholipid
Phospholipid
BCAA metabolism
Phospholipid
Phospholipid
Phospholipid
Lysolipid

Metabolic Subpathway(s)

TABLE 6
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1-stearoyl-2-linoleoyl-GPC (18:0/18:2)*
1-stearoyl-2-arachidonoyl-GPE (18:0/20:4)
1-linoleoyl-2-arachidonoyl-GPC (18:2/20:4n6)*
erucate (22:1n9)
1-(1-enyl-palmitoyl)-2-arachidonoyl-GPC (P16:0/20:4)*
N6-succinyladenosine
pyridoxal
benzoate
gamma-aminobutyrate (GABA)
1-(1-enyl-stearoyl)-2-arachidonoyl-GPE (P18:0/20:4)*
oxalate (ethanedioate)
stachydrine
1-palmitoyl-2-arachidonoyl-GPC (16:0/20:4)
1-palmitoyl-2-linoleoyl-GPC (16:0/18:2)
glycine
2-oleoylglycerol (18:1)
1,2-dioleoyl-GPC (18:1/18:1)*
ornithine
1-palmitoyl-2-oleoyl-GPC (16:0/18:1)
succinylcarnitine
pimelate (heptanedioate)
homostachydrine*
N-glycolylneuraminate
cytidine-5'-diphosphoethanolamine
1-(1-enyl-palmitoyl)-2-linoleoyl-GPC (P16:0/18:2)*
betaine
2-methylmalonyl carnitine
4-hydroxy-2-nonenal
N6-carboxyethyllysine
1-(1-enyl-palmitoyl)-2-arachidonoyl-GPE (P16:0/20:4)*
1-stearoyl-2-arachidonoyl-GPI (18:0/20:4)
sedoheptulose
phosphoethanolamine
asparagine
myo-inositol
4-cholesten-3-one

Metabolite
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HMDB03219
HMDB00224
HMDB00168
HMDB00211
HMDB00921

HMDB00043
HMDB13133
HMDB04362
-

HMDB05779
HMDB02329
HMDB04827
HMDB00123
HMDB03374
HMDB00857
HMDB33433
HMDB00833
HMDB01564

HMDB00912
HMDB01545
HMDB01870
HMDB00112

Identifier
(KEGG or
HMBD)
HMDB02068
<0.0001
<0.0001
0.0002
0.0140
0.0004
0.0488
0.0037
0.0365
0.0067
0.0020
0.0012
0.0120
<0.0001
<0.0001
0.0013
0.0232
0.0007
0.0260
<0.0001
<0.0001
0.0005
0.0416
0.0014
0.0052
0.0001
0.0016
0.0001
0.0042
0.0038
0.0032
0.0002
0.0104
0.0029
0.0019
0.0135
0.0022

1.49
1.46
1.45
1.45
1.44
1.44
1.44
1.44
1.42
1.41
1.41
1.38
1.38
1.37
1.37
1.36
1.36
1.35
1.35
1.33
1.32
1.31
1.31
1.30
1.29
1.29
1.28
1.28
1.27
0.79
0.79

p value

Relative Fold
Change
(GlycoHi/WT)
1.67
1.66
1.64
1.57
1.50

0.0024
0.0519
0.0198
0.0141
0.0650
0.0164

0.0127
0.0023
0.0226
0.0226
0.0207

0.0082
0.0877
0.0011
<0.0001
0.0120
0.0646
0.0071
0.1038
<0.0001
<0.0001
0.0053
0.1442
0.0120
0.0298
0.0022

0.1637
0.0226
0.1330
0.0362
0.0146

0.0001
<0.0001
0.0024
0.0661
0.0048

q value

Lipid
Lipid
Carbohydrate
Lipid
Amino acid
Lipid
Lipid

Lipid
Amino acid
Lipid
Lipid
Amino acid

Lipid
Cofactor/Vitamin
Xenobiotic
Lipid
Lipid
Amino acid
Lipid
Lipid
Amino acid
Lipid
Energy
Lipid
Xenobiotic
Xenobiotic
Lipid

Lipid
Nucleotide
Cofactor/Vitamin
Xenobiotic
Amino acid

Lipid
Lipid
Lipid
Lipid

Super Pathway

Plasmalogen
Phospholipid
Pentose metabolism
Phospholipid metabolism
Ala/Asp metabolism
Inositol metabolism
Sterol

Plasmalogen
Gly, Ser, Thr metabolism
Fatty acid synthesis
Fatty acid, oxidized
Lysine metabolism

Plasmalogen
Ascorbate/Aldarate metabolism
Food component
Phospholipid
Phospholipid
Gly, Ser, Thr metabolism
Monoacylglycerol
Phospholipid
Urea cycle; Arg, Pro metabolism
Phospholipid
TCA cycle
Fatty acid, dicarboxylate
Food component
Food component
Phospholipid metabolism

Plasmalogen
Purine, Adenine containing
Vitamin B6 metabolism
Benzoate metabolism
Glutamate metabolism

Phospholipid
Phospholipid
Phospholipid
Long chain fatty acid

Metabolic Subpathway(s)
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N1-methyladenosine
1-palmitoyl-GPC (16:0)
maleamate
2-piperidinone
mannose
N-delta-acetylornithine
1-(1-enyl-palmitoyl)-GPC (P-16:0)*
stearoyl sphingomyelin (d18:1/18:0)
sphingomyelin (d18:1/20:0, d16:1/22:0)*
citrulline
1-stearoyl-GPG (18:0)
hippurate
thiamin (Vitamin B1)
fructose
arabitol/xylitol
dihydroxyacetone phosphate (DHAP)
lactate
homocitrulline
mannitol/sorbitol
3-phosphoglycerate
1-palmitoyl-GPG (16:0)*
1-oleoyl-GPI (18:1)
carnosine
1-palmitoyl-GPI (16:0)*
anserine
phosphoenolpyruvate (PEP)
maltotetraose

Metabolite

Identifier
(KEGG or
HMBD)
HMDB03331
HMDB10382
C01596
HMDB00169
HMDB01348
HMDB00904
HMDB00714
HMDB00235
HMDB00660
HMDB01473
HMDB00190
HMDB00679
HMDB00247
HMDB00807
HMDB00033
HMDB61695
HMDB00194
HMDB00263
HMDB01296

Relative Fold
Change
(GlycoHi/WT)
0.78
0.77
0.77
0.76
0.76
0.76
0.74
0.74
0.74
0.73
0.72
0.71
0.69
0.68
0.68
0.66
0.63
0.62
0.59
0.58
0.58
0.48
0.46
0.46
0.45
0.36
0.27
0.0049
<0.0001
0.0193
0.0127
0.0025
0.0094
0.0013
0.0001
0.0004
0.0077
0.0303
0.0439
<0.0001
0.0035
0.0204
<0.0001
0.0015
0.0165
<0.0001
0.0200
0.0014
0.0003
0.0002
<0.0001
0.0004
0.0016
0.0336

p value
0.0287
0.0002
0.0873
0.0621
0.0180
0.0485
0.0114
0.0023
0.0045
0.0375
0.1185
0.1484
0.0007
0.0223
0.0887
<0.0001
0.0120
0.0765
0.0005
0.0880
0.0120
0.0035
0.0024
<0.0001
0.0048
0.0127
0.1256

q value
Nucleotide
Lipid
Cofactor/Vitamin
Xenobiotic
Carbohydrate
Amino acid
Lipid
Lipid
Lipid
Amino acid
Lipid
Xenobiotic
Cofactor/Vitamin
Carbohydrate
Carbohydrate
Carbohydrate
Carbohydrate
Amino acid
Carbohydrate
Carbohydrate
Lipid
Lipid
Peptide
Lipid
Peptide
Carbohydrate
Carbohydrate

Super Pathway

Purine, Adenine containing
Lysolipid
Nicotinate/Nicotinamide metabolism
Food component
Fructose, mannose, galactose metabolism
Urea cycle; Arg, Pro metabolism
Lysoplasmalogen
Sphingolipid
Sphingolipid
Urea cycle; Arg, Pro metabolism
Lysolipid
Benzoate metabolism
Thiamine metabolism
Fructose, mannose, galactose metabolism
Pentose metabolism
Glycolysis
Glycolysis
Urea cycle; Arg, Pro metabolism
Fructose, mannose, galactose metabolism
Glycolysis
Lysolipid
Lysolipid
Dipeptide derivative
Lysolipid
Dipeptide derivative
Glycolysis
Glycogen metabolism

Metabolic Subpathway(s)

TABLE 6
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Fig 17: Modulation of cardiac glycolytic rate regulates lipid, carbohydrate,
and amino acid metabolism. Spider charts showing average z-scores of (A) lipid
(B) carbohydrate and (C) amino acid and peptide metabolites that were
significantly different in GlycoLo or GlycoHi hearts compared with WT controls. N =
9 WT, 10 GlycoLo, 10 GlycoHi mouse hearts per group.
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FIGURE 17
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FIGURE 17
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GlycoHi
GlycoLo

120

mice (Fig. 15F, G and Fig. 17B). Changes in the steady-state abundances of
glycolytic and lipid metabolites are most consistent with increased propensity for
glucose oxidation in GlycoHi hearts and increased lipid oxidation in GlycoLo
hearts. These changes would be sufficient to explain the accumulation of
acylcarnitines and diminished levels of glycolytic intermediates occurring in
GlycoHi hearts, and the lower levels of acylcarnitines in GlycoLo hearts.
Polarization of myocardial metabolism also resulted in modest changes in amino
acid metabolites (see Fig. 17C and Tables 5, 6). Collectively, these results show
the high degree to which phosphofructokinase regulates the glucose-fatty acid
cycle in the heart.

Constitutively low glycolytic activity promotes structural and transcriptional
changes consistent with the exercise-adapted heart. To examine whether PFK
activity regulates cardiac growth, we assessed the structure and function of
GlycoLo and GlycoHi hearts. Both the GlycoLo and GlycoHi hearts showed a mild
increase in cardiac size, which was associated with increased cardiomyocyte
cross-sectional area (Fig. 18A-C, E, F); however, significantly increased capillaryto-myocyte ratio was observed only in GlycoLo hearts (Fig. 18A, D). Picrosirius red
staining showed no noteworthy myocardial fibrosis in either strain (Fig. 18A).
Interestingly, GlycoLo hearts showed elevated EDV and slightly increased wall
thicknesses compared with WT mice (Table 7), which is similar to that found in
WT, exercise-adapted mice (see Table 3). In contrast, GlycoHi hearts had
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Figure 18: Constitutive changes in glycolysis promote cardiac growth and
hypertrophy. Structural and molecular indices of cardiac growth/hypertrophy: (A)
Representative myocardial sections stained for: left panels, wheat germ agglutinin
(red), isolectin B4 (green) and DAPI (blue); and right panels, picrosirius red; (B,E)
Gravimetric measurement of cardiac size (HW/TL, heart weight/tibia length); (C,F)
Cardiomyocyte cross sectional area; (D,G) Capillary-to-myocyte ratio; (H) Basal
phosphorylation of AKT (Ser473); (I,J) Relative Mrna expression of genes
associated with the physiological growth program. Data are represented as mean
± SEM; *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001; n = 6–12 per group.
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FIGURE 18
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Table 7: Echocardiographic parameters from GlycoLo and GlycoHi mice
compared with WT controls. Cardiac structure and function were evaluated in
20-week-old, male, cardiac-specific, kd-PFK2 mice (GlycoLo mice), pd-PFK2 mice
(GlycoHI mice) and WT littermates by echocardiography. Abbreviations: HR, heart
rate; EDV, end-diastolic volume; ESV, end-systolic volume; SV, stroke volume;
EF, ejection fraction; CO, cardiac output; LVIDd, left ventricular internal diameter
in diastole; LVIDs, left ventricular internal diameter in systole; LVPWd, left
ventricular posterior wall in diastole; LVPWs, left ventricular posterior wall in
systole; LVAWd, left ventricular anterior wall in diastole; LVAWs, left ventricular
anterior wall in systole; RWT, relative wall thickness. *p<0.05, **p<0.01 vs.
corresponding WT controls.
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TABLE 7
WT
HR (bpm)
Endocardial Values
EDV (µl)
ESV (µl)
SV (µl)
EF (%)
CO (ml/min)
Chamber Diameter
LVIDd (mm)
LVIDs (mm)
Wall Thickness
LVPWd (mm)
LVPWs (mm)
LVAWd (mm)
LVAWs (mm)
RWT
(n=)

Mean
SD
486 ± 22
44
12
32
72
15

±
±
±
±
±

4
3
3
4
2

3.9 ± 0.2
2.3 ± 0.3
0.8
1.3
0.9
1.3
0.43

±
±
±
±
±
10

0.1
0.2
0.1
0.2
0.07

GlycoLo
Mean
SD
486 ± 26
49
15
34
70
16

±
±
±
±
±

5*
4
3
6
2

4.0 ± 0.3
2.3 ± 0.3
0.9
1.4
0.9
1.3
0.47

±
±
±
±
±
10
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0.1*
0.2
0.1
0.2
0.10*

WT
Mean
SD
492 ± 52
50
15
35
70
17

±
±
±
±
±

4
2
4
4
2

4.1 ± 0.2
2.5 ± 0.3
1.0
1.5
1.1
1.6
0.51

±
±
±
±
±
11

0.2
0.2
0.2
0.3
0.10

GlycoHi
Mean
SD
494 ± 38
54
20
34
63
17

±
±
±
±
±

7
5**
4
5**
2

4.4 ± 0.3*
2.9 ± 0.3**
1.0
1.4
1.2
1.6
0.45

±
±
±
±
±
11

0.1
0.1
0.2
0.2
0.07

elevated ESV, lower EF%, and larger chamber diameters, suggesting a more
dilated cardiac phenotype (Table S5).
To determine whether the signaling mediators and transcriptional programs
underlying exercise-induced cardiac growth43, 45, 46, 218 are affected by constitutive
changes in glucose utilization, we next examined the phosphorylation of AKT and
the relative expression of Cebpb and Cited4. While no differences in basal p-AKT
(S473) were observed in either strain (Fig. 18H), Cebpb expression was lower and
Cited4 expression was higher in GlycoLo hearts compared with WT counterparts
(Fig. 18I). Expression of these genes was unchanged in GlycoHi hearts (Fig. 18J).
Although Nfatc2 showed a trend toward lower expression in GlycoLo hearts, this
did not reach statistical significance. These data suggest that constitutively low or
high rates of glycolysis cause mild cardiac hypertrophy and that a low rate of
glycolysis, in the absence of AKT activation, is sufficient to promote a structural,
functional, and transcriptional phenotype resembling the exercise-adapted heart.

Metabolic inflexibility causes mitochondrial structural and functional abnormalities.
Because constitutive polarization of metabolism toward either glucose or fat
oxidation could have deleterious effects on mitochondrial structure and function,
we examined mitochondrial ultrastructure by transmission electron microscopy
and measured respiration in mitochondria isolated from the hearts of both GlycoLo
and GlycoHi mice. As shown in Fig. 19A, qualitative analysis of electron
micrographs showed disorganization of mitochondrial cristae and diminished
cristae density compared with WT littermates. Consistent with this observation,
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mitochondria from both GlycoLo and GlycoHi hearts showed lower respiration in the
presence of pyruvate+malate or succinate (Fig. 19B,C). In addition, respiratory
control ratios (RCR) were found to be lower in cardiac mitochondria from both
transgenic strains, suggesting diminished coupling of mitochondrial electron
transport to ATP synthesis (Fig. 19D). Thus, while constitutively low glycolysis
imparts some structural, functional, and transcriptional features characteristic of
the exercise-adapted heart, the mitochondrial compartment is damaged by
metabolic inflexibility.

Constitutively low glycolysis is sufficient for maximal cardiac growth. With the
observation that GlycoLo hearts have a cardiac phenotype partially resembling the
exercise-adapted heart, we next asked whether these mice are capable of
performing more work or adapting to a greater degree than their WT counterparts.
To address this question, we subjected both WT and GlycoLo mice to exercise
testing prior to and following 4 weeks of treadmill training. Although GlycoLo mice
were able to adapt systemically to the training regimen, they were not able to run
farther or perform more work than WT mice (Fig. 20A,B). Unlike WT mice, which
showed a ~15% increase in cardiac size, GlycoLo mice showed no further increase
in cardiac growth following training (Fig. 20C). Similarly, myocardial expression of
Cebpb and Cited4 were not found to be different in exercised GlycoLo mice
compared with sedentary GlycoLo mice (Fig. 20D), suggesting that their baseline
cardiac phenotype is sufficient to meet the increased cardiovascular demands
brought about by exercise. These results suggest that constitutively low glycolytic
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Figure 19: Metabolic inflexibility disrupts cristae structure and causes
mitochondrial dysfunction. (A) Electron micrographs of WT, GlycoLo, and GlycoHi
hearts. Arrows indicate areas of decreased cristae organization and density
compared to WT controls; (B) State 3 and (C) State 4 respiration in isolated cardiac
mitochondria measured using complex I (Pyruvate+Malate)- and complex II
(Succinate)-specific substrates; (D) Respiratory control ratios. Data are
represented as mean ± SEM; * p<0.05, ** p<0.01; n = 3 per group.

128

FIGURE 19
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Figure 20: Low myocardial glycolytic rates are sufficient for maximal cardiac
growth. Effects of exercise training on exercise capacity, cardiac growth, and
mitochondrial function in WT and GlycoLo mice: Pre- and post-training (A) distance
and (B) work; (C) Percent cardiac growth in exercise-adapted (Exe) mice
compared to sedentary (Sed) controls. N = 10–11 per group; (D) Relative Mrna
expression of genes associated with the physiological growth program. N = 5 per
group; (E) State 3 respiration in isolated cardiac mitochondria using complex I
(Pyruvate+Malate)-,

complex

II

(Succinate)-,

and

fatty

acid

oxidation

(Palmitoylcarnitine+malate)-specific substrates. N = 3 per group. Data are
represented as mean ± SEM; *p<0.05, ****p<0.0001.
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FIGURE 20
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D

rate is sufficient to maximally activate physiologic cardiac growth.
Because exercise could have beneficial effects on mitochondrial function,39
we next posited that it might restore mitochondrial function in GlycoLo hearts. In
WT mice, exercise did not affect state 3 respiration in the presence of any substrate
tested, and, in GlycoLo mice, exercise did not reverse mitochondrial dysfunction
caused by their metabolic phenotype (Fig. 20E).

Glycolysis regulates gene expression in the heart. To gain further insight into the
extent to which glycolysis might regulate myocardial gene expression, we
assessed relative transcript abundance in GlycoLo and GlycoHi hearts. Results of
Genechip® arrays showed that the expression of 2001 genes were significantly
different in GlycoLo and GlycoHi hearts compared with hearts of corresponding WT
mice (Up: GlycoLo, 7; GlycoHi, 309; Down: GlycoLo, 22; GlycoHi, 295 genes); 14
differentially expressed genes overlapped in GlycoLo and GlycoHi hearts). As
shown in Fig. 21A, the top 100 genes include genes critical for: intermediary
metabolism,

neurotransmission

and

ion

channel

activity/transport,

DNA

damage/repair, cell proliferation/differentiation, cell signaling, gene transcription,
inflammation and stress responses, detoxification and xenobiotic metabolism, and
cytoskeletal/contractile function. We were particularly interested in genes that are
differentially regulated by glycolysis, i.e., affected in diametric opposition with
respect to low or high glycolytic activity (Fig. 21B). In addition to Cited4, we found
that glycolysis regulates the expression of genes involved in one-carbon
metabolism and downstream methylation reactions (Pah, Phgdh, Mtr), lipid
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Figure 21: Myocardial glycolysis coordinately regulates gene transcription
in the heart. Results of transcriptomic analyses: (A) Robust Multi-array Average
(RMA) analysis of top 100 genes that were found to be the most different based
on the standard deviation across the samples; (B) Genes found to be
coordinately regulated by glycolysis: Bars indicate genes with fold-changes at
least 1.25-fold lower or higher in PFK2 mutant mice compared with WT controls.
All genes shown were significantly different between GlycoLo and GlycoHi mice at
p<0.05, after adjustment for the false discovery rate. Significant differences from
the WT controls (dotted line) using the same statistical analysis is shown by the
asterisks (*FDR-adjusted p-value<0.05); (C) Gene ontology analysis of
processes significantly regulated by low rates of glycolysis; and (D) Gene
ontology analysis of processes significantly regulated by high rates of glycolysis.
The 15 most significant processes are shown. n = 3 per group.
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FIGURE 21
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metabolism (Insg1, Angptl3), gluconeogenic activity (Fbp2), cell division (Cenpf),
osmoregulation (Cenpf, Aqp4), transcription (Tox3), G-protein signaling (Ramp1),
calcium-related processes (Rcan1, Cacna1g). Gene Ontology analysis showed
that low rates of glycolysis had a strong influence on genes involved in in oxidationreduction processes, lipid metabolism, and responses to cAMP (Fig. 21C). High
glycolytic rates also influenced genes involved in metabolism, responses to cAMP,
responses to hormonal stimuli, and transcription. Additionally, genes involved in
angiogenesis as well as differentiation showed highly significant changes (Fig.
21D). Collectively, the findings of this study indicate that the activity of
phosphofructokinase has pervasive effects on the metabolic, transcriptional,
structural, and functional characteristics of the adult heart.

Discussion
In this study, we provide evidence suggesting that exercise dynamically
regulates myocardial glycolytic activity at the level of phosphofructokinase. To
assess the importance of exercise-induced periodicity in glucose metabolism, we
used transgenic mice expressing mutant transgenes that constitutively increase or
decrease phosphofructokinase activity in the heart. Expression of a dominantnegative form of PFK2 (GlycoLo) in the heart decreased glycolytic rate and was
sufficient to modulate the Cebpb/Cited4 transcriptional program that regulates
physiologic cardiac growth.45,

46, 219

Mice in which myocardial glycolytic rate is

constitutively high also showed slight hypertrophy, but these hearts did not engage
the physiologic growth gene program. The corollary of these findings is that
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exercise-induced changes in phosphofructokinase activity are necessary to
activate transcriptional programs dictating cardiac growth and hypertrophy. This is
supported by our transcriptomics data from both GlycoLo mice and GlycoHi mice,
which revealed coordinated regulation of not only the Cited4 gene, but genes
important for epigenetic regulation, lipid metabolism, gluconeogenic activity,
contractility, and angiogenesis as well. Nevertheless, constitutive changes in
myocardial metabolism incited damage to the mitochondrial compartment.
Collectively, these results suggest that episodic decreases in glycolytic activity
caused by exercise are required for physiologic cardiac remodeling and that
metabolic flexibility is important to maintain mitochondrial health in the heart.
Our findings in the heart are reminiscent of exercise-induced changes in
skeletal muscle, where transient and repetitive changes in gene expression, likely
initiated by acute disruption of metabolic equanimity during exercise, stimulate
adaptation.8 Although testing the role of metabolic periodicity in the heart is difficult,
the post-translational regulation of PFK2 that we found to occur with exercise
provided a unique opportunity to test not only how glucose utilization affects the
cardiac phenotype, but how restricting fuel flexibility regulates cardiac structure,
function, and gene expression as well. The dominant-negative approach to
overcome the activity of endogenous myocardial PFK2, i.e., expression of the
kinase-deficient form of PFK2, was sufficient to trigger a physiologic cardiac growth
phenotype: GlycoLo hearts showed lower Cebpb and higher Cited4 expression,
which mirrored the transcriptional changes found in the exercise-adapted heart.
This transcriptional signature was complemented by a cardiac growth phenotype
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replete with enlarged myocytes and increased capillary density as well as cardiac
chamber volumes, wall thicknesses, and functional values that were nearly
identical to that found in the exercise-adapted heart. GlycoLo hearts appear to have
a maximal functional and structural physiologic growth phenotype because they
could not further activate the physiologic growth gene program or undergo
additional cardiac growth in response to the exercise regimen. Importantly, the
phenotype of GlycoLo hearts developed in the absence of AKT activation, which
has been suggested to underlie exercise-induced downregulation of Cebpb and
upregulation of Cited4 and the general cardiac growth phenotype.27,
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Thus,

these data help form a model in which exercise-induced modulation of glucose
metabolism is a proximal regulator of physiologic cardiac growth.
Several factors appear to contribute to acute, exercise-induced decreases
in glycolysis and phosphofructokinase activity. The lower circulating blood glucose
levels and increased levels of blood lactate and free fatty acids that we found to
occur immediately after a single bout of exercise suggest diminished glycolytic
activity occurring in the heart during and in the early recovery period after exercise.
Indeed, lactate and fatty acids are preferred substrates of the heart that suppress
glucose utilization both in vivo75, 77, 84 and ex vivo.78, 79 Moreover, previous studies
in humans and animal models suggest that changes in these substrates during
exercise contribute to diminished exercise oxygen extraction ratios for glucose and
lower glucose uptake and utilization.87, 109

Not only do increases in circulating

lactate and fatty acids with exercise appear to favor lower rates of glucose
utilization, they divert glucose from glycolysis to glycogen synthesis, which is
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thought to be caused in part by diminished phosphofructokinase activity.86, 130, 240
Consistent with this idea, our results show diminished phosphorylation of S483 of
PFK2 and increased levels of glycogen, which support the hypothesis that PFK1
activity and glycolysis are diminished with prolonged exercise or during the early
recovery period.

In the context of glucose utilization, changes in PFK1 are

particularly important because this node of metabolism represents the major
control point of glycolysis, exerting 65% control over flux through the pathway.235
Although constitutively low glycolytic rates appeared sufficient to drive
physiologic growth, metabolic inflexibility in both the GlycoHi and GlycoLo hearts
appeared sufficient to cause some pathology as well. While GlycoHi hearts were
enlarged, they did not demonstrate significantly increased capillary-to-myocyte
ratios; and, functionally, they presented with a mildly diminished ejection fraction,
significantly higher end systolic volume, and larger chamber diameters. These
findings are in agreement with previous studies221 and suggest that chronically
high rates of glycolysis promote a more pathological form of hypertrophy.
Furthermore, that mitochondria isolated from both GlycoHi and GlycoLo hearts
showed mitochondrial dysfunction suggests that deleterious changes in
mitochondria occurring in the heart in the context of type II diabetes or heart
failure—conditions associated with excessive myocardial reliance on fatty acids or
glucose, respectively

88, 241

—could be in part caused by severe metabolic

inflexibility. Although genetic downregulation of Cebpb and upregulation of Cited4
protect against pathologic insults,45,

46

mice with constitutively low glycolysis

subjected to pressure overload display exacerbated pathological remodeling,242
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which we suggest may be due to poor mitochondrial health caused by metabolic
inflexibility.
Although at steady state the exercise-adapted heart showed higher
glycolytic activity, we found relatively few changes in metabolite abundance. We
speculate that higher myocardial metabolic flux in the absence of changes in the
steady state abundance of metabolites may be an indication of a physiological form
of metabolic remodeling that occurs in the exercise-adapted heart. However, it
should be noted that our results contrast somewhat with a previous finding that
showed modestly lower abundances of acylcarnitines and organic acids in hearts
of female mice adapted to two months of voluntary wheel running.243

The

discrepancy between these two studies could be due to sex differences, strain
differences, differences in the training modality and/or intensity. Additionally, these
differences could be due to different methods by which hearts are handled prior to
freezing for metabolomics analysis, which is an important consideration given the
high-energy utilization of mouse heart.
Although our data support the idea that PFK-mediated modulation of
metabolism influences transcriptional programs relating to cardiac growth and
remodeling, it is possible that fat utilization or lactate oxidation, which are regulated
in concert with glucose metabolism, are also important triggers of cardiac
adaptation. Future studies to determine how exercise acutely changes the cardiac
metabolome could help answer whether changes in metabolites in each pathway
during or shortly after exercise promote biofeedback that coordinates
transcriptional programming. Moreover, identifying how exercise intensity and
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duration regulate cardiac metabolism and gene transcription would be important
for optimizing cardiac adaptations and for further understanding links between
metabolism and cardiac growth. Particularly intriguing is the question of how such
changes in metabolism may regulate epigenetic modifications. In our study, we
found that glycolysis regulated Phgdh, Mthfd2, and Mtr, which code for proteins
critical for serine biosynthesis, one-carbon metabolism, and methylation reactions.
This

could

be

significant

because

Cited4

is

epigenetically

regulated:

hypermethylation of Cited4-associated CpG islands causes lower expression of
Cited4 in oligodendroglial tumors.244 While our data do not address this
mechanism, they suggest that low glycolytic rates could prevent such methylation
events, thereby permitting Cited4 transcription, especially when appropriate stimuli
are present.
In summary, our results indicate that low rates of glycolysis during or shortly
after exercise regulate gene programs important for cardiac growth and that
invariantly high rates of glycolysis promote a more pathological form of
hypertrophy. While metabolic inflexibility is damaging to mitochondria, changes in
glucose utilization due to regular exercise appear to be important to maintain
mitochondrial health and to derive maximal cardiac benefits from physical activity.
In addition, by integrating metabolomic and transcriptomic data, these studies
provide new insights into how PFK-mediated changes in metabolism regulate gene
expression in the heart. Additional work is needed to further disclose how exercisemediated changes in metabolism regulate gene transcription and tissue
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remodeling and how these changes could be targeted to maximize the beneficial
cardiovascular effects of exercise.ii
ii

This chapter previously appeared as an article in the journal Circulation. The original
citation is as follows: Gibb AA, et al. Exercise-induced changes in glucose metabolism
promote physiologic cardiac growth. Circulation, 2017.
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CHAPTER IV
INTEGRATION OF FLUX MEASUREMENTS TO RESOLVE CHANGES IN
ANABOLIC AND CATBOLIC METABOLISM IN CARDIAC MYOCYTES

Introduction
Glycolysis is the central pathway of intermediary carbon metabolism. Not
only does catabolism of glucose via glycolysis provide useable energy for the cell,
but it contributes glycolytic intermediates that serve as branch-point metabolites
for the entry of glucose-derived carbon into ancillary pathways of glucose
metabolism. These pathways are required for de novo synthesis of cellular
components. For example, the activity of the pentose phosphate pathway (PPP) is
required for nucleotide biosynthesis and the maintenance of cellular redox state,
whereas the hexosamine biosynthetic pathway (HBP) regulates posttranslational
protein modifications, protein processing, and stress responses. The synthesis of
glycero(phospho)lipids and serine are also dependent on the production of
glycolytic intermediates.245 In the heart, the PPP is activated during hypertrophy132134

and heart failure,135 and modulating the activity of this pathway regulates the

severity of cardiac pathology.136-141 Similarly, O-linked β-N-acetylglucosamine (OGlcNAc)-modified proteins, which require synthesis of the sugar donor UDPGlcNAc via the HBP,147, 246 are elevated in hypertrophied and failing hearts.223, 247-
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Although less is known about the glycerolipid pathway (GLP), increased activity

of this pathway may underlie pathologic cardiac hypertrophy.142 In addition,
numerous studies have identified aberrant ancillary pathway behavior in the
context of diabetes [e.g., as reviewed in 250, 251].
The activities of ancillary pathways of glucose metabolism are regulated in
part through expression of their rate-limiting or committed-step enzymes, cofactor
availability, allosterism, and/or post-translational modifications [e.g.,

252-258

]. Flux

through these pathways may be regulated by other means as well. Specific
enzymatic reactions in the glycolytic pathway, especially the phosphofructokinase
1 (PFK1) reaction, can coordinate the activity of ancillary pathways in several cell
types143-146; however, the effects of PFK activity and glycolytic rate on biosynthetic
pathway flux in the heart remain unclear. Understanding how PFK regulates
ancillary biosynthetic pathway activity is important because its activity is modulated
by increased work ex vivo,259, 260 and catecholamines261 and pressure overload in
vivo.262
In this study, we examined how PFK activity regulates biosynthetic
pathways in cardiomyocytes. For this, we altered PFK1 activity by expressing
mutant forms of phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFK2) in
primary rat neonatal cardiomyocytes. This method of regulating glycolysis
leverages the strong allosteric regulation of PFK1 by F-2,6-P2184, 220, 221, 263 and is
relevant to mechanisms regulating cardiovascular homeostasis. For example,
kinases known to be important for cardiac responses to stress27, 264 are strong
regulators of PFK2 activity.236,

265-267

By integrating radiometric assays, stable
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isotope tracing, and extracellular flux analyses, we demonstrate that the amount
of glucose available for entry into ancillary pathways appears relatively high and
that the PFK node of glycolysis exerts varying degrees of control over glucose
incorporation in the end products of the PPP, the HBP, and the GLP by not only
diverting glucose carbon into these pathways, but by regulating mitochondrial
activity and cataplerosis as well.

Experimental Procedures
Materials. DMEM growth media, containing L-glutamine, D-glucose, and pyruvate,
was purchased from US Biological (Swampscott, MA, USA). Insulin, transferrin
and selenium (500×) were purchased from Lonza (Walkersville, MD, USA).
Humulin R was from Eli Lilly (Indianapolis, IN, USA). All other reagents were from
Sigma-Aldrich Corp. (St. Louis, MO, USA), unless indicated otherwise.

Rodent models. All procedures were approved by the University of Louisville
Institutional Animal Care and Use Committee and were in accordance with NIH
guidelines. The euthanasia procedures were consistent with the AVMA Guidelines
for the Euthanasia of Animals. Neonatal rat cardiomyocytes (NRCMs) were
isolated from 1- to 2-day-old Sprague-Dawley rats as previously described.149, 268,
269

Culture media was changed to serum-free DMEM media 24 h prior to each

experiment.
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Gene transfer and expression analysis. Replication-deficient adenoviral vectors
were constructed and purified by Vector BioLabs (Malvern, PA, USA) using cDNA
for mutated forms of rat liver 6-phosphofructo-2-kinase/Fru-2,6-P2 bisphosphatase
(PFKFB1 isoform of PFK2). The enzyme was engineered to have single amino
acid point mutations to foster a kinase deficient- (S32D and T55V; GlycoLo) or
phosphatase deficient- (S32A and H258A; GlycoHi) form of PFK2.220, 221, 270-272 A
1.4 kb BamHI/Nhe1 fragment of a pLenti6-3×FLAG-pd-PFK2 plasmid was
subcloned into a Dual-CCM(+) shuttle vector, which has dual CMV promoters to
drive both green fluorescent protein (GFP) and the insert. The backbone of the
adenoviral vector is type 5 (dE1/E3). An Ad-GFP control virus, in which GFP is
driven by the CMV promoter, was also purchased from Vector BioLabs.
Cardiac myocytes were transduced with adenovirus for 4 h in fresh media,
followed by PBS wash and addition of fresh media. For all viral treatments, a
multiplicity of infection (MOI) of 50 was used. Functional expression of the target
protein was confirmed by immunoblotting and eGFP fluorescence. For measuring
protein abundance, cells were lysed in a common lysis buffer containing 20 mM
HEPES, 110 mM KCl, 1 mM EDTA, 1% NP-40, 0.1% SDS, and phosphatase and
protease inhibitors. Cell lysates were then centrifuged at 13,000g for 20 min and
the supernatant was collected. Protein was measured using the standard Lowry
Assay (Bio-Rad Laboratories, Hercules, CA, USA) and separated by SDS-PAGE,
electroblotted to PVDF membranes, and probed for PFKFB1 (Novus Biologicals,
Littleton, CO, USA) according to manufacturer’s protocol. A horseradish
peroxidase-linked secondary antibody (Cell Signaling Technology, Danvers, MA,
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USA) was used to detect and visualize the protein band with a Typhoon 9400
variable mode imager (GE Healthcare, Chicago, IL, USA).

Radiolabeled glycolysis assay. The rate of glucose utilization was determined
using [5-3H]-glucose as previously described.224,

273, 274

Briefly, after 48 h of

transduction, the media was replaced with 2 ml of fresh, serum-free media
containing 5.5 or 25 mM glucose with the addition of 2 µCi/ml [5-3H]-glucose
(Moravek Biochemicals, Brea, CA, USA). Following incubation for 3 h, 100 µl of
media was collected and added to 100 µl of 0.2 M HCl in a microcentrifuge tube.
This tube, with the tube cap removed, was placed in a scintillation vial containing
500 µl of dH2O to allow for evaporation diffusion of [3H]2O in the microcentrifuge
tubes into the scintillation vials. To account for incomplete equilibration of [3H]2O
and background, known amounts (µCi) of [5-3H]-glucose and [3H]2O (Moravek
Biochemicals) were placed into microcentrifuge tubes, and these were placed into
separate scintillation vials containing 500 µl dH2O. After incubation at 37ºC for 72
h, the microcentrifuge tube was removed from the vial, 10 ml of scintillation fluid
was added, and scintillation counting was performed using a Tri-Carb 2900TR
Liquid Scintillation Analyzer (Packard Bioscience Company, Meriden, CT, USA).
Glucose utilization was then calculated as reported by Ashcroft et al.,224 with
considerations for the specific activity of [5-3H]-glucose, incomplete equilibration
and background, dilution of [5-3H]- to unlabeled-glucose, and scintillation counter
efficiency. To normalize glucose utilization to total protein, the cells were first
washed with PBS (to remove any adherent radioactivity) and then lysed in common
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lysis buffer. After centrifugation, protein concentration was measured using the
Lowry assay kit (Bio-Rad Laboratories).

Stable Isotope Tracing. NRCMs were incubated in 6-well plates for 18 h in glucosefree DMEM media containing 1 mM pyruvate and 4 mM glutamine and
supplemented with 25 mM [13C6]-glucose. Cell reactions were then quenched in
cold acetonitrile, and extracted in acetonitrile:water:chloroform (v/v/v, 2:1.5:1), as
described previously,184,

275-277

to obtain the polar, nonpolar, and insoluble

proteinaceous fractions. The nonpolar (lipid) layer was collected, dried under a
stream

of

nitrogen

gas,

and

reconstituted

in

0.1

ml

of

chloroform:methanol:butylated hydroxytoluene (2:1 + 1 mM) mixture. The extract
was diluted 10× with 1 mM butylated hydroxytoluene solution in methanol and used
for Fourier transform ion cyclotron resonance-mass spectrometry (FTICR-MS)
analysis.
For stable isotope nucleotide analysis, the samples were prepared using a
previously published protocol,184, 277 with slight modifications. Briefly, lyophilized
polar extracts were reconstituted in 50 μl of 5 mM aqueous hexylamine, adjusted
to pH 6.3 with acetic acid (solvent A). Samples were then loaded onto a 100-μl
capacity C18 tip (Thermo Fisher Scientific, Waltham, MA, USA) followed by
washing twice with 50 μl of solvent A. The metabolites were eluted with 70%
solvent A and 30% 1 mM ammonium acetate in 90% methanol, pH 8.5 (solvent B).
The resulting eluates were diluted 3× with methanol and analyzed via FTICR-MS.
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[13C6]-glucose and [13C3]-lactate measurements in the media. For quantification of
[13C6]-glucose and [13C3]-lactate in cell media, 10 μL of media were mixed with
9990 μL of 5 mM NH4OH in methanol containing 5 μM [D2]-glucose and 5 μM [D2]lactate internal standard and used without any additional pre-treatment for FTICRMS analysis and quantification.

Blank incubations without cells were run in

parallel. The concentrations of [13C]-labeled glucose and lactate were assessed
using seven-point calibration curves (0.3125 µM to 20 µM).

FTICR-MS Analysis. Lipid and nucleotide spectra and [13C]-glucose/lactate
spectra were acquired using a hybrid linear ion trap-FT-ICR mass spectrometer
(Finnigan LTQ FT; Thermo Electron, Bremen, Germany), equipped with a TriVersa
NanoMate ion source (Advion Bio-Sciences, Ithaca, NY, USA) with an A
electrospray chip (nozzle inner diameter, 5.5 μm). The TriVersa NanoMate was
operated by applying 1.5 kV with 0.5 psi head pressure in positive ion mode and
1.6 kV and 0.7 psi in the negative mode. High mass accuracy data were collected
using the FT-ICR analyzer over a mass range from 150 to 1600 Da (lipids; + and
– mode) for 15 min at the target mass resolution of 400,000 at 400 m/z. For
quantification of 13C6-glucose and 13C3-lactate in cell media, data were collected in
the negative ion mode for 2 min over a mass range from 50 to 250 Da at the target
mass resolution of 100,000 at 400 m/z. Prior to acquisition, the LTQ-FT was tuned
and calibrated according to the manufacturer’s default recommendations to
achieve mass accuracy of 2 ppm or less.
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Stable Isotope Data Analyses. The FT-ICR MS data were exported as exact mass
lists into a spreadsheet file using Qual-Browser 2.0 (Thermo Electron).
Isotopologue peak deconvolution, assignment, natural isotope abundance
stripping, and quantification were performed using MetSign software, as described
previously by us.184, 278

Extracellular flux analysis of cellular energetics. To measure cellular energetics in
intact cardiomyocytes, the Seahorse Bioscience XF24 extracellular flux analyzer
was used as previously described.279 For this, 75,000 cells were plated into each
well. An hour before each experiment, the media was replaced with 675 µl of assay
media, i.e., unbuffered DMEM containing glucose (5.5 mM), glutamine (4 mM), and
pyruvate (1 mM), pH 7.4. Following 1 h in a 37ºC, CO2-free incubator, the cells
were placed in the instrument for analysis. Basal oxygen consumption rates (OCR)
and extracellular acidification rates (ECAR) were measured using a programmed
protocol: 3 cycles of 2 min mix, 2 min wait, and 3 min measure. To interrogate the
effects of each treatment on cardiomyocyte bioenergetics, the following
compounds were injected into each well with 2 cycles of 2 min mix, 2 min wait, 3
min measure following each injection: Port A, oligomycin (Oligo; 1 µM); Port B,
carbonyl cyanide-p-(trifluoromethoxy)phenylhydrazone (FCCP; 1 µM); and Port C,
antimycin A and rotenone (AA/Rot; 10 µM / 1 µM). The OCR and ECAR values
were normalized to the total amount of protein in each well.
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Statistical Analysis. All values are mean ± S.E.M. All comparisons were made to
the relevant control group and performed using one-way analysis of variance
(ANOVA) with Dunnett’s correction for multiple comparisons. The null hypothesis
was rejected when p > 0.05.

Results
PFK regulates glycolysis and the distribution of glucose. To understand the role
of PFK activity in cardiac myocyte metabolism, we expressed kinase-deficient
(GlycoLo) or phosphatase-deficient (GlycoHi) PFK2 mutant constructs in NRCMs,
which are conducive to well-controlled and detailed metabolic flux analyses. The
mutant genes were driven by a CMV promoter (Fig. 22A), and the bicistronic
vector also contained GFP, used to determine relative transduction efficiency. As
shown in Fig. 22B, the vast majority of NRCMs were transduced with virus. These
PFK2 mutants were intentionally derived from the liver-specific isoform of PFK2
(i.e., PFKFB1) so that expression of the proteins could be assessed by
immunoblotting, without obfuscation by other isoforms (e.g., PFKFB2/PFKFB3).
Myocytes transduced with the GlycoLo or the GlycoHi constructs showed strong
bands at the predicted molecular mass for the mutant forms of PFK2, whereas
cells transduced with Ad-GFP showed no expression of PFKFB1 (Fig. 22C).
Although GlycoHi-expressing cells routinely displayed a higher level of mutant
protein expression relative to GlycoLo-expressing cells, the strength of the relative
effect of each PFK2 mutant on cellular glycolytic rate was equal, with a 2.1-fold
increase and 2.2-fold decrease in glycolytic rate for the GlycoHi and GlycoLo
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Figure 22: Phosphofructokinase activity regulates glucose metabolism in
isolated cardiomyocytes. Glucose utilization analyses in neonatal rat
cardiomyocytes: (A) Constructs of kinase-deficient and phosphatase-deficient
PFK2 engineered to decrease (GlycoLo) or increase (GlycoHi) glycolytic rate,
respectively; (B) GFP expression in cardiomyocytes 48 h after transduction (50
MOI) with adenoviruses expressing GFP only or the GlycoLo or GlycoHi
adenoviruses; (C) Immunoblot of mutant PFK2 protein expression; (D) Glycolytic
rate measured with [5-3H]-glucose under 5.5 or 25 mM glucose culture conditions.
n = 3–5 independent isolations per group; (E) 13C6-glucose uptake; (F) 13C3-lactate
production, and (G) the percentage of glucose converted to lactate following 18 h
incubation with isotopic glucose. Data in Panels E–G represent three replicates
per group. *p < 0.05, **p < 0.01, ***p < 0.001.
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FIGURE 22
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constructs, respectively (Fig. 22D). This effect on glycolytic rate was independent
of glucose concentration, as rates were similar for groups incubated with either 5.5
or 25 mM glucose.
To examine the effect of each mutant PFK2 enzyme on aerobic glycolysis,
we replaced the normal growth media with media containing [13C6]-glucose and,
after 18 h, measured the relative levels of [13C6]-glucose and [13C3]-lactate in the
media. As shown in Fig. 22E, the levels of [13C6]-glucose consumed by the cell
was 1.8-fold higher in GlycoHi-expressing cells compared with Ad-GFP, with no
difference in GlycoLo-expressing cells. Levels of [13C3]-lactate extruded into the
media was 2.5-fold higher in GlycoHi cells compared with GFP control cells and
>10-fold higher compared with GlycoLo virus transduced cells (Fig. 22F). As shown
in Fig. 22G, 29% of [13C6]-glucose was metabolized to [13C3]-lactate in GFP control
cells, whereas in GlycoLo-expressing cells, 6% of labeled glucose was metabolized
to lactate; in GlycoHi-expressing cells, 44% of labeled glucose was converted to
lactate.
Assessment of [13C6]-glucose uptake, [13C3]-lactate production, and [5-3H]glucose utilization provides estimates of not only how much glucose entered the
cell and was later extruded as lactate, but also how much made it through the
enolase step of glycolysis, where the tritiated label is eliminated as 3H2O. The
mean values of glucose uptake and lactate production (provided by stable isotope
tracing) and of radiometric measurements were used to calculate the amount of
glucose unaccounted for by catabolism to pyruvate. In GFP control
cardiomyocytes, only 44% of glucose was catabolized past the enolase step in
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glycolysis; of this fraction, the majority (65%) was converted to lactate (Fig.
23A,B). These data show that, under control conditions, a substantial amount of
glucose taken up by NRCMs is not catabolized to pyruvate and that the majority of
glucose that is catabolized to pyruvate is fated for lactate production.
As shown in Fig. 1E, glucose uptake was not different between GFP and
GlycoLo cells, yet GlycoLo myocytes demonstrated 2-fold lower glucose utilization
through the enolase step of glycolysis and 5-fold lower lactate production. In these
cells, 78% of glucose-derived carbon was partitioned upstream of the enolase
reaction, leaving 22% available for pathways downstream of enolase (Fig. 23B).
Although lactate production was markedly suppressed in GlycoLo cells, the
absolute amount of glucose-derived carbon available for either mitochondrial
oxidation, transamination to alanine, or carboxylation to oxaloacetate was identical
to that of control cells. Interestingly, while GlycoHi cells showed 80% higher levels
of glucose uptake compared with GFP control cells (see Fig. 1E), 44% of glucose
(by mass) was not catabolized via glycolysis. Nevertheless, a portion of glucose
equivalent to that apportioned upstream of enolase (0.67 nmol/h/µg protein) taken
into the cell could be accounted for as lactate (0.66 nmol/h/µg protein), and 21%
of glucose carbon that was catabolized past the enolase reaction was available for
fates other than lactate production (Fig. 23B).

PFK activity regulates glucose carbon partitioning into the PPP in NRCMs. To
determine how the activity of PFK regulates critical anabolic reactions derived from
glycolysis, we modulated glycolytic rate by expressing the GlycoLo or GlycoHi PFK2
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Figure 23. Phosphofructokinase-mediated glucose distribution in isolated
cardiomyocytes. Schematics illustrating glucose utilization in myocytes
transduced with GFP, GlycoLo or GlycoHi adenoviruses. Measurements from
radiometric and isotopic glucose utilization assays were used to delineate glucose
distribution in neonatal rat cardiomyocytes transduced with each virus. (A)
Schematic illustrating glucose distribution in control (GFP) myocytes. Distributions
of glucose are drawn to relative scale. (B) Pie chart illustrating distribution of
glucose: Numbers (in nmol/h/µg protein) and percentages (%) indicate the
absolute and relative distribution of glucose ascribed to the portions of glucose
metabolism: upstream of enolase (light red), through enolase (grey shading),
converted to lactate (yellow) and available for transamination to alanine,
anaplerotic formation of oxaloacetate (OAA), or glucose oxidation (light blue). Pie
charts are drawn to scale. Both schematics consider glucose uptake and lactate
production provided by 13C-glucose tracing and by glucose utilization measured by
radiometric assays, respectively.
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FIGURE 23
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mutants in cardiomyocytes and then assessed carbon incorporation into end
products of ancillary biosynthetic pathways using stable isotope-resolved
metabolomics.280 Expression of the GlycoHi mutant modestly diminished
incorporation of glucose-derived carbon into ATP. Lower fractional enrichment of
13

C in GlycoHi-expressing cells is attributable to decreased carbon allocation into

the phosphoribosyl ring of the nucleotide (m+5 isotopologue) (Fig. 24A, 24B),
suggesting diminished flux of 13C-labeled glucose-6-phosphate (G6P) through the
oxidative PPP (oxPPP). The higher level of the m+0 isotopologue of ATP (i.e., the
unlabeled ATP pool) in GlycoHi cells further indicates that the flux of

13

C6-G6P

through the oxPPP was lower in GlycoHi cells. Similar changes were observed in
other purines such as GTP (Fig. 24C). Myocytes expressing the GlycoLo mutant
showed

13

C fractional enrichment values into ATP that were similar to GFP-

transduced control cells (Fig. 24A, 24B), suggesting that low PFK activity does not
strongly affect purine synthesis in these cells.
For the pyrimidines CTP and UTP, we found a higher m+0 isotopologue
value in GlycoHi cells and a lower m+0 isotopologue value in GlycoLo cells
compared with GFP controls. These data suggest that high rates of glycolysis
diminish incorporation, and that low rates of glycolysis increase incorporation, of
glucose-derived carbon into pyrimidines (Fig. 24D, 24E). Interestingly, both the
GlycoLo and the GlycoHi NRCMs showed increased levels of CTP and UTP having
only the ribose ring labeled (m+5 isotopologue). These data could indicate that
either decreasing or increasing glycolysis augments oxPPP flux. This
interpretation would be consistent with the observation that both GlycoLo and
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Figure 24: Phosphofructokinase coordinates pentose phosphate pathway
activity. Isolated cardiomyocytes were transduced with GFP, GlycoLo, or GlycoHi
adenoviruses and incubated with

13

C6-glucose for 18 h. Stable isotope tracing of

nucleotides in NRCMs incubated with media containing U-13C-glucose: (A) Atomresolved map illustrating the biological and biochemical history of 13C incorporation
into the purine AMP (phosphates in ATP omitted to conserve space); Fractional
enrichment values of 13C in (B) ATP and (C) GTP after incubation with 13C-glucose;
(D) Atom-resolved map illustrating the biological and biochemical history of
incorporation into the pyrimidine UMP; Fractional enrichment values of

13

13

C

C in (E)

UTP and (F) CTP after incubation with 13C-glucose. Colored x-axis labels correlate
to the labeled molecule biosynthetic components indicated in the atom-resolved
maps. Graph represents three replicates per group from one isolation. *,$ p<0.05,
**,$$ p<0.01, ***,$$$ p<0.001, ****,$$$$ p<0.0001.
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GlycoHi cells show more glucose available for entry into ancillary biosynthetic
pathways (see Fig. 2); however, it is also possible that higher levels of m+5 labeling
could be due to an accumulation of these pyrimidine isotopologues, where the
contribution of

13

C-glucose to de novo synthesis of the uridine ring is diminished.

Indeed, examination of the m+7 and m+8 isotopologues of UTP, which likely
correspond to addition of carbons from 13C-labeled aspartate to the molecule (see
Fig. 3D), show that both the GlycoLo and GlycoHi cells have less incorporation of
13

C, which is known to derive from Krebs cycle- (m+7) or pyruvate carboxylase-

engendered (m+8) oxaloacetate. The m+6 isotopologue likely corresponds to
complete

13

C5-labeling of the ribose ring and

13

C1 labeling of aspartate, occurring

as a result of scrambling during the 2nd turn of the Krebs cycle, as suggested
previously.281 Overall, these data suggest that high PFK activity modestly
diminishes oxPPP flux and

13

C incorporation into purines. Pyrimidine synthesis

appears to be more robustly affected by PFK activity, with high rates of glycolysis
diminishing incorporation of glucose-derived carbon into UTP and CTP molecules.

High PFK activity diminishes glucose-derived carbon incorporation into UDPHexNAc. The molecular synthesis of UDP-N-acetyl hexosamines requires end
products or intermediates of several metabolic pathways, including those from the
Krebs cycle, the pyrimidine biosynthetic pathway, glutamine, and glycolysis;
hence, these pathways collectively contribute to UDP-HexNAc synthesis (Fig.
25A). To determine how the glycolytic activity affects glucose-derived carbon
allocation into the HBP, we measured fractional enrichment of
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13

C from [13C6]-

glucose into UDP-HexNAc in NRCMs transduced with GlycoLo or GlycoHi virus.
After 18 h, >90% of the UDP-HexNAc pool integrated 13C-glucose-derived carbon
(Fig. 25B), which suggests that UDP-HexNAc has a faster rate of glucose carbon
incorporation relative to purines and pyrimidines. That the m+0 isotopologue was
higher in GlycoHi cells indicates that high rates of glycolysis diminish glucose
carbon incorporation into UDP-HexNAc. The lower

13

C enrichment of many

isotopologues (e.g., m+7, m+14, m+15, m+16) appeared to be due to diminished
input of metabolites that require mitochondrial transformation of

13

C-glucose-

derived carbon; however, the m+5, m+6, and m+11 isotopologues (which are the
forms of UDP-HexNAc with the ribose, hexose, and ribose+hexose moieties
constituted with

13

C, respectively) demonstrate significantly higher fractional

enrichment in GlycoHi cells. Given that both the GlycoLo and the GlycoHi cells had
similar levels of glucose available for reactions upstream of enolase (see Fig. 2),
the simplest explanation for this result is that the mitochondrial cataplerotic
metabolites (deriving from the 13C-glucose-derived carbon source) are limiting for
the synthesis of UDP-HexNAc; as a result, the m+5 and m+6 isotopologues of the
metabolite accumulate as

13

C incorporation from cataplerotic metabolites slows

down. This would be consistent with findings in pyrimidines, which suggest that
cataplerotic generation of aspartate is limiting for the incorporation of glucosederived carbon into CTP and UTP.
Although low rates of glycolysis did not affect the overall level of
incorporation of glucose-derived carbon into UDP-HexNAc, that the m+11
isotopologue in GlycoLo cells was higher than that in control cells suggests that low
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Figure 25: High phosphofructokinase activity diminishes glucose carbon
incorporation into UDP-HexNAc. Isolated cardiomyocytes were transduced with
GFP, GlycoLo, or GlycoHi adenoviruses and incubated with

13

C6-glucose for 18 h.

Stable isotope tracing of UDP-HexNAc in NRCMs incubated with media containing
13

C-glucose: (A) Atom-resolved map illustrating the biological and biochemical

history of 13C incorporation into UDP-GlcNAc; (B) Fractional enrichment values of
13

C in UDP-HexNAc (which includes both UDP-GlcNAc and UDP-GalNAc) after

incubation with

13

C6-glucose Colored x-axis labels correlate to the labeled

molecule biosynthetic components indicated in the atom-resolved maps. Graph
represents three replicates per group from one isolation. *,$ p<0.05, **,$$ p<0.01, $$$
p<0.001, $$$$ p<0.0001.
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PFK activity promotes channeling of F6P not only into the HBP (contributing six
13

C), but, because the ribose ring is included (contributing five

13

C), the PPP as

well (Fig. 25A, 25B). Changes in the m+8 isotopologue are difficult to interpret
because this isotopologue could be comprised of 13C-labeled N-acetyl hexosamine
as well as stably labeled UDP. Altogether, these results suggest that high PFK
activity decreases glucose carbon allocation into UDP-HexNAc primarily via
limiting the mitochondria-derived and cataplerotic intermediates (e.g., acetyl CoA,
aspartate) derived initially from 13C-glucose.

PFK regulates glycerolipid synthesis in cardiomyocytes. In cardiac myocytes,
glycerolipid synthesis requires free fatty acids (FFAs) and glycerol-3-phosphate
(G3P). While FFAs can be derived from transporter-mediated uptake across the
plasma membrane,282 myocytes have a relatively low capacity for free glycerol
uptake; therefore, there is little contribution of glycerol kinase to G3P synthesis.283,
284

However, G3P can be generated from DHAP by glycerol-3-phosphate

dehydrogenase (Fig. 26A). Nevertheless, it is unclear whether or how the rate of
glycolysis affects glycerolipid synthesis. We found that in comparison with cells
transduced with GFP virus, the GlycoLo cells showed diminished incorporation of
13

C from

13

C6-glucose into the glycerol (m+3) moiety of phosphatidylcholine (PC;

Fig. 26B), phosphatidylinositol (PI; Fig. 26C), phosphatidylethanolamine (PE; Fig.
26D), and phosphatidylserine (PS; Fig. 26E). Incorporation of

13

C6-glucose-

derived carbon into fatty acids in PC, PI, PE, and PS was not different in GlycoLo
cells compared with control cells, suggesting that only the synthesis of the glycerol
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backbone portion of these phospholipids is affected by low rates of glycolysis.
High glycolytic rates affected

13

C incorporation into phospholipids to a

lesser extent. Although PE synthesis showed a slight increase in

13

C fractional

enrichment in glycerol (and a concomitant decrease in fractional enrichment of the
unlabeled pool) (Fig. 26D), PI showed diminished labeling characterized by lower
incorporation of

13

C into fatty acids. Glycerol

13

C labeling in PI from GlycoHi cells

was identical to that of control cells. This dichotomy in labeling patterns in different
phospholipids could suggest the presence of unique enzyme complexes that
participate in metabolic channeling for the synthesis of distinct glycerolipids.
Consistent with this idea, triacylglycerol (TAG) labeling was remarkably different
from that of other glycerolipids. As shown in Fig. 26F, TAG species collectively
showed little

13

C in the glycerol moiety. Furthermore, low rates of glycolysis had

little effect on glucose carbon incorporation into TAGs; however, GlycoHi cells
showed lower 13C incorporation into fatty acids. Collectively, these results suggest
that, in isolated NRCMs, low rates of glycolysis diminish phospholipid synthesis by
the DHAPàG3P pathway and that high rates of glycolysis decrease incorporation
of glucose-derived carbon into the fatty acyl chains of PI and TAGs.

PFK activity regulates mitochondrial activity in NRCMs: Stable isotope labeling
patterns of several end products of the PPP, HBP, and GLP suggest that high PFK
activity diminishes the relative abundance of those 13C isotopologues that require
metabolites derived from mitochondria. This suggests that cataplerosis285 is
diminished under conditions of high PFK activity. Because cataplerotic reactions
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Figure 26: Phosphofructokinase regulates glycerolipid biosynthesis. Stable
isotope tracing of phospholipids and triacylglycerols in cardiomyocytes incubated
with media containing 13C6-glucose for 18 h: (A) Atom-resolved map illustrating the
biological and biochemical history of 13C incorporation into glycerolipids; Fractional
enrichment

values

Phosphatidylinositol

of

13

(PI);

C

into:
(D)

(B)

phosphatidylcholine

phosphatidylethanolamine

(PC);
(PE);

(C)
(E)

phosphatidylserine (PS); and (F) triacylglycerols (TAG). Graph represents three
replicates per group from one isolation. *,$ p<0.05, **,$$ p<0.01,
p<0.0001.
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depend upon mitochondrial activity, we next measured respiration in cells
expressing either the control construct (GFP) or the GlycoHi or GlycoLo constructs.
GlycoHi-expressing cells showed 50% lower basal oxygen consumption, whereas
GlycoLo-expressing cells showed significantly higher basal OCR values (Fig. 27A,
27C). These PFK-mediated changes in mitochondrial OCR are likely due to the
Crabtree effect, which is characterized by decreases in mitochondrial activity under
conditions of increased glucose availability or glycolytic activity.286-289 Although
addition of oligomycin showed marginal effects on ATP-linked OCR, proton leak
was significantly diminished in GlycoHi cells. Upon addition of a mitochondrial
uncoupler, GlycoLo and GlycoHi cells showed relative changes in maximal
respiratory rate and in reserve capacity that mirrored the pattern found for basal
OCR and proton leak (Fig. 27A, 27C). These data are consistent with the notion
that high PFK activity diminishes mitochondrial activity, which limits the cataplerotic
generation of metabolites required for the synthesis of end products of the PPP,
HBP, and GLP.
Although cells transduced with the GlycoHi virus had >2-fold elevation in
basal extracellular acidification (ECAR) compared with Ad-GFP controls, we
observed no differences in ECAR in NRCMs expressing the GlycoLo PFK2 mutant
(Fig. 27B). Addition of oligomycin increased ECAR to similar values in all groups,
suggesting that inhibition of mitochondrial ATP production overrides PFK2mediated changes in glycolysis. Although extracellular acidification is a surrogate
measure of lactate extrusion and aerobic glycolysis, protons are also generated
during respiration via pyruvate dehydrogenase-mediated production of CO2 (i.e.,
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Figure 27: Phosphofructokinase activity regulates mitochondrial activity in
isolated cardiomyocytes. Extracellular flux analyses of NRCMs: (A) Oxygen
consumption traces (OCR), (B) Extracellular acidification rate (ECAR), and (C)
Calculated indices of respiration of cardiomyocytes transduced with GFP, GlycoLo,
or GlycoHi adenoviruses. n=3 independent isolations per group. *p < 0.05, **p <
0.01.
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; thus, the inconsistency of ECAR with absolute

measurements of glycolytic rate and

13

C3-lactate in GlycoLo cells (see. Fig. 1) is

likely due to an increase in mitochondrial activity. Taken together, measurements
from radiometric assays, stable isotope tracing, and extracellular flux analyses
indicate that PFK regulates ancillary pathways by not only direct partitioning of
glucose (e.g., in the PPP and the GLP) but by regulating mitochondrial cataplerotic
reactions as well.

Discussion
Most studies of cardiac metabolism have focused primarily on the catabolic
reactions required for energy provision.292 Considerably less effort has been
devoted to understanding the regulation of ancillary pathways of glucose
metabolism in the heart and how these pathways integrate with catabolic reactions.
In this study, we examined how PFK activity, which immediately precedes the
“lysis” step in glycolysis, regulates several 6-carbon- and 3-carbon-initiated
anabolic pathways that require glycolytic intermediates. Our results demonstrate
that in cardiac myocytes PFK regulates glucose carbon incorporation into ancillary
biosynthetic pathways by: (1) directly regulating carbon flow into purines and
phospholipids; and (2) indirectly influencing mitochondrial cataplerotic activity
required for the generation and subsequent incorporation of glucose-derived
carbon into products of the PPP, HBP, and GLP. These studies also illustrate how
radiometric measurements, stable isotope tracing, and extracellular flux analyses
can be integrated to examine substrate fate and develop detailed understanding
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of how interventions simultaneously affect anabolic and catabolic metabolism.
We chose to study the integration of anabolism and catabolism in the
context of glycolytic regulation at the PFK node. This enzyme controls 65% of the
flux through glycolysis in the heart,235 making it the major regulator of glycolytic
activity. It is unlikely that, under the experimental conditions used, glucose entry
was a major limiting step for its metabolism because NRCMs express both GLUT1
and GLUT4.110 Our stable and radiometric isotope tracing measurements show
that, under control conditions, <50% of glucose taken into myocytes is catabolized
past the enolase reaction. This suggests a majority of the glucose entering the
myocyte is not used for energy production, but is likely used by biosynthetic
pathways. Although PFK activity was found to be a potent determinant of
glycolysis-engendered lactate production, it did not have diametrically coordinate
effects on the relative amounts of glucose found upstream of the enolase reaction.
Surprisingly, both a decrease and an increase in glycolytic activity led to the
accumulation of glucose upstream of the enolase reaction; however, the
mechanisms by which low and high PFK activity augment the levels of glucosederived carbon upstream of the enolase reaction appear to differ: when PFK
activity was high, glucose uptake was increased, but glucose utilization was
elevated; when PFK activity was low, glucose uptake was the same as that found
in control cells, but glucose utilization was remarkably diminished. These results
suggest that conditions of low PFK activity promote accumulation of metabolites
(likely upstream of the PFK step), and that conditions of high glycolytic activity
support levels of glucose-derived carbon upstream of the enolase reaction by
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augmenting glucose uptake. Additionally, our data suggest that the level of glucose
available for glucose oxidation, alanine transamination, or pyruvate carboxylation
was relatively stable and independent of PFK activity.
Although studies in some cell types such as adipocytes suggest that the
HBP is a relatively minor pathway, utilizing only 2–3% of incoming glucose,293 our
stable isotope tracing data suggest that the rate of entry of glucose-derived carbon
into this pathway may be higher in cardiac myocytes. The unlabeled pool of UDPHexNAc was below 10% in all groups, suggesting that sugar donors such as UDPGlcNAc and UDP-GalNAc are synthesized and utilized at high rates. In contrast,
>20% of the pool of nucleotides was unlabeled and 13C enrichment of the glycerol
moiety of glycerolipids was below 20%. These findings appear to indicate that the
HBP utilizes more glucose-derived carbon than either the PPP or the GLP. Given
that up to 20% of glucose taken up by the heart could enter the PPP,294 our
comparisons of

13

C enrichment in end products of these pathways suggests that

HBP flux in cardiomyocytes may be much higher than currently appreciated.
Our results are consistent with previous findings in epithelial cells,144
fibroblasts,295, 296 and developing embryos297 which show that glycolysis regulates
glucose entry into the PPP. Our findings are also consistent with computational
predictions of the role of PFK in regulating the PPP in the intact heart.235 Similar to
findings in neurons,298 in cardiac myocytes high glycolytic rates driven by PFK
decreased the incorporation of glucose carbon into the ribose ring of purines. This
suggests that high rates of glycolysis decrease the flux of glucose through the
oxPPP. Nevertheless, we identified remarkable differences in 13C labeling in ATP
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and GTP versus CTP and UTP. Although both classes of nucleotides use the
metabolic precursor ribose-5-phosphate to form the ribose ring, purine ring carbon
atoms originate from N10-formyltetrahydrofolate, CO2 and glycine, while pyrimidine
ring carbons come from carbamoyl phosphate and glutamine, as well as aspartate
generated by cataplerosis.299 In the timeframe examined, purines did not
demonstrate incorporation of carbons that derive from metabolic products of the
serine biosynthetic pathway and one-carbon metabolism. Hence, it is possible that
glycine and N10-formyltetrahydrofolate derived from the serine biosynthetic
pathway might be inadequate to participate in purine ring synthesis during the 18
h incubation time used in our experiments. Alternatively, unlabeled serine and
folate present in the media could be used by these cells for de novo purine
biosynthesis.
The decrease in mitochondrial activity detected by extracellular flux analysis
in GlycoHi cells, paired with stable isotope tracing results in pyrimidines, suggests
low cataplerotic generation of aspartate. Oxaloacetate generated in the Krebs
cycle or via pyruvate carboxylation is transaminated to aspartate, which is
subsequently used for pyrimidine biosynthesis. That the m+7 and m+8
isotopologues were lower in GlycoHi cells shows that these pathways were
diminished under conditions of high PFK activity. From these data, we inferred that
the decrease in de novo pyrimidine biosynthesis in the GlycoHi cells may be due to
lower rates of cataplerosis. Because tricarboxylic acid anions are delicately
balanced by the input and output of intermediates involved in mitochondrial
substrate oxidation, anaplerosis, and cataplerosis,285 we reasoned that
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mitochondrial activity measurements could provide convergent evidence of PFKmediated regulation of auxiliary glucose biosynthetic pathways. Indeed, the
decrease in mitochondrial activity in GlycoHi cells, paired with the observation that
13

C-aspartate entry into pyrimidines was low, suggests that inhibition of pyrimidine

synthesis under conditions of high glycolytic activity is due to low rates of
cataplerosis.
Similar reasoning as well as previous modeling, validation, and biochemical
interpretation of 13C isotopologue data for UDP-GlcNAc300 were used to determine
how PFK affects the HBP, which is important given the known role of UDPhexosamines in modulating N- and O-linked glycosylation.147, 246 The fact that the
unlabeled pool of UDP-HexNAc was higher in GlycoHi cells suggests that the net
effect of high PFK activity is a decrease in HBP flux, and, like that found for
pyrimidines, this appears to be in part due to diminished mitochondrial activity.
Nevertheless, there are limitations for interpreting current data on HBP flux.
Because building UDP-HexNAc requires metabolites from many sources, it is
possible that the contribution of carbon from non-labeled pools of metabolites may
hinder interpretation. A potential solution to this problem would be to use a pulsechase approach, where isotopic labeling in the system is first saturated (e.g., with
both

13

C and

15

N) and then the stably labeled substrate(s) are replaced with

unlabeled substrate(s). The disappearance of the stable label over time in
isotopologues of UDP-HexNAc should, with higher confidence, reveal which
intersecting metabolic pathways limit HBP activity and UDP-Glc(Gal)NAc
synthesis under a given set of conditions.
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To date, little evidence exists for whether or how glycolysis regulates GLP
activity. Interestingly, G3P formed via glycerol-3-phosphate dehydrogenase 1 has
been shown to inhibit PFK2 and activate fructose bisphosphatase 2,301 suggesting
feedback regulation of the GLP on both glycolytic and gluconeogenic activity. An
indication that the glycolytic rate regulates GLP flux and glycerolipid synthesis is
provided by studies showing that genetic deletion or overexpression of PFKFB3,
a highly active form of PFK2, in adipose tissue coordinately regulates fat deposition
and obesity,302, 303 which is consistent with the notion that glycolysis in adipocytes
regulates TAG synthesis and storage. We found that low PFK activity directly limits
glucose-derived carbon incorporation into the glycerol backbone of several
phospholipids including PC, PI, PE, and PS; however, this was not the case with
triacylglycerols, where

13

C incorporation into glycerol was not different, but fatty

acyl chain labeling was diminished in GlycoHi cells. These results suggest that the
fatty acid pool derived from cataplerotic reactions is differentially channeled to
route newly synthesized fatty acids for esterification into triacylglycerols rather than
phospholipids.
There are several limitations to our study. Although NRCMs are beating
cardiac myocytes, they rely on glycolysis for energy to a much greater extent than
the adult heart.239 Thus, findings regarding pathways that involve metabolites
generated by cataplerosis may not entirely reflect metabolism in the adult heart.
Glucose carbon fate in NRCMs appears to differ from the adult heart primarily at
the level of coupling between glycolysis and glucose oxidation. In the adult human
heart, previous studies show that 26% of extracted glucose undergoes oxidation
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and 12% is released as lactate.84 In contrast, in NRCMs, we show that <13% of
glucose carbon undergoes oxidation and ~24% is released as lactate.
Nevertheless, our finding that a large portion of exogenous glucose extracted by
cardiac myocytes is apportioned for metabolic pathways other than glycolysis and
glucose oxidation is supported by human in vivo isotope tracing studies in the
myocardium, which demonstrate that 60% of exogenous glucose extracted by
contracting myocytes enters a slow turnover pool amenable to entry into ancillary
biosynthetic pathways.84 Another consideration is that the NRCM culture media is
devoid of fatty acids, which could influence the coupling between glycolysis and
glucose oxidation as well as biosynthetic pathway activity. Last, it is important to
consider that our stable isotope analyses did not include glycogen, glycine, serine,
or sorbitol, which limits our understanding of how glycolysis regulates glycogen
biosynthesis, serine biosynthesis, and the polyol pathway. Nevertheless,
computational models created by Cortassa et al.235 suggest that the polyol
pathway is under strong control by activation or inhibition of PFK. Similarly,
previous studies show that PFK activity regulates glycogen abundance in the
heart.220, 221 Such a behavior would be consistent with coordinate regulation of
ancillary biosynthetic pathway activity by PFK.
In summary, by using several methods to measure metabolic pathway
activity, we found that >40% of glucose consumed by NRCMs is not catabolized
to pyruvate, and that PFK has strong effects on the coupling between glucose
oxidation

and

glycolysis.

Pairing

results

from

stable

isotope-resolved

metabolomics with extracellular flux analysis demonstrated that PFK activity
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regulates glucose carbon incorporation directly into the ribose and the glycerol
moieties of purines and phospholipids, respectively, and that high PFK, by
indirectly limiting mitochondrial activity, diminishes

13

C incorporation into

pyrimidines, UDP-N-acetyl-hexosamine(s), and the fatty acyl chains of
phosphatidylinositol and triglycerides. These insights could help elucidate how
pathological or physiological changes in glucose metabolism regulate the anabolic
behavior and remodeling of the myocardium.iii
iii

This chapter previously appeared as an article in the Biochemical Journal. The original
citation is as follows: Gibb AA, et al. Integration of flux measurements to resolve changes in
anabolic and catabolic metabolism in cardiac myocytes. Biochem J. 2017.
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CHAPTER V
CONCLUDING DISCUSSION

The studies presented here were designed to develop an understanding of
the effects of exercise on cardiac metabolism and the potential role of these
changes in regulating the adaptive response, i.e., physiologic growth. We
reasoned that, because changes in metabolism present not only a material cause
but can also have direct and indirect roles in intracellular signaling, exerciseinduced changes in cardiac metabolism are essential for adaptation to training.
Our general hypothesis is that exercise-induced changes in glycolytic flux are
essential for activation of the physiological growth program. To test this hypothesis,
we assessed the effects of acute and chronic exercise on myocardial metabolism,
in particular glycolysis, and whether these changes contributed to the physiologic
growth of the heart.
To establish a model in which to test our hypothesis, we first examined
nocturnal/diurnal behavior, treadmill exercise compliance, and systemic as well as
cardiac-specific exercise adaptations in two commonly used mouse strains,
C57BL/6J, and FVB/NJ mice. As discussed in Chapter II, metabolic cage analysis
indicated a strong nocturnal nature of C57BL/6J mice, whereas FVB/NJ mice
showed no circadian element to activity, food or water intake, VO2, or VCO2. Initial
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exercise capacity tests revealed that, compared with C57BL/6J mice, FVB/NJ mice
are capable of achieving nearly 2-fold higher workloads prior to exhaustion.
FVB/NJ mice tested during the day were capable of achieving significantly more
work compared with their night-tested counterparts. Following 4 weeks of training,
FVB/NJ mice showed significant increases in exercise capacity as well as
physiologic cardiac growth characterized by enlarged myocytes and higher
mitochondrial DNA content. C57BL/6J mice showed no increases in exercise
capacity or cardiac growth regardless of whether they exercised during the day or
the night. This lack of adaptation in C57BL/6J mice was attributable, at least in
part, to their progressive loss of compliance to the treadmill training protocol. From
these results, we conclude that the FVB/NJ strain is a useful and robust mouse
model for examining cardiac adaptations to treadmill exercise and that treadmill
training during daytime hours does not negatively affect exercise compliance or
capacity.
In Chapter III, we examined the effects of exercise on myocardial
metabolism and the role these changes may play in contributing to exerciseinduced cardiac growth. As discussed, we found that exercise acutely decreased
glucose

utilization

by

modulating

circulating

substrates

and

reducing

phosphofructokinase activity; however, upon exercise adaptation and recovery
there was an increase in myocardial phosphofructokinase activity and glycolysis.
To assess the relevance of these changes in glycolytic activity, we determined how
cardiac-specific expression of mutant forms of 6-phosphofructo-2-kinase/fructose2,6-bisphosphatase (PFK2) affect cardiac structure, function, metabolism, and
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gene programs relevant to cardiac remodeling. Cardiac-specific expression of a
kinase-deficient PFK2 transgene (GlycoLo mice) lowered glycolytic rate and
regulated the expression of genes known to promote cardiac growth. Hearts of
GlycoLo mice had larger myocytes, enhanced cardiac function, and higher
capillary-to-myocyte ratios. Expression of phosphatase-deficient PFK2 in the heart
(GlycoHi mice) increased glucose utilization and promoted a more pathological
form of hypertrophy devoid of transcriptional activation of the physiologic cardiac
growth program. Modulation of phosphofructokinase activity was sufficient to
regulate the glucose-fatty acid cycle in the heart; however, metabolic inflexibility
caused by invariantly low or high phosphofructokinase activity caused modest
mitochondrial damage. Transcriptomic analyses showed that glycolysis regulates
the expression of key genes involved in cardiac metabolism and remodeling.
Collectively, these findings suggest that the exercise-induced decreases in
glycolytic activity stimulate physiologic cardiac remodeling and that metabolic
flexibility is important for maintaining mitochondrial health in the heart.
To gain insight into how these changes in glycolytic activity could contribute
to cardiac growth, we assessed the impact of changes in glycolytic activity on
cardiomyocyte anabolic metabolism. In Chapter IV, we show that expression of
mutant forms of PFK2 in rat neonatal cardiomyocytes coordinately regulate
catabolic and anabolic metabolism. An important finding was that >40% of glucose
consumed by myocytes was unaccounted for via catabolism to pyruvate, which
suggests entry of glucose carbons into ancillary pathways branching from
metabolites formed in the preparatory phase of glycolysis. Analysis of 13C fractional
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enrichment patterns from stable isotope tracing experiments suggests that PFK
activity regulates glucose carbon incorporation directly into the ribose and the
glycerol moieties of purines and phospholipids, respectively. Pyrimidines, UDP-Nacetyl-hexosamine, and the fatty acyl chains of phosphatidylinositol and
triglycerides showed lower 13C incorporation under conditions of high PFK activity;
the isotopologue 13C enrichment pattern of each metabolite indicated limitations in
mitochondria-engendered oxaloacetate, acetyl CoA, and fatty acids. Consistent
with this notion, high glycolytic rate diminished mitochondrial activity and the
coupling of glycolysis to glucose oxidation. These findings suggest that a major
portion of intracellular glucose in cardiac myocytes is apportioned for ancillary
biosynthetic reactions and that PFK coordinates the activities of the pentose
phosphate, hexosamine biosynthetic, and glycerolipid synthesis pathways by
directly modulating glycolytic intermediate entry into auxiliary glucose metabolism
pathways and indirectly regulating mitochondrial cataplerosis.
Collectively, the data obtained from these studies support the notion that
acute and chronic exercise is associated with changes in myocardial metabolism
and that the periodic decreases in myocardial glucose utilization occurring during
exercise are a stimulus for physiologic cardiac growth. Additionally, metabolic
flexibility, maintained in the exercised heart, appears to be a primary distinguishing
feature of mitochondrial health in the heart. These findings are summarized in Fig.
28 and are discussed in greater detail below.
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Figure 28: Exercise-induced effects on cardiac metabolism and its role in
regulating cardiac growth and mitochondrial health. Acute exercise increases
the circulating levels of FFA and lactate which act to decrease the utilization of
glucose by the myocardium; however, in the exercise-adapted state sustained
increases in circulating hormones contribute in part to enhanced glucose
utilization. At the cellular level, allosteric regulation of the rate-limiting step of
glycolysis, PFK1, is coordinately affected to and influence glucose utilization both
during exercise and in the adapted state. These exercise-induced decreases in
glycolysis are sufficient to promote physiological growth of the heart. While
decreases in glucose utilization are a key trigger for cardiac growth, exerciseinduced metabolic flexibility is essential for the preservation of mitochondrial health
in the physiological hypertrophied heart.
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FIGURE 28
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ErbB

Metabolic Regulation of Cardiac Growth
While exercise promotes cardiovascular wellness and overall health, the
mechanisms by which this is accomplished remain unclear. The three salient
findings from our studies, related to the heart, are: (1) that periodic decreases in
myocardial glycolytic activity are sufficient to promote physiologic cardiac
growth304; (2) that maintenance of metabolic flexibility in the heart is essential for
mitochondrial health304; and (3) that glycolytic activity in cardiomyocytes
coordinates

the

biosynthesis

of

nucleotides,

nucleotide

sugars,

and

glycero(phospho)lipids.305 Our findings have several implications, germane to both
the basic understanding of cardiac remodeling as well as future targets for therapy.
The finding that exercise acutely diminishes glucose utilization and that this
change in metabolism activates the gene program for physiologic growth provides
new knowledge and a metabolic target that could be leveraged for preventing
adverse remodeling in response to stress. In particular, controlled pharmacologic
modulation of the PFK node of metabolism could be used to activate the cardiac
growth gene program as well as to stimulate the heart to use multiple substrates,
which appears to be required for optimal mitochondrial function. Also, the finding
that PFK activity regulates ancillary biosynthetic pathway activity rouses new
concepts about the importance of coordinated anabolic activity in modulating
hypertrophic responses to stress. These findings and their potential impact with
respect to myocardial health and remodeling are discussed in detail below.
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Myocardial glycolysis coordinates cardiomyocyte biosynthetic activity: A principle
finding from our studies was that PFK activity in cardiomyocytes coordinated the
biosynthesis of materials required for growth (Fig. 29). One pathway affected by
PFK and glycolytic activity was the PPP, which contributes to growth by: (1)
replenishing NADPH levels required for anabolic reactions and the regeneration of
GSH; (2) synthesizing nucleotides for DNA repair and replication; and (3) providing
metabolites that can act as direct signaling modulators. Previously it has been
shown that glycolysis regulates glucose entry into the PPP in several cell types. In
particular, developing embryos increase PPP flux by decreasing PFK enzyme
abundance, rewiring glucose metabolism for normal development.297 In the context
of the adult heart, pathological hypertrophy132-134 and heart failure135 are both
associated with an increase in PPP activity. During short-intensive exercise, the
activities of the enzymes of the oxidative part of the PPP have been found to be
slightly diminished; however, in the immediate recovery period, an increase in
enzymatic activity was observed that persisted for up to 3 h.306 While the effectors
of increased PPP activity are not well known, a recent study identified that
overexpression of PGC-1α in skeletal muscle increased the enzymatic activities
and end-products of the PPP.307 This finding is important as upregulation of PGC1α is well-known to be initiated by acute bouts of exercise.
Our results provide additional mechanistic insight as to how PPP activity is
increased in the exercising and recovering heart. Our in vivo results show that
during and in the early recovery phase of exercise, PFK activity is diminished. This
likely results in the redistribution of glucose into other ancillary pathways, such as
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Figure 29: Metabolic regulation of the biosynthetic pathways involved in
the cardiac growth response.
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the PPP, that are upstream of PFK. In fact, several lines of evidence support this
assumption, such as the increase in myocardial glycogen shown to occur at this
time. Our in vivo model of diminished PFK activity (i.e., GlycoLo) validated that
regulation at this node of metabolism increases PPP activity as GlycoLo mice
displayed increased abundances of several PPP-derived metabolites. Our in vitro
studies also suggest that increased PPP activity may be a more coordinated and
selective process, as low rates of glycolysis increased the biosynthesis of
pyrimidines without affecting the purine pool.
Collectively, these results suggest that an increase in PPP activity occurs
when PFK activity is diminished. This results in increased nucleotide biosynthesis
for DNA replication and amino acid synthesis as well as regeneration of the
NADPH pool for anabolic reactions. As growth is an anabolic event, the cell must
appropriately coordinate the biosynthesis of these building blocks, priming itself for
the recovery phase when growth takes place. Also, the increase in PPP activity
may have a direct role in signaling the growth of the heart. Results from our
metabolomic screening showed that AICAR, an AMP-analog derived from the
PPP, was significantly elevated in GlycoLo mice compared to WT controls based
on a simple unpaired t-test. This increase in AICAR was associated with a
significant increase in AMPK activation (data not shown). This result could suggest
that changes in PPP activity are not only important for the building blocks for
growth, but also for regulating signaling pathways that instigate the growth
program.
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Our in vivo and in vitro data also collectively suggest that an increase in
PFK activity, such as occurs during the homeostatic phase in the exercise-adapted
heart, would be important for the synthesis of glycerol(phospho)lipids. In particular,
the synthesis of the glycerol moiety via the GLP is required to provide the backbone
for fatty acid esterification and phospholipid synthesis. We found that the synthesis
of abundant phospholipids in the cardiomyocyte, such as phosphatidylcholine,
phosphotidylethanolamine, and phosphatidylinositol,308 appear to be regulated
strongly by PFK-mediated changes in glycolytic activity.305 Higher levels of these
phospholipids would be required for de novo expansion of cellular membranes as
well as for maintaining larger myocytes, in response to stressors such as exercise.
We also found that changes in glycolytic activity cause significant
phospholipid remodeling. This observation is important as it has been shown that
changes in phospholipid composition, as occurs when phosphatidylethanolamine
synthesis is reduced, results in impaired cardiac function.309 Similarly, chronic
heart failure and diabetic cardiomyopathy, conditions in which metabolism
becomes inflexible, are associated with disturbances in cardiac sarcolemmal
membrane phospholipid homeostasis.310 In the exercise-adapted heart, proper
phospholipid homeostasis is maintained, with little to no change in phospholipid
composition.308 This could be a result of the acute periodic episodes of altered PFK
and glycolytic activity instigated by exercise as opposed to the constitutive
changes observed in disease.
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Metabolic flexibility and mitochondrial health: Another key finding from our studies
is that metabolic flexibility appears to be essential for maintaining mitochondrial
health. While it is generally accepted that mitochondrial dysfunction develops in
pathologic forms of hypertrophy, where metabolism becomes inflexible, the exact
mechanisms driving dysfunction remain ill-defined. Several proposed mechanisms
that have been suggested to contribute to mitochondrial dysfunction include
mitochondrial DNA depletion and swelling,311 disorganization and reduced density
of the cristae structures,312 increased oxidative stress,313 and mitochondrial
uncoupling.314 Our findings in vivo indicate that invariant inflexibility of cardiac
metabolism is sufficient to promote a mild form of mitochondrial dysfunction,
suggesting that the metabolic phenotypes of the heart in pathology (e.g., chronic
heart failure and diabetic cardiomyopathy) may in fact initiate the decline in
mitochondrial health.
In line with this idea, several of the manifestations of mitochondrial
dysfunction were identified in our in vivo mouse models. In both GlycoLo and
GlycoHi hearts, we observed disorganization and a decreased density of
mitochondrial cristae. Additionally, results from our metabolomics data suggest
that metabolic inflexibility results in chronic oxidative stress, indicated by elevations
in the lipid peroxidation product, 4-hydroxy-2-nonenal (4-HNE). Data from our in
vitro studies may provide insight as to why this oxidative stress occurs, as
increased rates of cardiomyocyte glycolysis diminished the biosynthesis of
glutathione (data not shown), a key antioxidant. Lastly, it is possible that the
mitochondria are more uncoupled which could contribute to the dysfunction
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observed. As reviewed by Lopashuk, the oxidation of FFA contributes to
mitochondrial uncoupling.82 Therefore, in instances of excessive FAO such as
occurs in the GlycoLo heart, chronic uncoupling of the mitochondria could be
detrimental. Our data indicate that the mitochondria from GlycoLo hearts are, in
fact, more uncoupled than control hearts.
Mitochondrial dysfunction is also likely a consequence of changes in
phospholipid homeostasis. As already discussed, both our in vivo and in vitro data
indicate that changes in PFK and glycolytic activity affect phospholipid metabolism.
Therefore, changes in one or several of the phospholipids found in the
mitochondrial membrane could affect mitochondrial health. One of the most
abundant phospholipids of the inner mitochondrial membrane is cardiolipin, which
plays an important role in regulating the enzymatic activity of the electron transport
chain.315, 316 In heart failure, mitochondrial cardiolipin content is reduced and is
correlated with mitochondrial dysfunction.317-319 While we did not measure the
cardiolipin abundance or its biosynthesis, identifying whether cardiolipin
metabolism is affected by changes in glycolytic activity could provide novel
mechanistic insights into mitochondrial damage in disease. Taken together, these
results provide evidence that metabolic flexibility is essential for the maintenance
of a healthy mitochondrial pool. Furthermore, our results provide a potential
therapeutic target, the PFK node of glycolysis, to increase metabolic flexibility and
improve mitochondrial health in disease.
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Periodic decreases in myocardial glycolysis activate the cardiac growth program:
As discussed, our data collectively indicate that changes in PFK and glycolytic
activity coordinate biosynthetic pathways (e.g., PPP, GLP) that are required for
cardiomyocyte growth. In addition, our data also suggest that metabolism plays a
critical role in the activation of gene sets that promote cardiac growth. Most
notably, our findings suggest that decreases in myocardial glycolytic rate, such as
occurs during exercise, is sufficient to activate the Cebpb/Cited4 axis. While it has
previously been shown that the activation of AKT was required for this
transcriptional regulation,45 we found that low rates of glycolysis were sufficient to
activate the physiologic gene program, suggesting that changes in metabolism are
likely a proximal cause of cardiac growth.
Results from our studies suggest that PFK activity regulates anabolic
pathways required for the synthesis of the amino acids alanine, serine, and glycine.
The stimulation of the serine biosynthetic pathway (SBP), in particular, would not
only increase serine/glycine biosynthesis, but it would control the one-carbon
metabolic reactions (i.e., those involving methyl tetrahydrofolate metabolites) that
are known to modulate the epigenetic landscape.320 Our data show not only that
the abundance of these metabolites are changed by PFK activity (i.e., increased
in GlycoHi), but that glycolysis regulates the transcription of enzymes involved in
one-carbon metabolism (e.g., Phgdh). This could be significant because Cited4 is
epigenetically regulated whereby hypermethylation of its CpG island causes lower
expression.244 Our results are in line with the general consensus showing that
altered metabolism regulates the epigenetic landscape.321-323 While additional
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work establishing the mechanistic link between metabolism and epigenetics is
required, our results provide new insights into the regulation of gene expression
via metabolism.
Expanding on the observation that metabolites involved in one-carbon
metabolism (e.g., serine, methionine, cysteine) are affected by PFK activity, the
metabolic flexibility induced by exercise at this same metabolic node could
contribute to the regulation of gene transcription. As these metabolites are involved
in the methylation events of DNA and RNA, controlled modulation of the SBP
pathway, by exercise-induced changes in PFK activity, could readily increase and
decrease methylating agents such as 5-methyl-THF, altering gene transcription at
the level of epigenetics. Our results support this notion as several genes, including
Cited4, were coordinately regulated; however, we have yet to address whether
changes in the SBP contribute to the physiologic gene program. The idea that PFK
activity affects the epigenetic landscape is important, as it provides a potential
therapeutic target that can be leveraged to prevent adverse remodeling.

Future Directions
Our results clearly demonstrate a key role for metabolism in regulating the
cardiac growth response to stress; however, several questions remain
unanswered. For instance, an experiment that would help to further identify how
metabolic pathways integrate to promote the physiologic growth program would be
to identify which pathways are similarly altered in the GlycoLo and acutely
exercising heart. For example, if one-carbon metabolites involved in methylation
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are similarly reduced in their abundance, this would provide further evidence of the
metabolic regulation of epigenetic modifications. Similarly, if flux through the HBP,
which we show to be affected by PFK and glycolytic activity, is similarly affected in
exercising and GlycoLo hearts, identification of the proteins that are analogously
post-translationally modified could provide additional targets to further dissect the
mechanisms that promote physiologic growth of the heart. Furthermore, identifying
how exercise intensity and duration regulate these metabolic pathways and gene
transcription would be important for optimizing cardiac adaptations and for further
understanding links between metabolism and cardiac growth.
Understanding how modulation of other nodes of glucose metabolism may
also provide insight as to the regulation imposed by metabolism on cardiac growth.
For example, cardiac-specific pyruvate dehydrogenase complex deficiency results
in a mild form of cardiac hypertrophy in mice,324 an interesting observation as it
could be reasoned that this genetic modification likely results in a phenotype
similar to our GlycoLo mouse. In mice subjected to pressure overload,
cardiomyocyte overexpression of hexokinase resulted in the attenuation of
pathological hypertrophy.139 Lastly, an interesting clinical finding in patients with
glycogen storage diseases is the presentation of a mild form of hypertrophic
cardiomyopathy.325 This suggests that myocardial glycogen contributes to the
growth of the heart and may be relevant to our findings as we see that exercise
and diminished PFK activity increase myocardial glycogen content. Therefore, it
would be interesting to determine whether glycogen accumulation during exercise
contributes to the cardiac growth response. These studies, in addition to our
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results, provide ample evidence of the role of metabolism in regulating the growth
responses to stress and indicate additional nodes of glucose metabolism that
potentially coordinate the biosynthetic pathways.
The conclusions from our studies also open up the possibility to explore the
contributions of metabolism in other forms of cardiac growth and hypertrophy. For
instance, little is known about the metabolic changes that occur in pregnancyinduced physiological hypertrophy. In healthy women, pregnancy is associated
with a transient increase in cardiac size, similar to that observed in the exercised
heart.326 This growth response has been linked to the activation of AKT and
ERK1/2 signaling pathways, both known to influence and control cellular
metabolism.327-329 with this knowledge in hand, it would be interesting to test
whether pregnancy-induced cardiac growth is associated with similar changes in
PFK activity and transcription regulation of Cebpb and Cited4 as we observed in
our exercise model.
The transcriptomics results from our study provided a large data set in which
to ask new and exciting questions in the field of cardiac health in disease. For
example, the expression of gluconeogenic genes, fructose-1,6-bisphosphatase 2
(Fbp2) and phosphoenolpyruvate (Pck1), were found to be altered by glycolytic
activity in the heart, with Fbp2 in a coordinate manner. The fact that these genes
are modifiable in an organ thought to have limited gluconeogenic potential is
noteworthy. This observation provides the opportunity to test the hypothesis that
an

increase

in

myocardial

gluconeogenic

enzyme

activity

would

be

cardioprotective from pathologic insult or promote myocyte proliferation by
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increasing the bioavailability of carbons for ancillary biosynthetic flux and through
regulation of gene transcription. Similarly, we found that centromere protein F
(Cenpf), a gene associated with chromosome segregation during mitosis,330 was
found to be coordinately regulated by glycolysis. Interrogation of the metabolic
regulation of such cell division genes in cardiomyocytes, thought to be terminally
differentiated and relatively incapable of division and proliferation, may provide
novel therapeutic approaches to regenerate the myocardium following injury.
In conclusion, we demonstrate a clear role of exercise-induced changes in
metabolism in coordinating the growth response of the heart and the importance
of metabolic flexibility in maintaining cardiac health. It is my hope that the
knowledge derived from these studies will form the basis for the development of
novel interventions to improve cardiac health (e.g., in patients with heart failure or
diabetic cardiomyopathy).
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APPENDIX
The contents of Chapters 2, 3, and 4 are derived from published
manuscripts. Copyright clearance from the publishers has been granted and the
manuscripts have been properly cited by the inclusion of footnotes and proper
citations within the reference section of this dissertation.
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